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Ca2+ homeostasis 
 
Ca2+ is the most abundant cation in the human body and is generally recognized as 
the main component of bone tissue. In addition, Ca2+ plays a vital role in many 
other physiological functions, including blood clotting, muscle contraction, cell 
signaling, neurotransmission and enzyme activity (1). Consequently, the 
maintenance of a balanced extracellular Ca2+ concentration is essential and, 
therefore, tightly controlled by the combined actions in the intestine, kidney and 
bone. In more detail, this interplay comprises intestinal absorption from the diet, 
renal filtration and tubular reabsorption regulating urinary Ca2+ excretion, while a 
dynamic bone turnover ensures Ca2+ storage during overload and favors Ca2+ 
release when needed. Ca2+ flux rates in these organs are directed via an extensive 
hormonal network, involving parathyroid hormone (PTH), 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3) and calcitonin (1). The Ca2+-sensing receptor (CaSR) in the 
parathyroid gland plays a central role in the coordination of these hormonal 
feedback mechanisms due to its ability to sense even subtle fluctuations in the 
blood Ca2+ concentration. When blood Ca2+ is low, the CaSR remains desensitized 
and PTH is released to trigger Ca2+ resorption from bone, stimulate Ca2+ 
reabsorption in the kidney and induce conversion of the vitamin D precursor into its 
active form 1,25(OH)2D3. This active metabolite, on its turn, stimulates renal Ca2+ 
reabsorption, but mainly promotes intestinal dietary Ca2+ uptake. On the other hand, 
when high Ca2+ levels activate the CaSR, calcitonin is secreted to enhance bone 
mineralization (Fig. 1). Importantly, any disturbance in this complex regulatory 
system has serious consequences, which emphasizes the significance of studies 
unraveling the molecular and physiological aspects of Ca2+ homeostasis.  
 
Epithelial Ca2+ transport: paracellular versus transcellular  
 
A pivotal element of Ca2+ homeostasis constitutes the transfer of Ca2+ across 
epithelial cell layers lining the intestinal lumen and the renal tubular system. 
Because the diet is the only source for the body to acquire Ca2+, many studies 
focus on the elucidation of intestinal Ca2+ absorption pathways. Typical for the 
gastro-intestinal (GI) tract is the gut wall architecture characterized by large folds 
that contain numerous extensions (villi) and invaginations (crypts) to expand 
absorptive area (Fig. 2). The continuous layer of epithelial cells covering each 
villus or crypt provides a selective barrier that prevents free exchange of solutes 
and ions from the luminal content into the circulation.  
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Figure 1. Ca2+ homeostasis. Continuous exchange of Ca2+ between the blood compartment and 
the transporting epithelia of bone, kidney and intestine remains serum Ca2+ levels within the 
physiological range (solid lines). The rate of Ca2+ fluxes in these tissues is under tight hormonal 
regulation (dashed lines). In case of high blood Ca2+, calcitonin stimulates bone mineralization. 
Conversely, under low calcemic conditions the parathyroid secretes PTH, which triggers Ca2+ 
release from bone, increases the amount of Ca2+ reabsorbed in the kidney and promotes the 
conversion of the vitamin D precursor into its active metabolite vitamin D3. Vitamin D3, on its turn, 
mainly promotes dietary Ca2+ uptake, but also stimulates renal Ca2+ reabsorption. PTH, 
parathyroid hormone; vitD, vitamin D.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nevertheless, this epithelium creates intercellular spaces enclosing apical localized 
tight junction (TJ) complexes and carries specialized transporters, allowing uptake 
of nutrients. Current knowledge provides evidence for two distinct epithelial Ca2+ 
absorption mechanisms (Fig. 2). In a paracellular route, Ca2+ passes the TJ and 
flows through the intercellular space, driven by both Ca2+ concentration and 
electrochemical gradients, the latter set by the Na+ balance (1). This non-saturable 
diffusion process does not require energy, however, has limitations in regulation, 
as it is mainly concentration-dependent. Hence, a second, transcellular, pathway 
takes place, which involves transfer of Ca2+ across plasma membranes. This route 
is saturable and demands energy to transmigrate Ca2+ across the basolateral 
membrane. On the other hand, the tight hormonal regulation, primarily via 
1,25(OH)2D3, allows  the  body  to fine-tune transcellular Ca2+ transport independent  
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Figure 2. The gastro-intestinal tract. (A) Total length of the GI tract divided into different 
functional segments (B) Typical gut wall anatomy including plicae circulares, villi and epithelial 
cells (enterocytes) with microvilli to enlarge total absorptive area. The enterocytes are involved in 
nutrient absorption via a transcellular or paracellular pathway.  
 
A 
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of luminal Ca2+ concentration (1-4). Ca2+ absorption occurs throughout the entire GI 
tract, but dominates in the small intestine. When Ca2+ supply is adequate or high, 
paracellular fluxes in the duodenum, jejunum and ileum absorb the main fraction of 
intestinal Ca2+ load (80-90%), whereas the transcellular contribution remains low (5, 
6). Under comparable physiological conditions, studies in rats and dogs analyzed 
net Ca2+ absorption in the individual segments, demonstrating that uptake prevails 
in the ileum (80-88%) followed by the jejunum and duodenum with 4-16% and 4-
8%, respectively (7, 8). Noteworthy, this divergence in net uptake is largely clarified 
by the long sojourn time of chyme in the ileum (>2h) compared to the jejunum (40 
min) and duodenum (3 min) (6, 9). Conversely, transcellular absorption, 
predominantly restricted to the duodenum, is upregulated via 1,25(OH)2D3 to 50% 
of total Ca2+ absorbed in case of high Ca2+ requirements or when dietary Ca2+ is 
limited (6, 10, 11). This enables the organism to respond to fluctuations in 
nutritional Ca2+, while it can also adapt to long-term changes of the body’s demand 
that occurs during growth, development, lactation and aging. However, some 
studies report that under low calcemic conditions each GI segment is capable of 
transcellular Ca2+ absorption, albeit to a far smaller amount than in the duodenum 
(12-15). The large intestine finally accounts for less than 10% of total Ca2+ uptake, 
both in a paracellular and transcellular manner (5). The latter mainly residing in the 
cecum and ascending colon (6).    
The abovementioned Ca2+ absorption pathways also apply to the kidney, where 
the majority of Ca2+ filtered in the glomeruli (70%) is reabsorbed from the tubular 
pro-urine back into the blood compartment. The proximal tubule (PT) and thick 
ascending limb (TAL) of Henle are the main sites of paracellular Ca2+ transport and 
account for 85% of total Ca2+ reabsorbed. In the more distal segments, enclosing 
the distal convoluted tubule (DCT2) and connecting tubule (CNT), transcellular 
transport controls the final amount of Ca2+ reabsorption (1, 16). Comparable to the 
intestine, the renal transcellular pathway becomes more significant in case of 
overall low calcemic state. In contrast, this renal effect is mainly PTH-mediated and 
to a lesser extent stimulated by 1,25(OH)2D3 (11, 17, 18).  
 
Transcellular Ca2+ absorption  
 
In the late 1950s, the existence of an energy- and 1,25(OH)2D3-dependent 
transcellular Ca2+ absorption process was first described in rat small intestine (19). 
Later studies identified the involvement of cytosolic Ca2+-binding proteins and 
described Ca2+ extrusion at the basolateral membrane via an ATP-dependent Ca2+ 
pump  (20, 21).  Only  recently,  the   complete   molecular   understanding  has  been 
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Figure 3. The intestinal transcellular Ca2+ absorption machinery. Dietary Ca2+ diffuses across 
the luminal membrane of epithelial cells via the Ca2+-selective channel TRPV6. Subsequently, 
Ca2+ is sequestered by cytosolic calbindin-D9k and extruded into the blood via the basolateral 
ATP-dependent transporter PMCA1b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
unraveled via the identification of Ca2+ entry channels at the luminal membrane of 
absorptive cells, namely the transient receptor potential vanilloid 6 (TRPV6) 
channels, cloned from rat intestine (22, 23). Subsequently, transcellular Ca2+ 
absorption is generally described as a three-step process, consisting of luminal 
entry via the Ca2+ selective channel TRPV6, buffering of cytosolic Ca2+ and 
diffusion to the basolateral membrane via the Ca2+-binding protein calbindin-D9k, 
and finally extrusion into the blood compartment mediated by the plasma 
membrane Ca2+- ATPase (PMCA1b) (Fig. 3).  
Comprehensive studies in the human, rat and mouse intestine detected by far 
the highest TRPV6 abundance in the duodenum (24-27). Here, TRPV6 is present 
at the apical brushborder of the villus tip where it co-localizes with calbindin-D9k 
and PMCA1b, while no TRPV6 expression is observed in the crypt (28). This apical 
localization underlines the central role of TRPV6 in luminal Ca2+ entry. Minor 
transcripts are identified in the proximal jejunum, cecum and ascending colon, 
implying that these segments share the capacity to absorb Ca2+ in a transcellular 
manner. In addition, the stomach contains high TRPV6 expression levels. 
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Nevertheless, its function in the gastric area remains elusive, since it is generally 
recognized that the stomach plays no significant role in dietary Ca2+ uptake. 
Cytosolic calbindin-D9k is greatly expressed throughout the entire GI tract, except 
for the stomach, with peak amounts found in the duodenum (27, 29). The function 
of calbindin-D9k in Ca2+ absorption is twofold. First, it supports the trafficking of Ca2+ 
through the cytosol, while secondly maintains a low intracellular Ca2+ level that 
facilitates a continuous inward driving force at the apical membrane. Of notice, in 
avian duodenum the main protein for intracellular Ca2+ binding is calbindin-D28k. 
The basolateral PMCA1, which is a universal transporter for the extrusion of Ca2+ 
and a main regulator of resting intracellular Ca2+ levels, is expressed in nearly all 
eukaryotic cells. However, PMCA1b is the major isoform in the intestine where it 
displays a ubiquitous expression throughout the entire length of the GI tract (1). 
The typical distribution pattern of TRPV6 and calbindin-D9k nicely correlates with 
the important role the duodenum fulfills in transcellular Ca2+ absorption and implies 
the essential role of both proteins in overall transcellular uptake. Studies in Caco-2 
cells report a strong dose-dependent increase of TRPV6 and calbindin-D9k mRNA 
after 1,25(OH)2D3 stimulation, however this relationship is markedly stronger for 
TRPV6 (30). In addition, mRNA upregulation of TRPV6 precedes that of calbindin-
D9k with several hours (31). Taken these results into account, luminal entry via 
TRPV6 is generally accepted as the rate-limiting step in transcellular Ca2+ 
absorption.  
In the kidney a similar three-step Ca2+ reabsorption process is applicable with 
the involvement of slightly different transport proteins, namely the apical TRPV5 
Ca2+ channel, cytosolic calbindin-D28k and a basolateral Na+/Ca2+ exchanger 
(NCX1). Detailed localization studies in human, rabbit and mouse kidney revealed 
the presence of TRPV5 at the apical membrane of DCT2 and CNT, the site of 
transcellular Ca2+ reabsorption in the kidney (27, 29, 32, 33). The same renal 
epithelial cells contain the other proteins of the transcellular Ca2+ transport 
machinery, including calbindin-D28k and NCX1. Although TRPV6, calbindin-D9k 
(only mouse) and PMCA1b are also present in the DCT2 and CNT region, their 
contribution to Ca2+ reabsorption is arguable, but generally acknowledged as minor 
under normal physiological conditions (1, 34). Equal to the intestine, studies in 
renal epithelial cells verified luminal influx via TRPV5 channels as the critical step 
in Ca2+ reabsorption (1). At last, mRNA levels of all six aforementioned Ca2+ 
transport proteins are detectable in bone tissue, however, their precise role in 
osteoclastic and osteoblastic transcellular Ca2+ fluxes remains elusive. 
Nevertheless, a recent study by van der Eerden et al. suggests that TRPV5 is 
essential for proper osteoclastic bone resorption (35).  
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Molecular and physiological features of TRPV5/6 channels 
  
The observation of luminal Ca2+ channels functioning as the rate-limiting step in 
transcellular Ca2+ transport, rapidly uncovered additional information about these 
key proteins. The tissue distributions of TRPV5 and TRPV6 vary significantly, 
although TRPV5 and TRPV6 co-localize in most organs involved in Ca2+ transport. 
TRPV6 is more widely expressed since abundant mRNA transcripts have been 
identified in the small intestine, stomach, placenta, testis, skin, salivary glands, 
pancreas, bone and kidney. TRPV5 is more specifically localized in the kidney 
where expression is high, although lower levels of TRPV5 are also detected in 
other Ca2+ transporting epithelia, such as placenta, bone and small intestine (24-
27).  
Both channels are member of the large transient receptor potential (TRP) 
superfamily, belong to the vanilloid subfamily (TRPV) and share 75% amino acid 
sequence identity. Their most unique feature is the high selectivity for Ca2+ in 
comparison to other ion channels. They are identified as 6 trans-membrane 
spanning proteins with a Ca2+ selective pore region between trans-membrane 
segments 5 and 6 (Fig. 4) (1, 36). The molecular determinant of their Ca2+ 
selectivity and permeation is a single aspartate residue present in the pore-forming 
domain (37, 38). Hoenderop et al. showed that TRPV5 and TRPV6 assemble into 
heterotetrameric channel complexes with altered channel properties. Therefore, it 
is postulated that the aspartic residues of 4 individual TRPV5/6 channels bind to 
form a negatively charged selective filter for Ca2+ (39). Furthermore, TRPV5 and 
TRPV6 contain large intracellular amino and carboxyl tails, where channel-
associated proteins can bind regulatory sites to influence channel trafficking and/or 
activity (40-46). 
 
 
 
 
 
 
 
 
 
 
 Figure 4. TRPV5/6 protein structure. (A) TRPV5/6 channels are 6 trans-membrane spanning 
proteins with a Ca2+-selective pore region between segment 5 and 6 (B) Four individual TRPV5/6 
proteins assemble forming heterotetrameric channels with altered pore properties. 
A B
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The generation and characterization of TRPV5 and TRPV6 knockout (KO) mouse 
models further unraveled the central role of these channels in the maintenance of 
Ca2+ balance. Mice lacking functional TRPV6 exhibit a profound 60% reduction in 
dietary Ca2+ absorption. This is accompanied by low bone mineral densities, 
decreased weight gain, urinary Ca2+ wasting and reduced fertility, of which the 
latter might be due to impaired placental Ca2+ transfer (47). In contrast, TRPV5 KO 
mice display a more renal phenotype, illustrated by severe hypercalciuria with a 
six-fold higher urinary Ca2+ excretion compared to wild-type littermates. 
Surprisingly, the TRPV5 KO mice remain normocalcemic since a compensatory 
increase in the active metabolite 1,25(OH)2D3 induces hyperabsorption of dietary 
Ca2+ from the intestine via upregulation of duodenal TRPV6 and calbindin-D9k (48). 
Opposite to the TRPV5/6 KO models, ablation of calbindin-D9k or calbindin-D28k in 
mice does not produce calcemic abnormalities. Calbindin-D9k KO mice are 
indistinguishable from wild-type littermates in phenotype and serum Ca2+ (49, 50). 
Moreover, in TRPV6/calbindin-D9k and TRPV5/calbindin-D28k double KO mice no 
aggravation of the channel-mediated Ca2+ defect was observed due to lack of 
calbindins (49, 51). These data confirm once more the rate-limiting position of 
TRPV5 and TRPV6 in transcellular Ca2+ transport. Accurate regulation of the 
epithelial Ca2+ channels is, therefore, highly important for overall Ca2+ homeostasis.  
 
Regulation of transcellular Ca2+ transport 
 
Regulation by 1,25(OH)2D3  
Vitamin D is generally considered as the most essential controller of the body’s 
Ca2+ balance, with the small intestine as its prime target (22, 31, 52-55). The body 
has two means to acquire this hormone, via dietary ingestion or through ultraviolet 
light-mediated synthesis in the epidermis. Vitamin D is biologically inactive and 
undergoes an enzymatic activation process, involving 25-hydroxylation in the liver 
followed by 1α-hydroxylation via the renal enzyme 25-hydroxyvitamin D3-1α-
hydroxylase (1α-OHase), to synthesize the biologically active 1,25(OH)2D3 (56). 
Whether these enzymes are triggered to produce 1,25(OH)2D3 depends on the 
Ca2+ status of the body. Low serum Ca2+ concentrations stimulate renal 1α-OHase 
activity via PTH release generating more 1,25(OH)2D3, whereas 1,25(OH)2D3 
regulates its own production via a negative feedback loop (57). Binding of 
1,25(OH)2D3 to the vitamin D receptor (VDR), present in the Ca2+ transporting 
epithelia of the intestine, kidney, bone and parathyroid glands, as well as to vitamin 
D responsive elements (VDRE) in the promoter regions of Ca2+ transport proteins, 
provokes 1,25(OH)2D3-mediated responses.  
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Numerous observations reflect the hormone’s key role in transcellular dietary 
Ca2+ absorption. Studies using confluent monolayers of the human-derived colon 
cancer cell line Caco-2, showed a robust time- and dose-dependent stimulation of 
transepithelial Ca2+ transport after 1,25(OH)2D3 treatment (58, 59). Wood et al. 
reported an early induction of TRPV6 mRNA by 4 and 8 hours following 
1,25(OH)2D3 treatment of Caco-2 cells, whereas calbindin-D9k mRNA increased 
above control levels 24 hours after exposure (31). At this time point the maximal 
TRPV6 and calbindin-D9k mRNA upregulation is 10-fold and 4-fold, respectively (20, 
30, 31). In addition, Ca2+ extrusion at the basolateral membrane was enhanced 
with a concomitant increase of PMCA1b gene expression in response to 
1,25(OH)2D3 (21, 60). Micro-array analysis using intestinal mRNA from 
1,25(OH)2D3-deficient rats showed upregulation of TRPV6, calbindin-D9k and 
PMCA1b after injection with 1,25(OH)2D3 (61). Likewise, studies in renal epithelial 
cells demonstrated 1,25(OH)2D3-induced gene transcription of the renal Ca2+ 
transporters (1). The identification of VDREs in the putative human and murine 
TRPV6, TRPV5 and calbindin-D9k promoter regions further strengthens these 
findings (27, 29, 52, 62-64).  
Additional in vivo evidence is gathered using different 1,25(OH)2D3-deficiency 
models, including VDR KO and 1α-OHase KO mice. These mouse strains display 
hypocalcaemia with a severe decrease in dietary Ca2+ absorption, correlating with 
diminished intestinal TRPV6, calbindin-D9k and PMCA1b mRNA levels. 
Furthermore, increased urinary Ca2+ wasting in combination with a marked 
downregulation of renal TRPV5, calbindin-D28k and NCX1 indicates the influence of 
1,25(OH)2D3 on renal transcellular Ca2+ reabsorption (52, 65, 66). Normalization of 
serum Ca2+ concentration by 1,25(OH)2D3 supplementation was associated with a 
restoration in the expression levels of intestinal and renal Ca2+ transporters (52, 67). 
Nevertheless, 1,25(OH)2D3 elicits its strongest effect on dietary Ca2+ uptake as 
demonstrated by highly induced intestinal Ca2+ transport in 1α-OHase KO, VDR 
KO and wild-type mice (68). Mutations in the human genes encoding 1α-OHase 
and the VDR are related to hypocalcaemia and pseudovitamin D-dependent rickets 
(69, 70). Taken together, 1,25(OH)2D3 controls transcellular Ca2+ (re)absorption via 
a genomic pathway involving altered gene transcription of transcellular Ca2+ 
transporters.   
      
Regulation by PTH 
When extracellular Ca2+ levels drop, chief cells in the parathyroid gland release 
PTH in the circulation where it primarily acts on bone and kidney through activation 
of the PTH/PTHrP receptor. The effect of PTH on intestinal Ca2+ absorption has 
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long been described as exclusively secondary due to increased 1α-hydroxylase 
activity and a subsequent induction of 1,25(OH)2D3 formation. However, studies in 
isolated rat and chick intestinal cells as well as perfusion studies in chick 
duodenum show a rapid stimulatory effect of PTH on Ca2+ transport within minutes 
after treatment, suggesting a direct pathway independent of 1,25(OH)2D3 (71-73). 
The identification of PTH/PTHrP receptor mRNA transcripts and immunoreactive 
protein in the villus and crypt epithelium, interstitial cells, and the surrounding 
smooth muscle layer of the rat intestine, further supports these results (74, 75). 
The described pathway involves binding of PTH to the intestinal PTH/PTHrP 
receptor causing a rapid modulation of intracellular signal transduction pathways, 
mainly by activation of adenylyl cyclase and the increase of 3’,5’-cyclic 
monophosphate (cAMP). These specific PTH-mediated cellular changes are 
convincingly confirmed using the adenylyl cyclase activator forskolin, or cAMP 
agonists/blockers (73, 76). Increased intracellular cAMP levels stimulate 
transcellular Ca2+ transport. Finally, the evidence that PTH potentiates calbindin 
synthesis in the presence of 1,25(OH)2D3, and that it increases proliferation of 
intestinal cells, demonstrates the occurrence of long-term effects (77, 78).  
In the kidney, PTH directly increases tubular Ca2+ reabsorption in the distal part 
of the nephron where PTH/PTHrP receptor mRNA has been localized to glomerular 
podocytes, PT, TAL and DCT, whilst no detection was found in the thin ascending 
loop of Henle or in the collecting duct (CD) (79, 80, 81). This function of PTH in the 
kidney has been underlined in parathyroidectomized rats, which develop 
hypocalcaemia due to a renal phenotype, comprising diminished Ca2+ reabsorption 
and a concomitant downregulation of TRPV5, calbindin-D28k and NCX1 proteins 
(82). Full recovery of serum Ca2+ levels was accomplished via PTH 
supplementation, which restored the expression of renal Ca2+ transporters 
independent of serum 1,25(OH)2D3 (82). Furthermore, blocking TRPV5 channel 
activity in polarized monolayers of rabbit renal CNT and cortical collecting duct 
(CCD) cells eliminated PTH-stimulated transepithelial Ca2+ transport and 
simultaneously decreased calbindin-D28k and NCX1 expression, whereas TRPV5 
mRNA abundance remained unaffected (82). In bone, PTH induces the rapid 
release of Ca2+ from the bone matrix, but it also mediates long-term changes in 
Ca2+ turnover by acting directly on the bone-forming osteoblasts and indirectly on 
bone-resorbing osteoclasts by increasing their number and activity (83).  
 
Regulation by calcitonin 
Calcitonin is a hormone produced in the thyroid gland and acts to reduce blood 
Ca2+ in case of hypercalcaemia, opposing the effects of PTH (84). It inhibits the 
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bone resorbing activity of osteoclasts, thereby decreasing the Ca2+ efflux from 
bone and eventually promoting Ca2+ accumulation in the skeleton (85-87). This 
feature makes calcitonin highly suitable in clinic for the treatment of bone disorders, 
such as osteoporosis. The effect of calcitonin on the intestine (and kidney) seems 
exclusively secondary via the enhancement of renal 1α-OHase gene expression 
and subsequent stimulation of 1,25(OH)2D3 production, consequently inducing 
intestinal (and renal) transcellular Ca2+ transport (88, 89). However, calcitonin is a 
less potent regulator of the transcellular Ca2+ transporters than the aforementioned 
1,25(OH)2D3 and PTH.   
 
Regulation by estrogens 
Estrogen deficiency in postmenopausal women is known to cause a negative Ca2+ 
balance associated with reduced bone mineral densities (90, 91). The concomitant 
high serum and urinary Ca2+ level is generally recognized as a secondary response 
due to enhanced bone resorption (92). However, some studies demonstrated that 
estrogen deficiency after menopause can also be linked to increased urinary Ca2+ 
loss and intestinal Ca2+ malabsorption, which can be corrected by estrogen 
replacement therapy (93-97). On the intestinal level, Ca2+ absorption is estrogen-
stimulated in several studies (96, 98, 99). Two different isoforms of the estrogen 
receptor (ER) are present in mouse and human intestine, namely ERα and ERβ 
(100, 101). Immunohistochemical localization identified ERα in certain submucosal 
interstitial cells and nerve cells of the Auerbach and Meissner plexuses, while ERβ 
is exclusively expressed in the latter cells. Furthermore, estrogen administration in 
ovariectomized mice resulted in an increase of ERα positive cells (100). The 
generation of KO mice verifies a 55% reduction of intestinal TRPV6 mRNA 
expression in ERα KO strains, while calbindin-D9k and PMCA1b are unaffected. No 
changes in Ca2+ transporter abundance are observed in the gut of ERβ KO mice, 
indicating that estrogen-induced alterations in Ca2+ absorption are solely mediated 
via ERα (102). Ovariectomy does not affect intestinal Ca2+ transporter expression 
in VDR KO, 1αOHase KO and wild-type mice (102, 103). However, subsequent 
estrogen injections induced a significant upregulation of intestinal TRPV6 mRNA, 
suggesting a 1,25(OH)2D3-independent pathway (102, 103). A simultaneous rise of 
duodenal calbindin-D9k and PMCA1b mRNA is only illustrated in an ovariectomized 
rat model on estrogen replacement therapy (104). Pregnancy and lactation 
markedly upregulate all the intestinal Ca2+ transporters according to variations in 
the hormonal cycle of female mice (102). Strikingly, estrogen-like dietary 
components (phytoestrogens) which compete with endogenous estrogen for the 
ER, did not accomplish an increase in intestinal Ca2+ absorption (105).   
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Also in the kidney estrogen has an effect on the expression of the Ca2+ 
transporters, e.g. in ovariectomized rats renal mRNA levels of TRPV5, calbindin-
D28k, NCX1 and PMCA1b increased after 17β-estradiol treatment at 
pharmacological doses (103). Furthermore, 17β-estradiol supplementation in 
ovariectomized 1α-OHase KO mice restored renal TRPV5 expression and 
normalized serum Ca2+ independent of 1,25(OH)2D3 (103, 104). Van Cromphout et 
al. confirmed these findings in ERα KO mice, showing reduced renal TRPV5 
expression (102). Interestingly, an estrogen-responsive element was identified in 
the promoter region of TRPV6, but not in TRPV5 (27). In conclusion, TRPV5 and 
TRPV6 transcription is controlled by estrogen in a 1,25(OH)2D3-independent 
manner.  
 
Regulation by dietary Ca2+ 
Transcellular Ca2+ transport is not only regulated at the hormonal level, but also via 
alterations in dietary Ca2+ content. Because the diet is the only source of Ca2+ for 
the body, clinicians already advise the consumption of Ca2+ rich products for many 
years and, in combination with 1,25(OH)2D3 supplementation, this proofs to be a 
powerful tool in preventing hypocalcaemia and bone related diseases, such as 
osteoporosis. Several studies show the influence of dietary Ca2+ on the process of 
intestinal Ca2+ absorption. Low dietary Ca2+ provokes enhanced intestinal Ca2+ 
transport via increased renal 1,25(OH)2D3 production (10, 60, 106), (107). This 
adaptation entails a compensatory mechanism in order to cover the Ca2+ needs of 
the body. To study primary effects on transcellular Ca2+ transport it is important to 
distinguish regulation via dietary Ca2+ and 1,25(OH)2D3. Therefore, the most 
valuable data are gathered using 1α-OHase and VDR KO mice on high Ca2+ diets. 
The impaired expression level of duodenal TRPV6, calbindin-D9k and PMCA1b in 
these models is completely restored after feeding the mice a Ca2+ enriched diet for 
several weeks. Likewise, the renal Ca2+ transporters are upregulated. Overall, 
feeding VDR and 1α-OHase KO mice a rescuing Ca2+ diet results in normalization 
of serum Ca2+ concentration and total abolishment of the severe bone phenotype 
(27, 66, 68). These findings strongly point towards a 1,25(OH)2D3-independent 
stimulatory effect of dietary Ca2+ on Ca2+ transporter abundance, most likely via a 
genetic pathway. Several Ca2+-responsive elements have been proposed to 
function as Ca2+-sensitive regulators including the serum responsive element and 
the cAMP/Ca2+-responsive element (108). To date, information about the presence 
of these elements in the promoter region of the Ca2+ transport genes is lacking.   
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Paracellular Ca2+ absorption via tight junctions 
 
The net amount of paracellular Ca2+ absorption is a function of Ca2+ and 
electrochemical gradients across the epithelium, the sojourn time of Ca2+ in a 
luminal segment and the permeability of the TJ. These latter complexes are located 
in the apical region of the lateral cell membrane and fully reside in the intercellular 
space (Fig. 5) (109). In more detail, the TJ comprises large strands of trans-
membrane proteins that adhere to similar protein strands located at the cell 
membrane of neighboring cells (110). This construction spans the paracellular 
space to limit free passage of solutes and, hence, provides a selective barrier 
between the apical and basolateral compartment, which preserves two important 
functions. First, it restricts the diffusion of membrane proteins and lipids, which is 
crucial for the maintenance of epithelial cell polarity. Secondly, the TJ regulates the 
passage of water, ions and various macromolecules via the paracellular route. In 
this way, the TJ defines the barrier tightness of epithelia. This barrier tightness can 
be measured via its transepithelial electrical resistance (TEER).  
For a long time the idea existed that paracellular Ca2+ fluxes are mainly 
concentration-dependent and not specifically regulated, like transcellular Ca2+ 
transport. This assumption changed when a study in Caco-2 cells demonstrated a 
dose-dependent 1,25(OH)2D3-mediated rise in TEER, accompanied by a significant 
increase in paracellular Ca2+ transport. The outcome suggests a genomic pathway 
of 1,25(OH)2D3 affecting the assembly and permeability of TJ complexes  (111). 
Furthermore, a mutation in a subunit of the renal TJ protein complex caused 
impaired paracellular Mg2+ reabsorption in humans, ultimately resulting in severe 
urinary Mg2+ wasting and hypomagnesaemia (112). Other studies hypothesize that 
the specific binding of trans-membrane proteins in the TJ creates pore-like 
structures showing size and charge selectivity (113). These findings imply an 
important role of TJs in the regulation of paracellular Ca2+ transport.  
To clarify the mechanism of cation-selective properties, a lot of progress has 
been made to further unravel the TJ structure. The key element consists of an 
extensive network of strands formed by associated trans-membrane proteins. Until 
now, four families of trans-membrane proteins have been identified in the TJ, 
including occludins (114), claudins (115), junctional adhesion molecules (116) and 
tricellulin (117). Occludins were the first integral trans-membrane proteins 
recognized to be exclusively located in the TJ. However, investigation of occludin-
deficient cell and mouse models demonstrated well-developed TJs, which indicates 
that occludins are not essential for TJ formation and barrier function (118). On the 
contrary, the identification of the large claudin family initiated a rapid progress in 
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our understanding of TJs (115, 119). It was already known that barrier strength 
varies among different epithelia. This can be partly explained by the number of 
sealing strands that correlates with epithelial tightness. However, new insights are 
pointing towards a more crucial role for claudins in determining barrier properties 
and cation selectivity.  
 
Molecular and physiological understanding of claudin proteins 
 
Claudins belong to a large family of 22-27 kDa integral membrane proteins that 
have four trans-membrane domains, one small intracellular loop, two extracellular 
loops (ECL) and N- and C-terminal cytoplasmic domains (120, 121) (Fig. 5). The 
first extracellular loop constitutes the ‘WWCC’ amino acid motif, which is highly 
conserved among members of the claudin family. In humans, over 20 different 
claudin isoforms are reported, which all show independent features and have 
highly specific expression patterns along tissues. In murine kidney and intestine 
extensive expression profiling studies have mapped the localization of individual 
claudins (122-124). In the mouse GI-tract, 8 claudin isoforms are abundantly 
present (claudin-2,-3,-4,-7,-8,-12,-14,-15), whereas others show minor expression 
(claudin-1,-5,-9,-10,-11,-18) or are undetectable (claudin-6,-13,-16,-17,-19). 
Furthermore, some isoforms demonstrate strong expression gradients throughout 
the length of the GI tract or are only located at specific sites, like claudin-18 in the 
stomach. Importantly, claudin isoforms are able to bind most other isoforms in the 
TJ complex (125, 126). Consequently, each strand contains a unique claudin 
composition, which determines the tightness of individual TJ strands and explains 
the diversified barrier properties between epithelia (120).  
Recent studies regarding claudin assembly have provided indications that the 
first extracellular loop (ECL1) of four individual claudins create the cation-selective 
pore structure (113) (Fig. 5). Such model is supported in vivo in the kidney with the 
discovery of a mutation in the ECL1 of claudin-16, resulting in familial 
hypomagnesaemia with hypercalciuria and nephrocalcinosis, an autosomal 
recessive disorder of renal Mg2+ and Ca2+ handling (112). In these patients there is 
a selective defect in paracellular Mg2+ and Ca2+ reabsorption in the TAL resulting in 
severe urinary Mg2+ and Ca2+ loss. Most likely, this impairment originates in the 
exchange of negative into neutral charged amino acids in ECL1, which creates a 
more cation-resistant pore. Mutations located in the ECL2 and C-terminus of 
claudin-16 result in hereditary hypomagnesaemia as well (127, 128). In addition, a 
recent study associated a mutation in the ECL1 of claudin-19 with 
hypomagnesaemia and renal Mg2+ wasting (129).  
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Figure 5. Tight junction structure with claudin proteins as building blocks. (A) TJs are 
localized near the apical region of the intercellular space, comprising numerous large strands of 
trans-membrane proteins, of which claudins (B) are the most important components. These 
strands adhere to trans-membrane chains localized at neighboring cells, thereby spanning the 
intercellular space to regulate epithelial barrier tightness and paracellular transport via the 
formation of pore-like structures with ion and size selectivity (C). The claudins strands are 
connected to cytosolic proteins, which provide a regulatory pathway for TJ assembly and 
permeability. Figure modified after Van Itallie et al. (2004) by Aron Kos. 
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The confirmation that claudins influence charge selectivity and change 
individual ion permeability provides strong indications that also other claudin 
isoforms might influence paracellular Ca2+ fluxes in renal and intestinal epithelia. 
However, the large number of claudin isoforms together with the variety in claudin 
arrangement makes it both challenging and difficult to discover which individual 
claudins are involved in epithelial Ca2+ permeability and related Ca2+ transport.  
 
Regulation of paracellular Ca2+ absorption 
 
Paracellular Ca2+ transport is mainly driven by the difference in Ca2+ concentration 
across epithelia, which implies that high Ca2+ concentrations in the intestinal lumen 
and renal tubular system results in enhanced paracellular (re)absorption. However, 
with the recognition of the important role claudins play in TJ barrier function, more 
research is focussed on specific regulation of these trans-membrane proteins. 
Claudins located at the cell surface are associated with cytosolic scaffolding 
proteins including zona occludens (ZO) proteins -1, -2 and -3 and the multiple-PDZ 
domain protein 1 (MUPP-1), via their C-terminal PDZ binding motif (130, 131). 
These homologues are coupled to the actin cytoskeleton, which provides a 
regulatory signal transduction towards and from the TJ (Fig 5). Such protein-
protein interactions play a role in TJ regulation since ZO-1 and ZO-2 have shown to 
be essential for TJ protein assembly and the arrangement of the trans-membrane 
strands (132). The regulation of claudin expression and related TJ function is 
strongly investigated and the information about regulatory compounds is emerging 
(121). Snail is the best characterized of several transcription factors that bind 
directly to claudin promoters and/or influence claudin gene expression. 
Overexpression of snail in various epithelial cell lines downregulates the 
abundance of numerous claudin isoforms (133-135). Also the role of inflammatory 
cytokines like interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α) and interleukins 
(ILs) in TJ barrier function has been thoroughly investigated. Several lines of 
evidence, obtained in Caco-2 cell models and using duodenal biopsy material from 
inflammatory bowel disease (IBD) patients, point towards a cytokine-induced 
downregulation of claudin, occludin and ZO-1 abundance, concomitantly reducing 
TEER (136-139). By contrast, IL-10, IL-17 and transforming growth factor-β 
increase TEER of intestinal cell layers (140-142). Furthermore, there are 
indications that claudin abundance is influenced at the hormonal level. In renal 
epithelial cells epidermal growth factor reduces claudin-2 and increases claudin-1, -
3 and -4 expression, consequently decreasing epithelial permeability (143). 
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Interestingly, like in active transcellular Ca2+ transport, 1,25(OH)2D3 is also thought 
to alter TJ structure via changes in claudin transcription. In VDR KO mice claudin-2 
and -12 are downregulated in jejunal and colonic tissue (144). Moreover, a study 
by Efrati et al. showed that 1,25(OH)2D3 modulates renal paracellular Mg2+ 
transport via binding to the claudin-16 promoter and influencing its transcription 
(145). Finally, manifold phosphorylations in the claudin cytoplasmic C-terminal 
domain catalyzed by proteins such as PKA, PKC, With-No-Kinase 4 (WNK4) and 
Mitogen-activated protein kinase (MAPK), can initiate short-term regulation via 
post-translational modifications (146-150). Currently, it is unknown if these 
regulatory pathways play an actual role in paracellular Ca2+ transport.  
 
Clinical manifestations of a dysregulated Ca2+ balance  
 
In clinic, numerous diseases of different origin are accompanied with disturbances 
in Ca2+ homeostasis. The role of transcellular and paracellular Ca2+ transport has 
been considered in many of these Ca2+-related disorders. Research has focused 
on the discovery of mutations in genes encoding transcellular Ca2+ transport and 
TJ proteins, whereas other studies extensively investigated the (hormonal) 
regulation of these proteins during different stages of disease or during the 
treatment with pharmaceutical compounds.  
 
Hypercalciuria / renal defects 
Patients diagnosed with idiopathic hypercalciuria (IH) are characterized by 
normocalcemic serum levels in combination with increased urinary Ca2+ loss of 
unknown underlying cause. The symptoms of this autosomal dominant disorder 
originate either from excessive intestinal Ca2+ absorption or defective renal tubular 
Ca2+ reabsorption. Of more clinical importance is the observation that enhanced 
urinary Ca2+ excretion is a major risk factor for the development of kidney stones. 
This correlation was established by a study of Asplin et al. showing that 40% of 
patients with kidney stone disease can be associated with hypercalciuria (151). 
Various studies aimed to unravel the pathogenesis of IH via identification of 
mutations in Ca2+ homeostasis-related genes. However, a large screening of the 
TRPV5 (152) and TRPV6 encoding genes in a collection of IH patients did not 
observe a genetic link between the disease and TRPV5/6 (Renkema et al. 
unpublished data). Other reports suggest the involvement of a 1,25(OH)2D3-related 
pathway. Clinical studies demonstrate that some VDR polymorphisms correlate to 
IH (153, 154). Additionally, in genetic hypercalciuric stone-forming (GHS) rats, an 
animal model for IH, the amount of VDR protein in the small intestine is increased 
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leading to hyperabsorption of Ca2+ (155, 156). These results suggest that, in part, 
the cause of the GHS phenotype is the VDR itself. Conversely, several patient 
studies excluded mutations in the VDR as well as polymorphisms in the 1α-OHase 
and CaSR genes (157-159). Finally, the recent detection of mutations in renal 
claudin-16 and the consequent impairment in tubular paracellular Ca2+ 
reabsorption (112), justifies the new focus on TJ proteins and related paracellular 
Ca2+ transport.  
 
Hypercalcaemia 
Under normal conditions, Ca2+ overload is removed from the blood compartment 
via renal filtration into the urine and storage in bone. When the body fails to 
dispose excess Ca2+, blood Ca2+ raises, which is referred to as hypercalcaemia. 
This physiological state is very harmful to the body, because it results in the 
deposition of Ca2+ on the vascular walls and is therefore associated with increased 
morbidity and mortality from cardiovascular events (160, 161). Moreover, 
hypercalcaemia is associated with increased formation of renal kidney stones.  
Frequently, hypercalcaemia is related to hyperparathyroidism (HPT), a disorder 
in which the parathyroid gland overproduces the hormone PTH, consequently 
stimulating both Ca2+ release from bone and active Ca2+ (re)absorption via 
enhanced 1,25(OH)2D3 conversion. HPT is primary for example in case of a 
malignancy or due to de-activating mutations in the CaSR (162). Secondary HPT is 
commonly observed during renal failure, when the kidney is unable to produce 
1,25(OH)2D3. Secondary HPT requires treatment with vitamin D3 compounds to 
minimize the detrimental effects on bone and has, therefore, been widely 
implemented in clinic. On the other hand, vitamin D3 supplementation can induce 
hypercalcaemia, increasing the risk of soft tissue and vascular calcification. 
Recently, new advances in VDR agonist development have provided drugs that are 
less calcemic and appear to be a good alternative for 1,25(OH)2D3 treatment in 
secondary HPT (163-165).  
Some studies indicate the involvement of the paracellular route in the etiology of 
Ca2+ disturbances via changes in claudin expression. For example, in a genetic 
disease called Williams-Beuren syndrome, patients have a large deletion within 
chromosome 7 (7q11). This deleted region contains more than 20 genes, including 
claudin-3 and claudin-4. One of the phenotypes of this disease is hypercalcaemia 
related to intestinal Ca2+ hyperabsorption (166). Possibly, the observed Ca2+ 
phenotype is linked to ablation of intestinal claudin-3 and claudin-4.  
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Overall, the results thus far implicate that changes in the hormonal coordination 
of active Ca2+ transport are involved in hypercalcaemia and that modification of 
paracellular Ca2+ fluxes via altered claudin expression could be a potential source. 
 
Osteoporosis 
One of the most frequent and serious side-effects of disturbed Ca2+ homeostasis is 
a reduction in bone mineral density (BMD) and a concomitant decline in bone 
strength, increasing the risk of bone fractures. These symptoms are generally 
termed osteoporosis. Under normal circumstances bone undergoes a constant 
remodeling process characterized by resorption in osteoclasts and bone formation 
in osteoblasts. When bone resorption is dysregulated it can exceed formation, 
ultimately initiating osteoporosis. Besides a primary effect on bone in which the 
number and activity of osteoclasts and osteoblasts is directly affected, for instance 
during drug treatment with glucocorticoids or via inflammatory cytokines, most 
frequently a chronic Ca2+ deficiency underlies the bone problems. When renal and 
intestinal control mechanisms fail to increase the body’s Ca2+ supplies and to 
adjust blood Ca2+, the ultimate pathway is the release of stored Ca2+ from the 
skeleton, for example after long-term ingestion of a low Ca2+ diet.  
However, the source can also be 1,25(OH)2D3-related in case of low UV 
exposure, malabsorption of dietary 1,25(OH)2D3 precursors due to gut disease, or 
when its activation pathway into the active metabolite 1,25(OH)2D3 is aborted. In 
the autosomal recessive disease vitamin D-deficiency rickets, mutations in the 1α-
OHase (type I) and VDR (type II) genes cause hypocalcaemia, rickets, 
osteomalacia and growth retardation (65, 70). In clinical practice, these patients are 
treated with vitamin D analogues and/or an enriched Ca2+ diet to correct the major 
perturbations in Ca2+ homeostasis and to prevent bone demineralization. A similar 
treatment strategy could counteract Ca2+ and bone abnormalities in the previously 
mentioned 1α-OHase and VDR KO mouse models (65, 66). Interestingly, TRPV5 
and TRPV6 KO mice show diminished BMD implicating a role for reduced renal 
and intestinal transcellular (re)absorption processes in the pathogenesis of 
osteoporosis (47, 48). In addition, lack of other calciotropic hormones, such as PTH 
or estrogen in postmenopausal women, correlate with a high incidence of low BMD.  
Furthermore, the use of a wide array of medicines is reported in connection with 
changes in bone mineralization. Immunosuppressants like tacrolimus and 
members of the glucocorticoid family enclosing dexamethasone and prednisolone 
are widely prescribed in numerous inflammatory disorders and after organ 
transplantations. Although each of these drugs is negatively associated with 
increased bone turnover, their molecular pathways leading to osteoporosis differ. A 
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study of Nijenhuis et al. revealed that tacrolimus induces low BMD via down-
regulation of renal TRPV5 and calbindin-D28k expression and a concomitant 
increase in urinary Ca2+ excretion (167). On the contrary, dexamethasone 
treatment in rats enhances renal TRPV5 and calbindin-D28k, excluding active Ca2+ 
transport as a primary source in hypercalciuria. However, this upregulation of 
TRPV5 and calbindin-D28k in the DCT is presumed as a secondary mechanism. 
Possibly, dexamethasone decreases paracellular Ca2+ reabsorption in the more 
proximal tubules. To compensate for the reduced amount of Ca2+ reabsorption in 
the PT, TRPV5 and calbindin-D28k are upregulated to enhance transcellular 
reabsorption in the more distal tubules (167). Finally, a few studies report the 
correlation between Ca2+ malabsorption and decreased intestinal calbindin-D9k 
expression after long-term treatment with the glucocorticoid prednisolone (168-171).  
Among the drugs that increase BMD are thiazides and bisphosphonates. 
Thiazides are particularly used as a first-line therapy in hypertension. In addition, 
they possess the unique feature of increasing renal Ca2+ reabsorption while 
reducing Na+ reabsorption. The consequent hypocalciuria in combination with a 
confirmed increase in BMD provides an effective therapeutic tool in counteracting 
osteoporosis. Similar to dexamethasone, high doses of thiazides have shown to 
decrease renal active Ca2+ transporters probably due to degeneration of DCT cells, 
whereas no changes are observed after thiazide therapy at pharmacological doses. 
Likely, the induced hypovolemia stimulates proximal passive electrolyte 
reabsorption explaining the hypocalciuria (172, 173). Whether variances in TJ 
proteins contribute to the observed changes in paracellular transport has not been 
evaluated to date. Furthermore, bisphosphonates like alendronate are widely used 
to treat osteoporotic symptoms owing to their potent inhibition of osteoclast-
mediated bone resorption. The upregulation of TRPV5 abundance in osteoclasts 
by alendronate treatment in rats (174) further strengthens the postulation that 
TRPV5 is critical in osteoclastic Ca2+ transport processes (35).  
                                                                                                                                                  
Ca2+ malabsorption and linked Ca2+ problems in the inflamed gut 
 
Inflammatory bowel diseases 
Human IBD is a chronic, recurring inflammatory condition of unknown etiology 
affecting the GI tract. The disease is clinically characterized by two overlapping 
phenotypes, Ulcerative colitis (UC) and Crohn’s disease (CD), which predominantly 
involve inflammations in the colon (UC and CD) and/or the terminal ileum (CD). 
The exact pathogenesis of IBD has not been fully elucidated, however, a 
multifactorial cause concerning both genetic and environmental factors is 
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implicated. To date, more evidence points towards a dysregulated mucosal 
immune response to one or more unknown antigens present in the normal bacterial 
flora. Subsequently, an immune reaction is mediated by T cells that produce large 
amounts of pro-inflammatory cytokines. IBD patients are characterized by elevated 
production of the T helper cell type1 (Th1) cytokines IL-2, IFN-γ and TNF-α (175). 
To counteract the inflammatory lesions chronic treatment with glucocorticoids, 
which have potent anti-inflammatory and immunosuppressive properties, is 
frequently prescribed.  
Beside the intestinal phenotype, patients with IBD are also prone to reduced 
BMD. The prevalence of low bone mass in IBD ranges from 31% to 59%. Various 
studies exploring the cause of low BMD in IBD found a significant correlation 
between glucocorticoid treatment and decreased BMD (176, 177). Therefore, it is 
generally accepted that the deleterious effects of glucocorticoids on bone 
metabolism greatly contribute to the risk of osteoporosis. Furthermore, 
glucocorticoids tend to decrease intestinal Ca2+ absorption possibly via diminished 
calbindin-D9k expression (171). However, osteoporosis may develop independent 
of glucocorticoid therapy. The primary disease-related risk factors include high 
circulating levels of pro-inflammatory mediators, which directly affect osteoclast 
and osteoblast activity to promote bone resorption, and the presence of intestinal 
Ca2+ and 1,25(OH)2D3 precursor malabsorption. Typically, a high Ca2+ diet in 
combination with 1,25(OH)2D3 or bisphosphonate treatment is sufficient to either 
maintain or increase BMD. 
The role of transcellular Ca2+ transporters and TJ proteins in IBD-related 
osteoporosis has not been thoroughly studied so far. However, knowledge about 
the possible role of TJ proteins in the pathogenesis of IBD via changes in intestinal 
barrier function is emerging. Analyses of colonic mucosa from patients with UC and 
inflamed mucosa from CD patients revealed a dramatic downregulation in claudin-1 
expression (178) and a reduction or redistribution of claudin-3 and claudin-4 in 
diseased epithelium (138), whilst claudin-2 showed a strong upregulation along 
inflamed colon epithelium from IBD patients compared to normal colon (138). 
Furthermore, a study using genome-wide cDNA micro-arrays showed an increase 
of claudin-3 and claudin-4 as well as a decline of occludin mRNA in intestinal 
biopsies from CD patients. Noteworthy, these results were not found in UC 
samples (179). These changes in TJ proteins are associated with an increased 
epithelial permeability, which affects the barrier function against pathogens and, 
therefore, might play an important role in the pathogenesis of IBD. Increased 
proinflammatory mediators during active IBD is the most plausible explanation for 
the described effects, as cytokines like TNFα, INF-γ and interleukins have shown 
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to affect occludin, ZO-1 and claudin expression in vitro (136). No proof has been 
gathered so far whether these proteins are also directly involved in Ca2+ 
malabsorption and IBD-related osteoporosis. 
 
Coeliac disease 
Coeliac disease is an auto-immune disorder characterized by inflammations in the 
small intestine. In genetically predisposed people an immune reaction is activated 
after the ingestion of dietary gliadin, a gluten protein found in wheat. As a result of 
the inflamed gut, the lining of the intestinal wall is flattened (villous atrophy) and the 
epithelial structure affected, causing disruption of the barrier function and 
malabsorption of nutrients (180). The reduced uptake of nutrients also interferes 
with Ca2+ and 1,25(OH)2D3 precursor absorption, inducing secondary 
hyperparathyroidism that can, on its turn, initiate osteoporosis (181, 182). The 
prevalence of osteoporosis in coeliac disease is 3.4% compared to 0.2% in non-
coeliac disease patients. However, there are only small increases in relative 
fracture risk, indicating that concerns about markedly increased fracture hazard is 
unwarranted, when treated accordingly (183, 184). Adherence to a gluten-free diet, 
which is the only efficient therapy for coeliac disease, reverses the histological 
changes in the intestine as well as the intestinal Ca2+ malabsorption and 
significantly improves BMD (185).   
In coeliac disease, like in IBD, increased presence of inflammatory cytokines is 
thought to cause variations in TJ protein expression and localization. Reduced 
paracellular membrane staining of occludin and phosphorylated ZO-1 protein could 
be detected in duodenal specimens of patients with active coeliac disease 
compared to inactive coeliac disease patients and healthy controls. These findings 
were supported in vitro when Caco-2 cells were treated with TNF-α and INF-γ 
suggesting that in active coeliac disease the absence of phosphorylated ZO-1 
might be responsible for the absence of membranous localization of occludin (137). 
Finally, zonulin, a modulator of small intestinal TJs, is secreted from the small 
intestine upon exposure to enterobacteria, resulting in TJ disassembly. During the 
acute phase of coeliac disease zonulin is overexpressed, accompanied by an 
increase in the intestinal permeability (186, 187).  
Overall, many results point towards alterations in intestinal barrier properties via 
changes in TJ proteins. However, knowledge about the possible involvement of 
active Ca2+ transporters is still lacking.  
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Reduced Ca2+ absorption among the elderly 
 
Probably the largest group of osteoporotic patients is the elderly. Advanced age is 
generally known to be associated with a negative Ca2+ balance and a serious bone 
demineralization. This decrease occurs, at least in part, because of a declination in 
blood 1,25(OH)2D3 levels. In addition, a resistance to the actions of 1,25(OH)2D3 
has been reported to induce Ca2+ malabsorption (26, 188). Possibly, VDRs 
become less sensitive to their agonist with increasing age. Recent data showed 
that in heterozygous VDR KO mice low levels of the VDR produce resistance to 
1,25(OH)2D3-dependent intestinal Ca2+ absorption. This resistance appears to be 
generated by the low translation of calbindin-D9k that is mediated by binding of 
VDR to the ligand (189). Furthermore, aging is associated with an increase in 
serum PTH. The detrimental effect of this hormone on bone turnover certainly 
contributes to the observed loss in bone mineralization (190). Finally, there are 
age-related changes in renal Ca2+ handling that reduce the capacity of the kidney 
to reabsorb Ca2+ when needed (106).  
 
Aim of the thesis 
 
The project enclosing this thesis was designed to identify different missing pieces 
regarding our understanding of Ca2+ homeostasis with the main focus on the 
regulation of intestinal Ca2+ absorption in health and disease. In chapter 2, the 
effect of aging on TRPV5 and TRPV6 protein expression was evaluated regarding 
age-related changes in renal Ca2+ handling and decreased BMD. Special interest 
received the intestinal Ca2+ malabsorption problems as frequently observed in 
patients with IBD, such as Crohn’s disease, Ulcerative colitis and Coeliac disease. 
The effect of prednisolone, a glucocorticoid widely prescribed in IBD, on intestinal 
Ca2+ absorption and concomitant TRPV6 expression is described in chapter 3.  
Because it is difficult to investigate Ca2+ fluctuations and expression of various Ca2+ 
transporters in humans, we characterized the Ca2+ status of a mouse model for 
Crohn’s disease and discussed its use as a proper in vivo model for IBD-related 
Ca2+ problems (chapter 4). Furthermore, in chapter 5, we were able to collect 
unique human biopsies from different segments covering the whole GI tract to, 
subsequently, evaluate the expression pattern of different transcellular Ca2+ 
transporters and the TJ claudin proteins. Such data had been lacking for the 
human situation and provide important insights into the exact localization of 
transcellular and paracellular Ca2+ transport pathways in the GI tract. In addition, 
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we sampled duodenal biopsies from IBD patients and healthy controls to determine 
if there is a correlation between Ca2+ malabsorption during IBD and the expression 
of various Ca2+ transport proteins. Finally, in chapter 6 experiments are described 
regarding intestinal claudin-3 and claudin-4 expression and changes in paracellular 
Ca2+ absorption. First, patients suffering from intestinal Ca2+ hyperabsorption were 
screened for mutations encoding claudin-3 and claudin-4. Secondly, stably 
transfected Caco-2 cells were generated overexpressing claudin-3 and claudin-4. 
In conclusion, we were able to obtain more insight into the effects of ageing and 
glucocorticoid treatment on transcellular Ca2+ transporter expression, we gathered 
information about IBD-related disturbances in Ca2+ homeostasis and acquired 
preliminary information about intestinal claudin expression and Ca2+ permeability. 
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Abstract  
 
Aging is associated with alterations in Ca2+ homeostasis, which predisposes elder 
people to hyperparathyroidism and osteoporosis. Intestinal Ca2+ absorption 
decreases with aging and in particular active transport of Ca2+ by the duodenum. In 
addition, there are age-related changes in renal Ca2+ handling. To examine age-
related changes in expression of the renal and intestinal epithelial Ca2+ channels, 
control (TRPV5+/+) and TRPV5 knockout (TRPV5-/-) mice with the age of 10, 30 
and 52 weeks were studied. Aging of TRPV5+/+ mice resulted in a tendency 
towards increased renal Ca2+ excretion and significantly decreased intestinal Ca2+ 
absorption, which was accompanied by reduced expression of TRPV5 and 
TRPV6, respectively, despite increased serum 1,25(OH)2D3 levels. Similarly, in 
TRPV5-/- mice the existing renal Ca2+ loss was more pronounced in elder animals, 
whereas the compensatory intestinal Ca2+ absorption and TRPV6 expression 
declined with aging. In both mice strains, aging resulted in a resistance to 
1,25(OH)2D3 and diminished renal vitamin D receptor mRNA levels, while serum 
Ca2+ levels remained constant. Furthermore, 52-weeks old TRPV5-/- mice showed 
severe hyperparathyroidism, whereas PTH levels in elder TRPV5+/+ mice remained 
normal. In 52-weeks old TRPV5-/- mice, serum osteocalcin levels were increased in 
accordance with the elevated PTH levels, suggesting an increased bone turnover 
in these mice. In conclusion, down-regulation of TRPV5 and TRPV6 is likely 
involved in the impaired Ca2+ (re)absorption during aging. Moreover, TRPV5-/- mice 
likely develop age-related hyperparathyroidism and osteoporotic characteristics 
prior to TRPV5+/+ mice, demonstrating the importance of the epithelial Ca2+ 
channels in Ca2+ homeostasis. 
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Introduction 
 
Regulation of the Ca2+ absorptive activity of the intestine and kidney is crucial for 
the maintenance of normal extracellular Ca2+ levels. Intestinal Ca2+ absorption and 
renal tubular reabsorption of filtered Ca2+ are modulated on the basis of the body’s 
overall need for Ca2+ gain or loss. Part of the Ca2+ (re)absorption occurs through 
the active transcellular pathway, which can be envisaged as a three-step process. 
In the distal convoluted tubule (DCT) and connecting tubule (CNT) cells of the 
kidney, Ca2+ from the pro-urine enters the epithelial cells via the luminal Ca2+ 
channel TRPV5. Subsequently, Ca2+ is transported across the cell in association 
with the Ca2+-binding protein calbindin-D28k and is finally extruded into the 
bloodstream via the Na+/Ca2+-exchanger (NCX1) and the plasma membrane Ca2+-
ATPase (PMCA1b) in the basolateral membrane. In enterocytes the main proteins 
involved in active Ca2+ absorption are the homologous TRPV6 channel at the 
luminal membrane, calbindin-D9k as Ca2+-binding protein and only PMCA1b at the 
basolateral side. In general, TRPV5 seems to be the major isoform in kidney, 
whereas TRPV6 is ubiquitously expressed with the highest concentrations in the 
prostate, stomach, brain, lung and small intestine (1-4). Moreover, active Ca2+ 
(re)absorption is the primary target for regulation by the calciotropic hormones 
1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the active metabolite of vitamin D3, and 
parathyroid hormone (PTH). Also estrogens can stimulate active Ca2+ 
(re)absorption in both kidney and duodenum (5).  
It is well known that aging is accompanied by alterations in Ca2+ homeostasis, 
which predisposes older patients to certain Ca2+-related disorders, including 
hyperparathyroidism and osteoporosis. For instance, intestinal Ca2+ absorption 
decreases with aging and in particular active transport of Ca2+ by the duodenum 
(6, 7). Furthermore, there are age-related changes in renal Ca2+ handling, like 
reduced renal tubular function and a decline in response of the kidney to PTH 
during aging (8-11). Renal and intestinal calbindins play an important role in active 
Ca2+ transport, and their expression decreases with age in parallel with the age-
related decline in Ca2+ (re)absorption (7, 12, 13). In addition, the capacity of 1,25-
dihydroxyvitamin D3 to stimulate Ca2+ absorption also reduces with age, whereas 
circulating levels of PTH rise in rat and man (14, 15). Moreover, age-related 
increases in PTH levels may play an important role in bone remodeling. Bone loss 
occurs with aging, leading to reduced bone strength and, therefore, of osteoporotic 
fracture risk in the elderly (10, 16, 17). 
Interestingly, TRPV5 knockout (TRPV5-/-) mice display several alterations in 
Ca2+ homeostasis. For instance, they are impaired in active Ca2+ reabsorption, 
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despite enhanced vitamin D levels, causing severe hypercalciuria (18). In contrast 
to the excessive renal Ca2+ wasting, intestinal TRPV6 and calbindin-D9k expression 
and Ca2+ absorption are increased, which could function as a compensatory 
mechanism to maintain a normal serum Ca2+ concentration. Furthermore, TRPV5-/- 
mice exhibited significant disturbances in bone structure, including reduced 
trabecular and cortical bone thickness (18).  These findings suggest an essential 
role for both TRPV5 and TRPV6 in Ca2+ homeostasis. Moreover, dysfunction of 
these channels may contribute to disturbances in Ca2+ homeostasis and have 
implications for age-related changes in Ca2+ metabolism.  
The present study investigated the physiological role of TRPV5 and TRPV6 in 
the aging kidney and intestine. Our results suggest that down regulation of the 
renal and duodenal proteins involved in transcellular Ca2+ transport, including 
TRPV5 and TRPV6, are responsible for the impaired renal Ca2+ reabsorption and 
duodenal Ca2+ absorption in aging. Moreover, TRPV5-/- mice develop age-related 
hyperparathyroidism and osteoporotic characteristics earlier as compared to 
control mice, demonstrating the importance of these epithelial Ca2+ channels in 
Ca2+ homeostasis. 
 
Materials and Methods 
 
Animals 
TRPV5-/- mice were generated and genotyped as described previously (18). 
TRPV5-/- and wild-type mice (TRPV5+/+) were fed standard chow and given water 
ad libitum. Seven to nine littermates of both genotypes of different ages were used. 
At the age of 10, 30 and 52 weeks, mice were placed in metabolic cages 
(Techniplast, Buguggiate, Italy) for 48 hours. Mice were allowed to adapt to these 
cages for 1 day, and then 24-hours urine samples were collected. Mice were 
sacrificed and blood, kidney and duodenum samples were collected. The animal 
ethics board of the Radboud University Nijmegen approved all animal experimental 
procedures. 
 
Analytical procedures 
Serum and urine Ca2+ concentrations were analyzed using a colorimetric assay kit 
as described previously (19). Serum phosphorus levels were measured on a 
Hitachi autoanalyzer (Hitachi Corp., Tokyo, Japan). Serum PTH levels were 
measured using mouse intact PTH ELISA kit (Immunotopics, San Clemente, CA, 
USA). Serum osteocalcin and 1,25(OH)2D3 concentrations were determined by a 
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radioimmunoassay (RIA) (20) and immunoextraction followed by quantitation by 
125I-RIA (IDS, Boldon, UK) (21), respectively.  
 
In vivo 45Ca2+ absorption assay 
Ca2+ absorption was assessed by measuring serum 45Ca2+ at early time points 
after oral gavage. Mice were fasted overnight (12 hours) before the test. Animals 
were hemodynamically stable under anesthesia (urethane, 1.4 mg/g body weight) 
during the experiment. The solution used to measure Ca2+ absorption contained 
0.1 mM CaCl2, 125 mM NaCl, 17 mM Tris, and 1.8 g/l fructose and was enriched 
with 20 µCi 45CaCl2/ml (18 Ci/g; New England Nuclear, Newton, Massachusetts, 
USA). For the oral tests, 15 µl/g body weight of this solution was administrated by 
gavage as described previously (22). Blood samples were obtained at 2, 4, 8 and 
12 minutes after oral gavage and serum (10 µl) was analyzed by liquid scintillation 
counting. The change in the serum Ca2+ concentration (ΔμM) was calculated from 
the 45Ca2+ content of the serum samples and the specific activity of the 
administrated 45Ca2+. 
 
RNA isolation and quantitative PCR  
Total RNA from kidney and duodenal mucosa was isolated using Trizol Reagent 
(Gibco BRL, Life Technologies, Breda, The Netherlands) according to the 
manufacturer’s protocol. Total DNAse-treated RNA (2 μg) was reverse-transcribed 
using Moloney Murine Leukemia Virus Reverse Transcriptase (Gibco BRL) as 
described previously (23). Expression of TRPV5, TRPV6, calbindin-D28k, calbindin-
D9k, NCX1, PMCA1b, and the vitamin D receptor (VDR) as well as mRNA levels of 
the housekeeping gene hypoxanthine-guanine phosphoribosyl transferase 
(HPRT), as an endogenous control, were determined by quantitative real-time PCR 
on an ABI Prism 7700 Sequence Detection System (PE Biosystems, Rotkreuz, 
Switzerland). The following sequences for mouse VDR primers and probe were 
used: forward, 5’-AATGGAGATTGCCGCATCAC-3’; reverse, 5’-TGTCCACGCAG 
CGTTTGA-3’; probe, 5’-AGGACAACCGGCGACACTGCCA-3’. The sequences of 
other target genes used are as described previously (24, 25). 
 
Immunohistochemistry 
Kidney tissue was cut into pieces, placed in 1% (w/v) periodate-lysine-
paraformaldehyde fixative for 2 hours at room temperature, and incubated 
overnight at 4ºC in PBS containing 15% (w/v) sucrose. Subsequently, kidney 
tissue was frozen in liquid nitrogen and 7 μm sections were cut for the staining 
procedure. For detection of TRPV5 abundance, kidney sections were stained with 
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guinea pig anti-TRPV5 antiserum (1:50) (23). To visualize TRPV5, sections were 
stained with goat anti-guinea pig Alexa 488-conjugated anti-IgG (1:300, Sigma). To 
quantify TRPV5 protein expression, digital images of the kidney sections were 
taken with a Zeiss Axioskop microscope (Thornwood, NY, USA) and the integrated 
optical density was measured by computer analysis with the Image-Pro Plus 
version 3.0 software (Media Cybernetics, Silver Spring, MD, USA).  
 
Immunoblotting 
For protein analysis, frozen kidney tissue was homogenized in ice-cold 
solubilization buffer as previously described (26). Total protein fractions (10 μg) 
were separated on 12% (w/v) SDS-PAGE gels and blotted to PDVF-nitrocellulose 
membranes (Immobilon-P, Millipore Corporation, Bedford, MA). Blots were 
incubated with rabbit anti-calbindin-D28k (1:10,000, (27)) or mouse anti-β-actin 
(1:25,000, Sigma) and thereafter with peroxidase-conjugated goat anti-
rabbit/mouse antibody (1:2,000, Sigma). Immunoreactive protein was detected 
using the enhanced chemiluminescence method as described by the manufacturer 
(Amersham, Buckinghamshire, UK). Protein expression was quantified by 
computer-assisted densitometry with the use of the Image-Pro Plus version 3.0 
software (Media Cybernetics). 
 
Statistical analysis 
Values are expressed as means ± SE. Statistical significance of differences 
between groups was determined by ANOVA followed by pair-wise comparisons 
using the method of least significant difference. Differences in means with P<0.05 
were considered statistically significant.  
 
Results 
 
Serum parameters  
No significant differences were observed in body weight between TRPV5-/- and 
TRPV5+/+ mice, except at the age of 52 weeks TRPV5+/+ mice have an increased 
body weight compared to TRPV5-/- mice. With advancing age, body weight 
increased significantly (Table 1). Serum Ca2+ concentrations were slightly elevated 
in TRPV5-/- mice compared to TRPV5+/+ mice, but did not significantly change with 
increasing age in both strains. In addition, serum PTH levels were not different 
between TRPV5-/- and TRPV5+/+ mice, except for a substantial increase in 52-
weeks old TRPV5-/- mice. Levels of serum phosphorus were higher in 30-weeks 
old 
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TRPV5+/+, wild-type mice; TRPV5-/-, homozygous knockout mice. Data are presented as means ± 
SE (n = 7-9). *P<0.05 versus All; ¥ P<0.05 versus TRPV5+/+, 10-weeks old and TRPV5-/-, 10-weeks 
old; †P<0.05 versus TRPV5-/- all ages; ‡P<0.05 versus TRPV5+/+, 30- and 52-weeks old; #P<0.05 
versus TRPV5+/+ all ages; ╫P<0.05 versus TRPV5-/-, 30-weeks old. 
Table 1. Effect of age on serum parameters in TRPV5+/+ and TRPV5-/- mice. 
 10-weeks old 30-weeks old 52-weeks old 
 +/+  -/- +/+  -/- +/+  -/- 
body weight (g) 25.0 ± 1.3 23.2 ± 1.1  27.9 ± 1.5 27.5 ± 1.2  36.0 ± 2.8* 30.5 ± 1.7¥ 
Ca2+ (mM)  2.76 ± 0.02 2.84 ± 0.02#  2.70 ± 0.03† 2.82 ± 0.03  2.71 ± 0.04† 2.79 ± 0.04 
phosphorus (mM) 2.10 ± 0.25 2.25 ± 0.28  2.06 ± 0.27 2.72 ± 0.32* 2.22 ± 0.31 2.26 ± 0.23 
PTH (pg/ml) 7.9 ± 1.4 23.3 ± 3.5  24.1 ± 8.0 23.2 ± 5.6  26.9 ± 5.3 67.1 ± 16.2* 
1,25(OH)2D3 (pM) 121 ± 13* 539 ± 81  295 ± 65† 448 ± 39  433 ± 76 562 ± 50 
osteocalcin (μg/l) 117 ± 4‡ 164 ± 10#, ╫  53 ± 3 105 ± 11‡  51 ± 8 140 ± 12‡, ╫ 
 
 
 
 
 
old TRPV5-/- mice compared to all other groups (Table 1). Circulating levels of 
1,25(OH)2D3 were significantly elevated in TRPV5-/- mice compared to TRPV5+/+ 
mice at 10 weeks of age. Interestingly, in TRPV5+/+ mice, serum 1,25(OH)2D3 
concentrations increased with aging, whereas in TRPV5-/- mice, levels remained 
constantly elevated (Table 1). Serum concentrations of the bone turnover marker, 
osteocalcin, were significantly higher in TRPV5-/- mice compared to TRPV5+/+ mice 
and decreased in both mice strains with age. Moreover, osteocalcin levels rose 
again in 52-weeks old TRPV5-/- mice (Table 1).  
 
Aging results in increased renal Ca2+ excretion and decreased expression of 
Ca2+ transport proteins 
To investigate the effect of aging on renal Ca2+ handling, mice were placed in 
metabolic cages and 24-hours urine samples were collected to determine the 
amount of Ca2+ excretion. Urinary Ca2+ loss in TRPV5-/- mice was significantly 
higher compared to TRPV5+/+ mice. Moreover, Ca2+ excretion increased during 
aging. Likewise, in TRPV5+/+ mice there was a tendency of elevated Ca2+ excretion 
with increasing age (Fig. 1A). Furthermore, the expression of genes encoding the 
Ca2+ transport proteins involved in transcellular Ca2+ reabsorption was examined 
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Figure 1. Effect of aging on renal Ca2+ excretion and mRNA expression levels of genes 
encoding renal Ca2+ transport proteins. (A) Total excretion of Ca2+ in 24-hours urine samples of 
TRPV5+/+ (black) and TRPV5-/- (white) mice 10-, 30- and 52-weeks old (n = 9 mice, 3 mice per 
cage). Using real-time quantitative PCR, renal mRNA expression of TRPV5 (B), TRPV6 (C), 
calbindin-D28k (D), NCX1 (E), and VDR (F) of the different experimental groups were measured 
and presented as a ratio to HPRT expression (N=7-9). Data are presented as means ± SE. 
*P<0.05 versus All; #P<0.05 versus TRPV5+/+; †P<0.05 versus TRPV5-/-; ‡P<0.05 versus 
TRPV5+/+, 10-weeks old. 
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hCa2+ transport proteins invoscellular Ca2+ reabsorption was examined using 
quantitative real-time PCR. In TRPV5+/+ mice a decline in TRPV5 mRNA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
using quantitative real-time PCR. In TRPV5+/+ mice a decline in TRPV5 mRNA 
expression was observed with increasing age (Fig. 1B). In addition, a similar 
reduction in calbindin-D28k expression was detected in TRPV5+/+ mice during aging, 
whereas the expression was significantly decreased in TRPV5-/- mice independent 
of age (Fig. 1D). Expression of the extrusion protein NCX1 was also lower in 
TRPV5-/- mice, but no changes were measured in either TRPV5-/- or TRPV5+/+ mice 
with increasing age (Fig. 1E). No differences in TRPV6 mRNA expression were 
observed between TRPV5-/- and TRPV5+/+ or with aging, except for a remarkable 
upregulation in 52-weeks old TRPV5-/- mice (Fig. 1C).  Furthermore, VDR mRNA 
levels were significantly lower in TRPV5-/- mice compared to TRPV5+/+ mice. 
During aging, expression of VDR was decreased in both groups of mice (Fig. 1F).  
Subsequently, examination of renal Ca2+ transport protein expression by 
immunohistochemistry revealed a marked decrease of TRPV5 protein abundance 
with increasing age, as indicated by the reduced immunopositive staining (Fig. 
2A). The corresponding integrated optical density analysis confirmed a significant 
decline in TRPV5 protein abundance (Fig. 2B). Furthermore, Western blot analysis 
*
C
a2
+
ex
cr
et
io
n 
   
   
   
   
   
(μ
m
ol
/2
4 
h/
m
ic
e)
0
20
40
60
80
100
10 30 52
A
#
#
TR
PV
6 
m
R
N
A
   
   
   
   
   
 
(r
at
io
 H
PR
T)
0.01
0.02
0.03
10 30 52
C
*
N
C
X1
 m
R
N
A
   
   
   
   
  
(r
at
io
 H
PR
T)
0
0.02
0.04
0.06
10 30 52
E
† † †
0
weeks weeks weeks
C
a2
+
ex
cr
et
io
n 
   
   
   
   
   
(μ
m
ol
/2
4 
h/
m
ic
e)
TR
PV
6 
m
R
N
A
   
   
   
   
   
 
(r
at
io
 H
PR
T)
N
C
X1
 m
R
N
A
   
   
   
   
  
(r
at
io
 H
PR
T)
Age-dependent alterations in Ca2+ homeostasis 
 53 
 
10
52
30
+/+ -/-
10
52
30
Calbindin-D28k
β-Actin
C
TR
PV
5 
   
   
   
   
ab
un
da
nc
e 
(%
)
0
40
80
120
10 30 52
B
*
C
al
bi
nd
in
-D
28
k
ab
un
da
nc
e 
(%
)
0
40
80
120
10 30 52
D
*
†
†
A
3010 52
weeks
weeks
TR
PV
5 
   
   
   
   
ab
un
da
nc
e 
(%
)
C
al
bi
nd
in
-D
28
k
ab
un
da
nc
e 
(%
)
of calbindin-D28k demonstrated decreased protein abundance in TRPV5-/- mice 
compared to the TRPV5+/+ mice. In addition, a down-regulation of the calbindin-
D28k abundance in 52-weeks old TRPV5+/+ mice was observed compared to 
younger wild-type animals (Fig. 2C). Densitometrical analysis of the intensity of the 
immunocomplexes confirmed this decrease in calbindin-D28k protein expression 
with age in TRPV5+/+ mice (Fig. 2D). The corresponding β-actin bands did not vary 
significantly in density, which precludes unequal loading as an explanation for the 
differences.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aging results in reduced Ca2+ absorption and duodenal expression of Ca2+ 
transport proteins 
Following renal analysis, the effect of aging on intestinal Ca2+ absorption was 
examined. Although the 45Ca2+ absorption rate in TRPV5-/- mice was significantly 
higher compared to TRPV5+/+ littermates (Fig. 3A), aging reduced the amount of 
Figure 2. Effect of aging on protein expression levels of TRPV5 and calbindin-D28K in 
kidney. Immunofluorescence staining of kidney cortex sections of TRPV5+/+ mice of different 
ages showing the abundance of TRPV5 (A), which was quantified by computer analysis of the 
integrated optical density and expressed in relative percentages (B). Immunoblots of samples (10 
μg protein each) from homogenates of kidney tissue were labeled with antibodies against 
calbindin-D28k and β-actin (C). Abundance of calbindin-D28k protein was quantified in TRPV5+/+ 
(black) and TRPV5-/- (white) mice by computer-assisted densitometry analysis and expressed in 
relative percentages (D). Data are presented as means ± SE (N=7-9). *P<0.05 versus All; 
†P<0.05 versus TRPV5-/-. 
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45Ca2+ absorbed in both mice strains as shown by the peak 45Ca2+ absorption 
values at 4 minutes after oral gavage of mice from different ages (Fig. 3B). To 
address the molecular mechanism responsible for the decreased absorption, the 
expression of genes encoding proteins involved in intestinal Ca2+ absorption was 
examined. The expression of TRPV6 and calbindin-D9k mRNA was significantly 
upregulated in TRPV5-/- mice (Fig. 3C, D). Moreover, aging resulted in a decline of 
TRPV6 levels in both mice strains (Fig. 3C), whereas no changes were observed 
in the expression of calbindin-D9k (Fig. 3D). PMCA1b mRNA levels decreased with 
age in TRPV5+/+ mice, whereas no significant changes were present in the 
expression of PMCA1b in TRPV5-/- mice with increasing age (Fig. 3E). In addition, 
no significant changes in the expression of duodenal VDR were observed during 
aging in TRPV5+/+ or TRPV5-/- mice (Fig. 3F). Finally, aging did not affect the 
expression of the housekeeping gene HPRT in both kidney and duodenum (data 
not shown). 
 
 
 
 
 
 
 
Figure 3. Effect of aging on intestinal Ca2+ absorption and mRNA expression levels of 
genes encoding duodenal Ca2+ transport proteins. (A) Changes in serum Ca2+ within 12 
minutes after 45Ca2+ administration by oral gavage in TRPV5+/+ (■) and TRPV5-/- (▲) mice 10-
weeks old. ΔμM is obtained by the equation: (cpm 10 µl serum/cpm 10 µl stock solution) × 102 
μM. (B) Comparison of the change in serum Ca2+ (ΔμM) at 4 minutes after 45Ca2+ administration 
between TRPV5+/+ (black) and TRPV5-/- (white) mice 10-, 30- and 52-wks old. Using real-time 
quantitative PCR, duodenal mRNA expression of TRPV6 (C), calbindin-D9k (D), PMCA1b (E), and 
VDR (F) of the different groups were measured and presented as a ratio to HPRT. Data are 
presented as means ± SE (N=7-9). *P<0.05 vs. all; #P<0.05 vs. TRPV5+/+; †P<0.05 vs. TRPV5+/+, 
30-wks old; ‡P<0.05 vs. TRPV5+/+, 52-wks old; ╫P<0.05 vs. TRPV5-/-, 10- and 30- wks old. 
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Discussion 
 
The present study demonstrated that an age-related decrease in the expression of 
the key players responsible for active Ca2+ transport, including TRPV5 and TRPV6, 
contributes to the decline in intestinal and renal Ca2+ (re)absorption with aging. 
Furthermore, our results indicated that mice lacking TRPV5 develop severe 
hyperparathyroidism with aging, suggesting that these mice are more susceptible 
to age-related osteoporosis.   
A significant increase in the rate of Ca2+ absorption was observed in TRPV5-/- 
mice compared to their wild-type littermates, which was accompanied by an 
upregulation of duodenal TRPV6 and calbindin-D9k expression. Importantly, 
despite the renal Ca2+ wasting in TRPV5-/- mice, serum Ca2+ levels remained 
normal and were even slightly increased compared to TRPV5+/+ mice. As 
suggested previously, the increased duodenal expression of TRPV6 and calbindin-
D9k, thereby increasing Ca2+ absorption, could act as a compensatory mechanism 
triggered by the elevated 1,25(OH)2D3 levels in TRPV5-/- mice (18). This was 
confirmed recently in a study by Renkema et al. demonstrating that the 
compensatory upregulation of intestinal Ca2+ transporters and Ca2+ 
hyperabsorption were abolished in TRPV5/25-hydroxyvitamin-D3-1α-hydroxylase 
double knockout mice, which have undetectable serum 1,25(OH)2D3 levels (28). 
The slightly elevated serum Ca2+ levels in these knockout mice could be due to an 
overcompensation by 1,25(OH)2D3 and intestinal Ca2+ absorption to correct renal 
Ca2+ loss (29, 30). Moreover, aging was associated with a decline in duodenal 
Ca2+ absorption in both mice strains. In addition, the expression of duodenal 
TRPV6 in TRPV5-/- and TRPV5+/+ mice as well as PMCA1b in TRPV5+/+ mice was 
significantly reduced with age. Previous studies in rats and humans also showed a 
reduction in intestinal Ca2+ absorption as well as a decline in the expression of the 
Ca2+ transporting proteins (31-33). Our results imply that TRPV6 is crucial for 
duodenal Ca2+ absorption and that the decline in expression of this protein is the 
main cause of the decrease in duodenal Ca2+ absorption with aging. 
In kidney of TRPV5+/+ mice, expression of TRPV5 and calbindin-D28k mRNA 
decreased during aging. Previous studies demonstrated a reduction in renal 
calbindin-D28k expression with increasing age (12, 13). Decreased expression of 
TRPV5 and calbindin-D28k could lead to a reduced Ca2+ reabsorption ability 
resulting in hypercalciuria, as shown in the TRPV5-/- mice and described previously 
(18, 34). These results suggest that TRPV5 is a key component in renal Ca2+ 
reabsorption. In accordance with the decreased expression of TRPV5, a tendency 
towards increased urinary Ca2+ excretion was observed in the aging TRPV5+/+ 
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mice. Although the hypercalciuria is even more pronounced in elder TRPV5-/- mice, 
no further decline in the expression of the Ca2+ transporting proteins is observed 
with increasing age. Interestingly, TRPV6 expression was increased in the 1-year 
old TRPV5-/- mice. TRPV6 is present in DCT and CNT as well as other tubular 
segments (35). However, the presence of TRPV6 does not rescue the renal Ca2+ 
loss in TRPV5-/- mice (18) and, therefore, its role in active Ca2+ reabsorption is 
questionable. Future investigations should unravel the role of TRPV6 in the various 
renal tubules and the possible involvement during aging. 
Aging in TRPV5+/+ mice was accompanied by increasing serum 1,25(OH)2D3 
levels, while no differences were observed in aging TRPV5-/- mice. This latter 
finding could be explained by the fact that 1,25(OH)2D3 in these knockout mice is 
already maximally elevated. 1,25(OH)2D3 is a known stimulator of intestinal and 
renal Ca2+ (re)absorption and upregulates the expression of proteins involved in 
active Ca2+ transport, including TRPV5 and TRPV6 (25, 36, 37). Therefore, the 
decline in the expression of the Ca2+ transporting proteins shown in our study 
suggests that there is a decrease in 1,25(OH)2D3 sensitivity. Indeed, VDR mRNA 
levels in kidney of both TRPV5+/+ and TRPV5-/- mice gradually decrease with age, 
suggesting that the kidney develops a refractoriness to 1,25(OH)2D3 levels. 
Evidently, Li et al. showed that VDR knockout mice have impaired Ca2+ 
conservation capability in the kidney, despite increased serum 1,25(OH)2D3 levels 
(22). Furthermore, intestinal Ca2+ absorption as well as expression of duodenal 
TRPV6 is decreased in VDR knockout mice (22). However, no significant 
differences were found in duodenal VDR mRNA levels during aging in both 
TRPV5+/+ and TRPV5-/- mice. Although several reports described a decrease in 
intestinal VDR expression (38, 39), other studies showed that receptor occupancy 
was reduced in elder rats (40). Our findings indicate an age-related intestinal 
resistance to the action of 1,25(OH)2D3, which is apparently not due to a reduction 
in duodenal VDR mRNA levels, thereby resulting in the decline of TRPV6 
expression and Ca2+ absorption with aging.  
Interestingly, aging of TRPV5+/+ was not associated with a change in serum 
PTH levels, whereas 52-weeks old TRPV5-/- mice show severe 
hyperparathyroidism. Interestingly, serum phosphorus levels were elevated in 30-
weeks old TRPV5-/-. Hyperphosphatemia leads to parathyroid cell proliferation 
(41), which could result in the observed hyperparathyroidism in 52-weeks old 
TRPV5-/- mice, thereby reducing the serum phosphorus levels back to normal. 
Furthermore, PTH is, in addition to 1,25(OH)2D3, involved in renal and intestinal 
Ca2+ reabsorption (42-44). Recent findings by our group show that PTH stimulates 
the expression of renal TRPV5, calbindin-D28k and NCX1 (34). Although serum 
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PTH levels remained constant or increased, renal Ca2+ reabsorption and intestinal 
Ca2+ absorption declined with age. This would be compatible with a mechanism of 
desensitization as has been described in previous reports, which demonstrated the 
blunting of PTH-mediated signal transduction pathways as well as loss of renal 
and intestinal PTH receptors (45-48). Moreover, the elevated PTH levels in elder 
TRPV5-/- mice have also been found in humans and may play an important role in 
age-related bone loss or senile osteoporosis (10, 16, 49). Indeed, the relatively 
constant levels of serum Ca2+ and the decline in renal and intestinal Ca2+ 
(re)absorption in aged animals observed in the present study, may suggest that 
bone resorption increases with aging. Osteocalcin levels in TRPV5-/- mice are 
significantly elevated compared to TRPV5+/+ mice, suggestive for increased bone 
turnover, which could be the result of the reduced bone thickness in TRPV5-/- mice 
described previously (18). After the decline in osteocalcin levels in both mice 
strains, which is probably due to the lower need of bone formation and turnover to 
build the skeleton in adult animals, serum osteocalcin levels increased in 52-weeks 
old TRPV5-/- mice in accordance with the elevation of serum PTH. PTH indirectly 
activates osteoclasts and modifies the phenotype of the osteoblast from a cell 
involved in bone formation to a cell directing bone resorption (50, 51). Thus, the 
age-associated hyperparathyroidism in TRPV5-/- could lead to increased bone 
turnover, thereby resulting in net bone loss and aggravating the existing reduction 
in bone volume.  
Previous studies indicated that estrogens can upregulate active Ca2+ 
(re)absorption in both kidney and duodenum (5). This was accompanied by an 
increased expression level of the Ca2+ transport proteins in female compared to 
male mice in both kidney and duodenum. However, our data do not allow to 
conclude that the age-dependent regulation of Ca2+ transporters is gender 
(in)dependent.  
In summary, the present findings demonstrated a decline in renal and intestinal 
Ca2+ (re)absorption through TRPV5 and TRPV6 during aging, which is of 
physiological significance in understanding the imbalance in mineral metabolism 
associated with aging. Moreover, TRPV5-/- mice likely develop age-related 
hyperparathyroidism and osteoporotic characteristics earlier as compared to 
TRPV5+/+ mice, corroborating the importance of the epithelial Ca2+ channels in 
Ca2+ homeostasis. 
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Abstract 
 
Glucocorticoids, like prednisolone, are often used in clinic because of their anti-
inflammatory and immunosuppressive properties. However, glucocorticoids reduce 
bone mineral density (BMD) as a side-effect. Malabsorption of Ca2+ in the intestine 
is supposed to play an important role in the aetiology of low BMD. To elucidate the 
mechanism of glucocorticoid-induced Ca2+ malabsorption, the present study 
investigated the effect of prednisolone on the expression and activity of proteins 
responsible for active intestinal Ca2+ absorption including the epithelial Ca2+ 
channel TRPV6, calbindin-D9k and the plasma membrane ATPase PMCA1b. 
Therefore, C57BL/6 mice received 10 mg/kg bwt prednisolone daily by oral gavage 
for 7 days and were compared with control mice receiving vehicle only. An in vivo 
45Ca2+ absorption assay indicated that intestinal Ca2+ absorption was diminished 
after prednisolone treatment. We showed decreased duodenal TRPV6 and 
calbindin-D9k mRNA and protein abundance in prednisolone-treated compared to 
control mice, whereas PMCA1b mRNA levels were not altered. Importantly, 
detailed expression studies demonstrated that in mice these Ca2+ transport 
proteins are predominantly localized in the first 2 cm of the duodenum. 
Furthermore, serum Ca2+ and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) 
concentrations remained unchanged by prednisolone treatment. In conclusion, 
these data suggest that prednisolone reduces the intestinal Ca2+ absorption 
capacity through diminished duodenal expression of the active Ca2+ transporters 
TRPV6 and calbindin-D9k independent of systemic 1,25(OH)2D3. 
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Introduction 
 
Reduced BMD is particularly present in the elderly and women, which implies that 
age and gender are important risk factors for developing low BMD. However, in 
clinical practice low BMD is frequently observed in several patient groups, including 
IBD patients. Estimates of osteopenia in IBD range from 31% to 59% and 
osteoporosis from 5% to 41%. Various studies exploring the cause of low BMD in 
IBD found a significant correlation between glucocorticoid treatment and decreased 
BMD (1-5). Glucocorticoids, like prednisolone, are well-known drugs for their potent 
anti-inflammatory and immunosuppressive properties. As a consequence, 
glucocorticoids are widely used in clinic as drugs to treat inflammatory conditions, 
such as IBD. To date, glucocorticoids are generally accepted to reduce BMD, 
despite the fact that in a number of studies an effect on bone mass could not be 
observed (2, 6) or only in male glucocorticoid users (7).  
This effect of glucocorticoids on BMD is caused by the combined activity of 
increased bone resorption and malabsorption of vitamin D and Ca2+ from the 
intestine. Reduced vitamin D levels, as observed in IBD patients, are associated 
with impaired Ca2+ absorption and a compensatory increase in serum parathyroid 
hormone (PTH) levels which, in turn, stimulates bone resorption (7). Furthermore, 
in most studies high glucocorticoid dosage and long-term treatment are positively 
associated with low BMD. Glucocorticoids are generally prescribed in high doses 
for a short period in acute exacerbations and are subsequently given in low 
maintenance doses for a prolonged time. Taken together, prevention of low BMD in 
glucocorticoid-treated patients deserves serious attention and treatment. 
Disturbance of the intestinal Ca2+ absorption likely plays an important role in 
glucocorticoid-induced bone problems. Ca2+ is absorbed by two distinct 
mechanisms including passive (paracellular) and active (transcellular) transport 
and the relative importance of each pathway is set by the dietary Ca2+ content (8). 
Active Ca2+ absorption is mainly localized in the duodenum and tightly regulated, 
enabling the organism to adapt to changes in Ca2+ demands. Transcellular Ca2+ 
transport can be described in three sequential cellular steps including transfer of 
luminal Ca2+ into the enterocyte by the epithelial Ca2+ channel TRPV6, 
translocation of cytosolic Ca2+ towards the basolateral membrane by calbindin-D9k 
and finally active extrusion into the circulatory system by the plasma membrane 
Ca2+-ATPase 1b (PMCA1b) (8, 9). Active Ca2+ absorption is predominantly 
regulated by 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the active form of vitamin D 
in the body. This is exemplified in 1,25(OH)2D3-deficient 1α-hydroxylase knockout 
mice. This strain has a deletion in the enzyme 25-hydroxyvitamin D3-1α-
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hydroxylase responsible for the biosynthesis of active 1,25(OH)2D3 in the kidney. 
As a consequence, these mice show impaired intestinal Ca2+ absorption, 
decreased serum Ca2+ concentration and a compensatory increase in serum PTH 
levels (10, 11).   
Glucocorticoids diminish active Ca2+ absorption, however, the responsible 
molecular mechanism has not been elucidated. Hypothetically, glucocorticoid-
induced Ca2+ malabsorption is exerted through reduced levels of intestinal proteins 
involved in active Ca2+ transport. The aim of the present study was, therefore, to 
investigate the effect of prednisolone on the expression level of the Ca2+ transport 
proteins TRPV6, calbindin-D9k and PMCA1b in mouse duodenum. To this end, 
mice were treated with prednisolone for 7 days and characterized by in vivo 45Ca2+ 
absorption assays. Expression levels of the intestinal Ca2+ transporters were 
measured by real-time PCR analysis and immunoblotting.  
 
Materials and Methods 
 
Animal protocol  
Twelve-week old C57BL/6 mice were kept in a light- and temperature-controlled 
room with ad libitum access to standard pelleted diet and water. For studying the 
localization of duodenal Ca2+ transporters in  mice (N=4), the first 6 cm of the small 
intestine were sampled and divided into three parts of 2 cm each. In the 
prednisolone experiment, mice were randomly assigned to either the control group 
receiving vehicle only (N=8) or the treatment group (N=8), receiving 10 mg/kg body 
weight prednisolone-hemisuccinate sodium salt (Sigma-Aldrich, Zwijndrecht, The 
Netherlands) dissolved in phosphate-buffered saline (PBS) daily in two doses by 
oral gavage during 7 days (12, 13). Mice were housed individually in metabolic 
cages for 24 hours to collect urine samples. Subsequently, blood samples were 
taken and the mice were sacrificed. The first 2 cm of the duodenum (whole 
segment) were sampled and immediately frozen in liquid nitrogen. Samples were 
stored at -80ºC until further processing. The animal ethics board of the Radboud 
University Nijmegen approved all experimental procedures.  
 
Serum und urine biochemistry 
Serum and urine Ca2+ concentrations were determined using a colorimetric assay 
as described previously (14). Serum 1,25(OH)2D3 concentrations were analyzed 
using immunoextraction followed by 125I-RIA (IDS, Boldon, UK) (15).  
 
 
Prednisolone-induced Ca2+ malabsorption 
 67
Quantitative real-time PCR analysis 
Total RNA was extracted from the duodenum using Trizol Total RNA Isolation 
Reagent (Life Technologies BRL, Breda, The Netherlands). The obtained RNA was 
subjected to DNAse treatment to prevent genomic DNA contamination. Thereafter, 
1.5 μg of RNA was reverse transcribed by Moloney-murine leukemia virus-reverse 
transcriptase (Life Technologies BRL), as described previously (16). The obtained 
duodenal cDNA was used to determine TRPV6, calbindin-D9k, and PMCA1b mRNA 
levels, as well as mRNA levels of the housekeeping gene hypoxanthine-guanine 
phosphoribosyl transferase (HPRT) as an endogenous control. Polymerase chain 
reaction (PCR) primers and fluorescent probes were designed using the computer 
program Primer Express (Applied Biosystems, Foster City, CA, USA) and 
purchased from Biolegio (Malden, The Netherlands). The primer and probe 
sequences are described previously (32, 33). Expression levels were quantified by 
real-time PCR on an ABI Prism 7700 Sequence Detection System (PE Biosystems, 
Rotkreuz, Switzerland). 
 
Immunoblotting 
For protein analysis, frozen duodenal tissues were homogenized in ice-cold 
solubilization buffer as previously described (17). Protein concentration of the 
homogenates was determined (Bio-Rad Protein Assay; Bio-Rad München, 
Germany) and samples were normalized accordingly. Subsequently, total duodenal 
protein fractions (10 μg) were separated on a 16.5% (wt/vol) sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and blotted to 
polyvinylidine difluoride (PVDF)-nitrocellulose membranes (Immobilon-P; Millipore 
Corporation, Bedford, MA, USA). Blots were incubated o/n at 4ºC with calbindin-D9k 
antibody (Swant, Bellizona, Switzerland) (1:5,000) or β-actin antibody (1:25,000). 
Thereafter, blots were incubated with a goat anti-rabbit (calbindin-D9k) or goat anti-
mouse (β-actin) peroxidase coupled secondary antibody (Sigma, St. Louis, MO, 
USA) (1:10,000). Immunoreactive protein was detected using the 
chemiluminescence (ECL) method as described by the manufacturer (Amersham, 
Buckinghamshire, UK). Immunopositive bands were scanned using an imaging 
densitometer (Bio-Rad Gs-690) to determine pixel density (Molecular Analyst 
Software; Bio-Rad Laboratories, Hercules, CA, USA).  
 
45Ca2+ in vivo absorption assay 
In vivo Ca2+ absorption was assessed by measuring serum 45Ca2+ at early time 
points after oral gavage of a 45Ca2+ buffer. Mice were fasted overnight (12 hours) 
before the test. Animals were hemodynamically stable under anesthesia (urethane, 
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1.4 mg/g body weight) during the experiment. The solution used to measure Ca2+ 
absorption contained 0.1 mM CaCl2, 125 mM NaCl, 17 mM Tris, and 1.8 g/l 
fructose and was enriched with 20 µCi 45CaCl2/ml (18 Ci/g; New England Nuclear, 
Newton, Massachusetts, USA). For the oral tests, 15 µl/g body weight of this 
solution was administrated by gavage as described previously (18). Blood samples 
were obtained at 1, 2, 3, 4 and 7 minutes after oral gavage and serum (10 µl) was 
analyzed by liquid scintillation counting. The change in the serum Ca2+ 
concentration (ΔμM) was calculated from the 45Ca2+ content of the serum samples 
and the specific activity of the administrated 45Ca2+ solution. 
 
Statistical analyses 
Data are expressed as means ± SEM. Statistical comparisons were analyzed using 
ANOVA for the in vivo 45Ca2+ absorption study and unpaired Student’s t-test for the 
other experiments. P<0.05 was considered statistically significant. All analyses 
were performed using the Instat Statistical Software on an Apple iMac computer.  
 
Results 
 
Body weight, urine and serum analysis 
Mice were placed in metabolic cages to collect 24 hours urine samples. 
Prednisolone-treated mice showed equal amounts of urinary Ca2+ loss compared 
to controls (Table 1). Likewise, no effect of prednisolone was observed on serum 
Ca2+ and 1,25(OH)2D3 levels. To investigate the effect of prednisolone on body 
weight, mice were weighted before and after 7 days of oral treatment. Body weight 
significantly reduced after prednisolone treatment compared to controls (Table 1). 
 
 
Table 1. Effect of prednisolone on urine and serum biochemistry and body weight in mice. 
 Controls Prednisolone 
Serum Ca2+ (mM) 2.42 ± 0.04 2.43 ± 0.03 
Urine Ca2+ (μmol/24h) 4.9 ± 0.7 3.7 ± 0.5 
Diuresis (ml/24h) 0.8 ± 0.1 0.9 ± 0.2 
Serum 1,25(OH)2D3 (pmol/l) 91.8 ± 15.8 86.4 ± 16.6 
Change body weight (g) -0.9 ± 0.3 -2.7 ± 0.4 * 
 
 
Data are presented as mean ± SEM (N=8). *p<0.01 versus control. 
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Figure 1. Effect of prednisolone on 
in vivo intestinal 45Ca2+ absorption. 
At t=0 45Ca2+ is loaded in the stomach 
of the mouse by oral gavage. After 
the indicated time points blood was 
collected by orbita punction and 
subsequently analyzed for the 
amount of 45Ca2+ in serum. Control 
group (♦) received vehicle only, 
treatment group (□) received 10 
mg/kg bwt prednisolone daily by oral 
gavage. Data are presented as mean 
± SEM (N=8). *P<0.05 versus control. 
 
Figure 2. Localization of Ca2+ 
transporters in the duodenum. The 
first 6 cm of the duodenum was 
sampled and divided into three parts 
of 2 cm each. Using quantitative real-
time PCR, duodenal mRNA 
expression of the Ca2+ transporters 
TRPV6 (black), calbindin-D9k (grey) 
and PMCA1b (white) were measured 
in each of the three parts, corrected 
for HPRT and presented as % of total 
expression. Calbindin-D9k protein 
abundance was analyzed by 
immunoblot analysis. Data are 
expressed as mean ± SEM (N=4). 
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Effect of prednisolone on in vivo intestinal Ca2+ absorption  
In addition, we used an in vivo 45Ca2+ absorption assay to evaluate the effect of 
prednisolone on intestinal Ca2+ absorption. At several time points after oral 45Ca2+ 
intake, the amount of 45Ca2+ in the blood was measured in controls and 
prednisolone-treated mice. Fig. 1 shows that prednisolone resulted in a diminished 
uptake of Ca2+ from the intestinal lumen. Two minutes after oral gavage, the Ca2+ 
absorption in prednisolone-treated mice was 47 ± 8 % compared to controls. After 
4 minutes an equilibrium for Ca2+ uptake was reached. 
 
 
 
 
 
 
 
 
 
 
 
 
Localization of active Ca2+ transporters in the duodenum 
Subsequently, the molecular mechanism of prednisolone-induced Ca2+ 
malabsorption in the intestine was investigated. First,  the main localization of 
variou 
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Figure 3. Effect of prednisolone on 
duodenal and renal mRNA levels 
of genes encoding Ca2+ transport 
proteins. Using quantitative real-time 
PCR, duodenal mRNA expression of 
TRPV6, calbindin-D9k, PMCA1b (A) 
and renal mRNA expression of 
TRPV5, calbindin-D28k and NCX1 (B) 
were measured, corrected for HPRT 
and presented as % of the control 
group. Control group (black) received 
vehicle only, treatment group (white) 
received 10 mg/kg bwt prednisolone 
daily by oral gavage. Data are 
presented as means ± SEM (N=8). 
#P<0.01 versus control; *P<0.05 
versus control. 
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active intestinal Ca2+ uptake was determined. Therefore, the first 6 cm of the 
duodenum was divided into three equal parts in which the expression level of 
active Ca2+ transporters was quantified by real-time PCR and immunoblotting (Fig. 
2). All Ca2+ transporters displayed a robust mRNA expression gradient, which was 
highest near the stomach and decreased towards the jejunum. Intriguingly, more 
than 90% of TRPV6 and calbindin-D9k mRNA was localized in the first 2 cm directly 
after the stomach. This was less evident for PMCA1b, where 61% of PMCA1b 
mRNA was expressed in the first 2 cm. Similar results were obtained when 
analyzing duodenal calbindin-D9k protein abundance (Fig. 2).  
 
Effect of prednisolone on duodenal expression of active Ca2+ transporters 
To study the effect of prednisolone on duodenal expression of the Ca2+ transport 
proteins TRPV6, calbindin-D9k and PMCA1b, mRNA levels were measured in the 
first two cm using quantitative real-time PCR (Fig. 3A). Prednisolone treatment 
induced a two-fold decrease in TRPV6 mRNA expression compared to controls 
and also calbindin-D9k expression was slightly but significantly reduced. However, 
no significant effect of prednisolone was observed on PMCA1b mRNA levels and, 
therefore, we did not perform immunoblot analysis. Unfortunately, there is no 
appropriate antibody available to measure duodenal TRPV6 expression by 
kkkkkkkk 
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Figure 4. Effect of prednisolone on 
calbindin-D9k protein abundance in 
mouse duodenum. Immunoblot from 
mouse duodenal homogenates 
labeled with antibodies against 
calbindin-D9k (A). Expression of 
calbindin-D9k protein was quantified 
by computer-assisted densitometry 
analysis and expressed as % of 
controls (B). Control group (black) 
received vehicle only, treatment 
group (white) received 10 mg/kg bwt 
prednisolone daily by oral gavage. 
Data are presented as means ± SEM 
(N=8). *P<0.05 versus control. 
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immunoblot analysis. Subsequently, immunoblot analysis of duodenal samples 
consistently demonstrated a reduction in calbindin-D9k protein abundance in the 
prednisolone-treated group (Fig. 4A). Densitometric analysis of the intensity of the 
immunocomplexes confirmed this reduction and showed a significant decrease in 
calbindin-D9k protein expression after prednisolone treatment (Fig. 4B).  
 
Effect of prednisolone on expression of renal Ca2+ transporters  
To study the effect of prednisolone on renal expression of the Ca2+ transport 
proteins TRPV5, calbindin-D28k and NCX1, mRNA levels were measured using 
quantitative real-time PCR (Fig. 3B). Prednisolone treatment had no significant 
effect on mRNA expression level of the renal Ca2+ transporters compared to 
controls. 
 
Discussion 
 
The present study demonstrated that prednisolone impaires Ca2+ absorption, which 
is accompanied by diminished TRPV6 and calbindin-D9k expression in the early 
part of the duodenum. These findings strongly suggest that inhibition of active Ca2+ 
transport is at least in part responsible for the Ca2+ malabsorption during 
glucocorticoid treatment. This defect  likely contributes to the markedly decreased 
BMD after prolonged glucocorticoid usage. 
Prednisolone could exert a direct inhibitory action on Ca2+ transport proteins, 
which can, however, also be due to a secondary response to decreased 
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1,25(OH)2D3 serum levels. Importantly, we have previously shown that the 
expression of intestinal Ca2+ transport proteins is under the tight control of 
1,25(OH)2D3 (9, 18, 19). Available data about the effect of glucocorticoids on 
vitamin D metabolism are, however, inconclusive. Serum levels of 25-
hydroxyvitamin D were low in a number of studies (20) and normal in others (21). 
Serum 1,25(OH)2D3 levels also varied between studies (20, 22, 23). In addition, 
increased mRNA levels of the vitamin D receptor (VDR) were measured in both 
intestine and kidney after dexamethasone treatment (23, 24). Our finding 
demonstrating a decline in expression of the duodenal Ca2+ transporters TRPV6 
and calbindin-D9k in combination with constant serum 1,25(OH)2D3 levels, indeed 
implies a 1,25(OH)2D3 independent effect of glucocorticoids on Ca2+ absorption. 
These data are in line with a previous study of Hahn et al. (25) who demonstrated 
that 20 mg of prednisone per day for 14 days had a minor effect on serum 
1,25(OH)2D3 levels in 12 patients, whereas intestinal Ca2+ absorption fell by 30%, 
suggesting that the glucocorticoid-related impairment in Ca2+ absorption may be 
independent of vitamin D. Moreover, renal 1α-hydroxylase mRNA abundance and 
enzyme activity was not altered (23) and glucocorticoids did not alter the vitamin D 
binding protein expression (26). The 1,25(OH)2D3-independent effect of 
glucocorticoids on Ca2+ absorption, in turn, could implicate a direct effect of 
prednisolone. Lee et al. examined the effect of mifepristone, a glucocorticoid 
receptor antagonist. They observed that the decline of calbindin-D9k caused by 
dexamethasone was completely abolished by mifepristone (27). Altogether this 
implicates that the decline of intestinal Ca2+ uptake is 1,25(OH)2D3 independent 
and might be caused by a direct effect on the glucocorticoid receptor.  
The duodenum is generally implicated as the main site of active Ca2+ 
absorption, however, the precise localization of active Ca2+ transporters in the 
intestine has not been evaluated to date. Interestingly, the Ca2+ transporter 
expression did not gradually decrease towards jejunum, but Ca2+ transporters were 
almost exclusively localized in the first part (2 cm) of mouse duodenum. This holds 
true for TRPV6 and calbindin-D9k and to a lesser extent for PMCA1b. Because the 
expression level of the Ca2+ transporters was measured in duodenal segments 
instead of isolated mucosa preparations the presence of PMCA1b in duodenal 
muscle layers could theoretically contribute to the determined mRNA levels. 
However, Walters and co-workers demonstrated significant higher levels of the 
PMCA1b transcript in duodenal mucosa compared with duodenal muscle layers 
(28). Thus it is unlikely that PMCA1b contamination from another layer (e.g. muscle 
cells) does significantly contribute to the PMCA1b expression in duodenal mucosa. 
Our study suggests that active Ca2+ transport is restricted to the duodenal part 
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directly after the stomach. In addition, previous data indicated that TRPV6 is 
abundantly expressed in stomach (29, 30), where Ca2+ is ionized by gastric acid 
enabling absorption in the duodenum. Possibly, the stomach plays a role in active 
dietary Ca2+ absorption next to the duodenum. Taken together, the strong 
duodenal gradient of the Ca2+ transport proteins is a unique finding and suggests 
that active intestinal Ca2+ absorption occurs only in the first part of the duodenum. 
In the aetiology of low BMD, it is emphasized that there is interplay between 
Ca2+ waste from bone, increased renal Ca2+ wasting and diminished Ca2+ 
absorption from the duodenum. The involvement of this last pathway is supported 
by previous studies. With the in situ intestinal loop technique it was evaluated that 
the net active Ca2+ flow over the duodenal membrane is inhibited by prednisolone 
(31, 32). A study in children on dexamethasone treatment observed a 61% to 42% 
fall in Ca2+ absorption (33). Moreover, in rats injected with other glucocorticoid 
drugs including dexamethasone or methylprednisolone, a decline of duodenal 
calbindin-D9k mRNA was observed (24, 34). Furthermore, Li et al. demonstrated a 
dose-dependent decrease of duodenal calbindin-D9k after dexamethasone 
treatment in mice (35). Recently, Lee et al. showed that dexamethasone reduces 
duodenal calbindin-D9k expression in mice when exposed for more than 3 days, 
while an exposure time shorter than 3 days did not affect calbindin-D9k expression. 
This finding implies a time-dependent effect of glucocorticoids on intestinal Ca2+ 
uptake (27). These studies together with our observation that prednisolone reduces 
duodenal TRPV6, conclusively demonstrates that disabled active Ca2+ uptake is 
involved in glucocorticoid-induced Ca2+ malabsorption. Our findings indicated that 
the abundance of the renal Ca2+ transporters including TRPV5, calbindin-D28k and 
the Na+/Ca2+ exchanger (NCX1) is not affected by prednisolone treatment. These 
results could explain the normal Ca2+ excretion in mice administrated with 
prednisolone. 
Although glucocorticoids are not likely to affect 1,25(OH)2D3 levels, 1,25(OH)2D3 
supplementation may still be an important treatment to prevent glucocorticoid-
induced malabsorption, because of its stimulatory effect on active Ca2+ transport.  
This can protect  patients against the negative side-effects of glucocorticoids on 
BMD (36). Furthermore, glucocorticoid treatment can only partly explain decreased 
BMD. For example in IBD, also patients who did not receive a glucocorticoid 
treatment showed a reduction in BMD (37). Beside Ca2+ malabsorption, 
inflammatory cytokines, which are released during IBD, can directly stimulate 
osteoclast activity and decrease osteoblast function. Dresner-Pollak et al. using an 
IL-10 knockout IBD mouse model measured enhanced serum TNFα, IL-1β and IL-6 
levels, and showed an increased incidence of osteopenia (38, 39). It is evident that 
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the occurrence of reduced BMD has multifactoral causes and cannot be explained 
by just one mechanism.   
In conclusion, this study shows that prednisolone decreases intestinal Ca2+ 
absorption via impaired active duodenal Ca2+ absorption, mainly through 
diminished duodenal TRPV6 expression. This process takes place independently 
of blood 1,25(OH)2D3 levels. The described decline in active Ca2+ absorption may 
explain the Ca2+ malabsorption observed in patients using glucocorticoids and may 
on the long-term contribute to the development of osteoporosis.   
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Abstract 
 
Patients suffering from Crohn’s disease (CD) show increased incidence of low 
bone mineral density. Investigating this complication is difficult because the exact 
etiology of CD remains elusive. Mice carrying a deletion in the tumor necrosis 
factor (TNF) AU-rich elements (ARE) are reported as a model for human CD and 
are characterized by elevated TNFα levels and inflammations in the terminal ileum. 
To evaluate whether these mice have a Ca2+ handling problem, this study analyzed 
the Ca2+ homeostasis in heterozygous TNFΔARE mice (TNFΔARE/+) in comparison to 
its wild-type littermates. Beside serum Ca2+ and vitamin D levels, the expression of 
Ca2+ transporters was analyzed in intestine, kidney and bone using quantitative 
real-time PCR, Western blot and immunohistochemical staining. Bone scans were 
performed to measure bone thickness. Ca2+ transporters in duodenum (TRPV6, 
calbindin-D9k, PMCA1b) and kidney (TRPV5, calbindin-D28k, NCX1) showed 
significantly reduced mRNA expression levels in TNFΔARE/+ mice, except for renal 
TRPV5. In bone, only calbindin-D9k mRNA displayed a significant down-regulation. 
These findings were supported by declined duodenal calbindin-D9k and renal 
calbindin-D28k protein values. Likely, this down-regulation of Ca2+ transporters in 
TNFΔARE/+ mice is mediated by the 58 ± 9% reduction in serum 1,25(OH)2D3 levels. 
Diminished expression of Ca2+ transporters combined with unchanged serum Ca2+ 
levels assumes Ca2+ loss from bone to compensate for the body’s overall Ca2+ 
shortage. Indeed, microcomputed tomography scanning demonstrated reduced 
trabecular and corticol bone thickness and volume in TNFΔARE/+ mice. This finding 
is further supported by increased total deoxypyridinoline in serum. In conclusion, 
our results implicate that TNFΔARE/+ mice have a disturbed Ca2+ homeostasis 
characterized by reduced duodenal and renal Ca2+ transporters, diminished 
1,25(OH)2D3 levels and increased bone resorption associated with profound bone 
abnormalities. 
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Introduction 
 
Crohn’s disease (CD) patients suffer from severe gastrointestinal inflammations 
which are mainly confined to the terminal ileum and colon. To date, the exact 
etiology of CD has not been elucidated, however, a multifactorial cause is 
implicated. This includes both genetic factors, such as carrying a variant of the 
nucleotide oligodimerisation domain 2 (NOD2) gene (1, 2) and environmental 
influences like nutrition and bacterial flora of the intestine (3-5). Furthermore, 
immunologic factors are likely to play a primary role. An immune response is 
mediated by T cells that produce large amounts of pro-inflammatory cytokines. CD 
patients are characterized by elevated production of the Th1 cytokines IL-2, 
interferon (IFN)-γ and tumor necrosis factor alpha (TNFα) (6). Moreover, anti-TNFα 
therapy has shown to be highly effective to inhibit inflammation (7). 
Additionally, it has been revealed that patients with CD have an increased 
incidence of low bone mineral density (BMD). Previous studies reported that 36-
55% of CD patients are osteopenic, whereas 6-58% are osteoporotic (8-12). This 
low BMD has been associated with increased fracture risk and its cause is, 
therefore, extensively studied. The main potential risk factors for developing low 
BMD are the presence of intestinal Ca2+ and vitamin D malabsorption, high 
circulating levels of inflammatory cytokines which can directly affect osteoclast and 
osteoblast activity, sex hormone deficiency, corticosteroid therapy and 
malnourishment. 
Ca2+ is an essential bone component and plays a key role in bone 
mineralization. In the body, serum Ca2+ is maintained at constant levels via the 
concerted action of intestinal uptake from the food, renal reabsorption from the pro-
urine and skeletal storage. Intestinal Ca2+ absorption and renal tubular 
reabsorption of filtered Ca2+ are modulated on the basis of the body’s overall need 
for Ca2+ gain or loss. Part of the Ca2+ (re)absorption in kidney and intestine occurs 
through the active transcellular pathway. This is a three-step process in which Ca2+ 
first enters the epithelial cell via the apical (luminal) Ca2+ channels, TRPV5 and 
TRPV6, respectively. Subsequently, Ca2+ is transported across the cell in 
association with Ca2+-buffering proteins, calbindin-D9k and calbindin-D28k, and 
finally Ca2+ is extruded across the basolateral membrane into the bloodstream via 
the Na+/Ca2+-exchanger (NCX1) in the kidney and the plasma membrane Ca2+-
ATPase (PMCA1b) in duodenum (13-15). This active transport occurs in the distal 
convoluted tubule (DCT) and connecting tubule (CNT) in kidney and in the 
enterocytes of the duodenum. In bone, Ca2+ transporters are present in osteoblasts 
and osteoclasts where they are thought to be involved in bone modeling (16). 
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Moreover, these Ca2+ absorptive cells are the primary targets for regulation by 
calciotropic hormones, including 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the 
active metabolite of vitamin D, and parathyroid hormone (PTH) (17). Alterations in 
expression of the abovementioned active Ca2+ transporters in duodenum, kidney 
and bone can disturb the Ca2+ homeostasis which might contribute to the 
establishment of low BMD.  
However, to study the involvement of active Ca2+ absorption in the occurrence 
of low BMD in CD, a proper animal model is required. In literature, several murine 
models have been developed to mimic this human disease. Besides chemically, 
immunologically or genetically-induced models there are also mice which 
spontaneously develop CD. Recently, a new murine model of Crohn’s-like ileitis 
has been reported, the TNFΔARE model, that closely resembles human 
characteristics of CD. These mice have a deletion in the TNF AU-rich elements 
(ARE), which are responsible for TNFα mRNA destabilization and translational 
repression (18). As a consequence, they exhibit markedly increased TNFα serum 
levels and develop a specific human CD-like phenotype characterized by 
inflammations primarily localized to the terminal ileum and occasionally to the 
proximal colon. Heterozygous TNFΔARE mice (TNFΔARE/+) at 4 months of age display 
severe inflammation in the ileum illustrated by mucosal and submucosal infiltration 
of chronic and acute inflammatory cells (19). No prominent signs of diarrhea have 
been observed. Furthermore, these mice show features of arthritis. 
The aim of the present study, therefore, was to evaluate the Ca2+ homeostasis 
in heterozygous TNFΔARE/+ mice compared to its wild-type littermates. To this end, 
we investigated serum Ca2+, 1,25(OH)2D3 and 25-hydroxyvitamin D (25(OH)D) 
levels and analyzed the abundance of active Ca2+ transporters in the small 
intestine, kidney and bone. Finally, bone conditions were examined performing 
microcomputed tomography scanning and total deoxypyridinoline (tDPD) serum 
measurements. Ultimately, this information could be important to develop new 
therapies for CD related bone abnormalities.   
 
Materials and Methods 
 
Animal protocol  
Ca2+ homeostasis was analyzed in female heterozygous TNFΔARE/+ mice which 
were generated as previously described (18). Homozygous TNFΔARE/ΔARE mice die 
between 5 and 12 weeks of age, therefore experiments were performed with 
heterozygous TNFΔARE/+ mice which develop severe intestinal inflammation and 
arthritis (18). The mice (N=8) were 4 months old with established inflammation in 
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the ileum and occasionally in the proximal colon. Wild-type littermates were used 
as controls (N=8). All mice were bred and maintained on a mixed C57BL/6J & 
129S6 genetic background in the animal facilities of the Biomedical Sciences 
Research Center “Alexander Fleming” under specific pathogen-free conditions. The 
mice were used in accordance with the guidance of the Institutional Animal Care 
and Use Committee of B.S.R.C. “Alexander Fleming”. After four months, when the 
inflammations in the ileum were fully developed, blood samples were taken and the 
mice were sacrificed. Duodenum, kidney and femurs were sampled and 
immediately frozen in liquid nitrogen. Samples were stored at -80ºC until further 
processed. The animal ethics board of the Radboud University Nijmegen has 
approved all experimental procedures.  
 
Serum biochemistry 
Serum Ca2+ concentrations were determined using a colorimetric assay as 
described previously (20). Serum 1,25(OH)2D3 and plasma 25(OH)D levels were 
measured using immuno-extraction followed by 125I-RIA quantification (IDS, 
Boldon, UK; Diasorin, Stillwater, USA, respectively). tDPD, a marker for the amount 
of bone resorption, was analyzed in serum utilizing the Metra total DPD EIA kit 
(Quidel, San Diego, USA).  
 
Quantitative real-time PCR analysis 
Total RNA was extracted from duodenum, kidney and bone using Trizol Total RNA 
Isolation Reagent (Life Technologies BRL, Breda, the Netherlands). For isolation of 
bone mRNA, femurs were pulverized using a Dismembrator (Sartorius, Goettingen, 
Germany) at 2,800 rpm for 1 minute. The obtained total RNA was subjected to 
DNase treatment to prevent genomic DNA contamination. Thereafter, 1.5 μg of 
total RNA was reverse transcribed by Moloney-murine leukemia virus-reverse 
transcriptase (Life Technologies BRL), as described previously (21). The obtained 
cDNA was used to determine TRPV5, calbindin-D28k, and NCX1 mRNA levels in 
kidney cortex as well as TRPV6, calbindin-D9k, and PMCA1b mRNA expression in 
duodenum. Moreover, all six abovementioned Ca2+ transporters were analyzed in 
bone. Additionally, the enzyme 25-hydroxyvitamin D3-1α-hydroxylase (1α-OHase) 
was measured in renal tissue. The housekeeping gene hypoxanthine-guanine 
phosphoribosyl transferase (HPRT) was used as an endogenous control. 
Expression levels were quantified by real-time quantitative polymerase chain 
reaction (PCR) on an ABI Prism 7700 Sequence Detection System (PE 
Biosystems, Rotkreuz, Switzerland). The primers and fluorescent probes used are 
as previously described (Biolegio, Malden, The Netherlands) (21, 22).  
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Immunoblotting 
For protein analysis, frozen duodenal and kidney tissues were homogenized in ice-
cold solubilisation buffer as previously described (23). Protein concentration of the 
homogenates was determined (Bio-Rad Protein Assay; Bio-Rad Munich, Germany) 
and samples were normalized accordingly. Subsequently, total protein fractions (10 
μg) were separated on 12% or 16.5% (wt/vol) SDS-PAGE gels for renal calbindin-
D28k and duodenal calbindin-D9k respectively, and blotted to polyvinylidine difluoride 
(PVDF)-nitrocellulose membranes (Immobilon-P, Millipore Corporation, Bedford, 
MA, USA). Blots were incubated overnight at 4ºC with calbindin-D9k antibody 
(Swant, Bellizona, Switzerland) (1:5,000), calbindin-D28k antibody (1:10,000) or β-
actin antibody (1:25,000) as an internal control. Thereafter, blots were incubated 
with a goat anti-rabbit (calbindin-D9k and calbindin-D28k) or goat anti-mouse (β-actin) 
peroxidase coupled secondary antibody (Sigma Chemical Co.) (1:10,000). 
Immunoreactive protein was detected using the chemiluminescence (ECL) method 
as described by the manufacturer (Amersham, Buckinghamshire, UK). 
Immunopositive bands were scanned using an imaging densitometer (Bio-Rad Gs-
690) to determine pixel density (Molecular Analyst Software; Bio-Rad Laboratories, 
Hercules, CA, USA).  
 
Immunohistochemistry 
Staining of TRPV5 protein in kidney samples was performed on periodate-lysine-
paraformaldehyde fixed cryosections as described previously (24). For semi-
quantitative determination of protein abundance, images were made using a Zeiss 
fluorescence microscope equipped with a digital camera (Nikon DXM1200), and 
subsequently analyzed with the Image Pro Plus 4.1 image analysis software 
(Media Cybernetics, Silver Spring, MD), resulting in quantification of the protein 
levels as the mean of integrated optical density (IOD).  
 
Bone structural analysis 
After fixation in 10% formalin and measuring their lengths, femurs from both wild-
type (N=7) and TNFΔARE/+ (N=8) mice were studied in detail by scanning them in a 
micro-computed tomography (μCT) scanner (Skyscan 1076, Skyscan, Aartselaar, 
Belgium). Scans were processed and a 3-dimensional morphometric analysis of 
the bone was performed, using free software of the 3D-calculator project 
(http://www.eur.nl\fgg\orthopaedics\Downloads.html) as described earlier (25, 26). 
All parameters were expressed according to the bone histomorphometry 
nomenclature (27). The region of interest was confined to a region from halfway the 
femoral head until the metaphysis. This region contained both cortical and 
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tDPD; total deoxypyridinoline. Data are presented as mean ± SE (N=8). *P<0.05 vs. wild-type. 
 
trabecular bone structures, enabling accurate analysis of a number of parameters 
in both compartments.  
 
Statistical analyses  
Data are expressed as means ± SE. Statistical comparisons were performed by 
Student’s t-test. P<0.05 was considered statistically significant. All analyses were 
performed using the StatView Statistical Package software (Power PC version 
4.51, Berkeley, California, USA) on an Apple iMac computer.  
 
Results 
 
Serum biochemistry 
Blood was collected from TNFΔARE/+ mice and wild-type littermates after which 
serum and plasma analyses were performed to determine Ca2+, 25(OH)D and 
1,25(OH)2D3 concentrations as well as the amount of tDPD. The results are shown 
in Table 1. Serum Ca2+ concentrations were comparable between both groups, 
while both 25(OH)D and 1,25(OH)2D3 values were reduced in TNFΔARE/+ mice, of 
which serum 1,25(OH)2D3 illustrated a two-fold decline. Furthermore, tDPD was 
significantly elevated in TNFΔARE/+ mice compared to their wild-type littermates.  
 
Table 1. Serum parameters of wild-type and TNFΔARE/+ mice 
 wild-type TNFΔARE/+ 
Ca2+ (mmol/L) 2.36 ± 0.03 2.32 ± 0.04 
1,25(OH)2D3 (pmol/L) 178 ± 8 79 ± 16 * 
25(OH)D (nmol/L) 18.1 ± 2.0 12.8 ± 1.2 * 
tDPD (nmol/L) 5.8 ± 0.3 6.8 ± 0.3 * 
 
 
Duodenal expression of active Ca2+ transporters  
By quantitative real-time PCR analysis, mRNA expression levels of the Ca2+ 
transporters TRPV6, calbindin-D9k and PMCA1b in the intestine were quantified in 
wild-type and TNFΔARE/+ mice. The results demonstrated a reduction in TRPV6, 
calbindin-D9k and PMCA1b mRNA levels to 30 ± 9%, 38 ± 8% and 71 ± 8%, 
respectively, in TNFΔARE/+ mice compared to wild-type littermates (Fig. 1A). In line 
with   the   mRNA  data,  calbindin-D9k   protein   abundance   was   declined   in   the 
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TNFΔARE/+ group, as confirmed by immunoblotting (Fig. 1B). Furthermore, the pixel 
density of the obtained immunopositive bands was semi-quantified, disclosing a 
two-fold down-regulation of duodenal calbindin-D9k protein in TNFΔARE/+ mice. 
 
Renal expression of active Ca2+ transporters  
To evaluate the expression of renal Ca2+ transporters in TNFΔARE/+ versus wild-type 
mice, TRPV5, calbindin-D28k and NCX1 mRNA levels were determined by 
quantitative real-time PCR analysis, and protein abundance was analyzed by 
immunohistochemistry and immunoblotting. Calbindin-D28k and NCX1 mRNA levels 
were significantly down-regulated to 59 ± 6% and 43 ± 10%, respectively, 
compared to wild-type littermates (Fig. 2A). In addition, calbindin-D28k protein 
measurements illustrate that the observed decline in calbindin-D28k mRNA is 
accompanied by a similar reduction on protein level (Fig. 2B). In contrast, renal 
TRPV5 mRNA levels were unaffected in TNFΔARE/+ mice (Fig. 2A). This observation 
was confirmed by additional immunohistochemical staining of kidney sections with 
a TRPV5 antibody showing no difference in TRPV5 protein abundance between 
TNFΔARE/+  and  wild-type  mice (Fig. 3).  Finally, the  mRNA  level  of  1α-OHase, the 
Figure 1. Duodenal expression 
of Ca2+ transporters in 
TNFΔARE/+ mice. Using 
quantitative real-time PCR 
analysis, duodenal mRNA 
expression of the Ca2+ 
transporters was measured, 
corrected for HPRT and 
presented as relative percentage 
of expression in wild-type mice 
(A). Immunoblot from mouse 
duodenal homogenates labeled 
with a calbindin-D9k antibody and 
quantified by measuring pixel 
density as a relative percentage 
of expression in wild-type mice 
(B). Wild-type (black), TNFΔARE/+ 
(white). Data are presented as 
mean ± SE (N=8), *P<0.05 vs. 
wild-type.  
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Figure 3. Renal TRPV5 protein 
abundance in TNFΔARE/+ mice. 
Sections of kidney cortex from 
wild-type and TNFΔARE/+ mice 
were stained with a TRPV5 
antibody (A). Semi-quantification 
of TRPV5 protein abundance 
was performed by computerized 
analysis of immunohistochemical 
images. Data were calculated as 
IOD (arbitrary units) and depicted 
as percentage of expression in 
wild-type mice (B). Wild-type 
(black), TNFΔARE/+ (white). Data 
are mean ± SE (N=6). 
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enzyme responsible for 1,25(OH)2D3 biosynthesis in kidney, was quantified. 
However, no significant difference (P=0.14) in mRNA expression level was 
observed in the TNFΔARE/+ group (68 ± 13%) compared to control littermates (100 ± 
17.3%).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Renal expression of 
Ca2+ transporters in TNFΔARE/+ 
mice. Using quantitative real-
time PCR, renal mRNA 
expression of the Ca2+ 
transporters was measured, 
corrected for HPRT and 
presented as relative percentage 
of expression in the wild-type 
group (A). Immunoblot from 
mouse kidney homogenates 
labeled with a calbindin-D28k 
antibody and quantified by 
measuring pixel density as a 
percentage of expression in wild-
type mice (B). Wild-type (black), 
TNFΔARE/+ (white). Data are 
presented as mean ± SE (N=8), 
*P<0.05 vs. wild-type.  
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Figure 4. mRNA expression of Ca2+ transporters in bone of TNFΔARE/+ mice. Mouse femurs of 
wild-type (black) and TNFΔARE/+ (white) mice were analyzed for mRNA expression levels of Ca2+ 
transporters by real-time PCR. Levels were corrected for HPRT and expressed as percentage of 
wild-type. Data are presented as mean ± SE (N=8), * P<0.05 vs. wild-type.  
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Bone mRNA expression of active Ca2+ transporters  
Total RNA was isolated from wild-type and TNFΔARE/+ mouse femurs and 
subsequently analyzed by quantitative real-time PCR for the presence of the active 
Ca2+ transporters TRPV5, TRPV6, calbindin-D9k, calbindin-D28k, NCX1 and 
PMCA1b. The results are illustrated in Fig 4. The mRNA values indicate that the 
amount of active Ca2+ transporters was comparable between both groups except 
for calbindin-D9k, which was significantly down-regulated in TNFΔARE/+ mice. 
Calbindin-D28k could not be detected in mouse femur. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bone structural analysis 
Detailed structural analysis of the femurs demonstrated dramatic changes in 
TNFΔARE/+ mice compared to wild-type littermates (Fig. 5A). The femurs were 
smaller in size, as shown by reduced femur length, circumference (perimeter) and 
femoral head volume (Fh.V) (Fig. 5B). In the trabecular compartment of TNFΔARE/+ 
mice femurs, the trabeculae were thinner (trabecular thickness, Tb.Th) and less 
numerous (trabecular number, Tb.N) compared to wild-type mice, leading to a 
smaller trabecular bone fraction (BV/TV) with less connections between trabeculae 
(connectivity density, CD/Ec.V) (Fig. 5B). At the cortical bone level, cortical 
thickness (Ct.Th) and volume (Ct.V) were dramatically reduced, which can be 
partially explained by the reduced perimeter and femoral head volume, but the 
moment of inertia (MOI), a proxy for bone strength, was also strongly decreased 
(Fig. 5B). 
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Figure 5. Bone structural analysis of femurs from wild-type and TNFΔARE/+ mice. Femurs 
from wild-type (N=7) and TNFΔARE/+ (N=8) mice were analyzed in detail by μCT (A). The scanned 
region was from halfway the femoral head (1) until the metaphysis (2). Cross-sections of a wild-
type femur (left panels) contained more bone compared to TNFΔARE/+ femurs (right panels). 
Arrows indicate more intense trabecular network in femoral head (top panels) and increased 
cortical thickness in the metaphysis (lower panels) of wild-type mice. (B) Femoral length was 
determined. Parameters measured by μCT included perimeter, femoral head volume (Fh.V), 
trabecular volume (Tb.V), total bone marrow volume including trabeculae (Ec.V), trabecular bone 
volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), connectivity 
density (CD/Ec.V) (measure of the interconnectivity of the trabecular network), cortical thickness 
(Ct.Th), cortical volume (Ct.V) and moment of inertia (MOI) (measure of the geometrical 
distribution indicative of the mechanical strength per transversal cross-section). Data are 
presented as means ± SE. *P<0.05 vs. wild-type mice. 
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Discussion 
 
This study demonstrated that TNFΔARE/+ mice, as a model for human CD, have a 
disturbed Ca2+ homeostasis. This conclusion is supported by a down-regulation of 
the relevant Ca2+ transporters in organs involved in Ca2+ handling, e.g. kidney, 
duodenum and bone, accompanied by decreased serum 25(OH)D and 
1,25(OH)2D3 levels. Furthermore, elevated tDPD values and structural bone 
analysis revealed increased bone resorption in TNFΔARE/+ mice, presumably to 
replenish serum Ca2+ which remained unchanged. Altogether, this indicates that 
the TNFΔARE/+ mouse is a suitable model to study low BMD in CD.  
Previous studies have elucidated that the TRPV5 and TRPV6 channels are the 
rate-limiting step in active Ca2+ (re)absorption in kidney and duodenum, 
respectively. A causal relationship was observed between diminished renal TRPV5 
expression and increased urinary Ca2+ wasting, whereas reduced duodenal TRPV6 
was associated with a decline in Ca2+ uptake from the food, as analyzed by in vivo 
45Ca2+ absorption assays (28). This connection was further supported in a TRPV5 
knockout (TRPV5-/-) mouse model. TRPV5-/- mice showed markedly increased 
urinary Ca2+ excretion and a compensatory intestinal Ca2+ absorption accompanied 
by enhanced duodenal TRPV6 levels (25). Furthermore, 1α-OHase-/- mice, 
deficient in renal 1,25(OH)2D3 biosynthesis, displayed a strong reduction in renal 
and duodenal active Ca2+ transporters. Consequently, these mice were unable to 
sufficiently (re)absorb Ca2+ in both kidney and duodenum resulting in severe 
hypocalcaemia. 1,25(OH)2D3 supplementation completely restored the phenotype 
of the 1α-OHase-/- mice by normalizing the Ca2+ transporter expression levels. This 
mouse model illustrates the stimulatory effect of 1,25(OH)2D3 on the abundance of 
the Ca2+ transporters (29-31).  
Hypothetically, reduced vitamin D levels in CD patients could negatively affect 
the Ca2+ balance via diminished active Ca2+ (re)absorption that eventually could 
result in the observed high incidence of low BMD. Data about serum vitamin D 
levels in CD patients are, however, not unequivocal. Most studies report subnormal 
serum 25(OH)D levels, a vitamin D precursor which is converted to the active 
1,25(OH)2D3 by the enzyme 1α-OHase (32-34). Hypovitaminosis D might 
contribute to an increased risk in the development of low BMD. Contradictory, a 
study by Abreu et al. measured increased serum 1,25(OH)2D3 levels and enhanced 
intestinal 1α-OHase activity (35). Although the majority of studies reported 
hypovitaminosis D in CD, controversy exists whether there is a correlation between 
serum vitamin D metabolites and low BMD, because both positive (34) and 
negative correlations (36, 37) have been reported. It is postulated that 
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malabsorption of vitamin D from the diet plays an important role in the etiology of 
hypovitaminosis D. During inflammation or absence of the ileum, which is one of 
the main inflammatory sites in CD, interruption of the enterohepatic circulation may 
reduce bile salt secretion, which affects the absorption of vitamin D (38, 39). This 
malabsorption is in line with the fact that low BMD is more profound in CD when 
the inflammatory activity in ileum is increased. Our study, investigating TNFΔARE/+ 
mice as a model for CD, displayed both decreased 25(OH)D and1,25(OH)2D3 
values, likely caused by malabsorption of vitamin D precursors from the diet. A 
possible effect on renal 1α-OHase was unlikely since no significant differences in 
mRNA levels were observed between both groups. The diminished 1,25(OH)2D3 
values explain the reduction in duodenal and renal Ca2+ transporters as reported in 
this study. Surprisingly, although serum 1,25(OH)2D3 levels declined and the renal 
Ca2+ transporters calbindin-D28k and NCX1 decreased, renal TRPV5 was 
unaffected both on mRNA and protein level. Hypothetically, the kidney can 
compensate the negative Ca2+ balance in the body by restoring renal TRPV5 
expression to normal levels, resulting in reduced urinary Ca2+ loss. Further 
research is necessary to unravel the underlying mechanism. Altogether, the 
inflammation in the ileum of TNFΔARE/+ mice resulting in reduced serum 25(OH)D 
and 1,25(OH)2D3 levels is an important similarity with the human CD situation and 
supports the notion that hypovitaminosis D and disease activity are linked to low 
BMD. 
The majority of the body’s Ca2+ content is stored in bone, where the balanced 
processes of bone formation in osteoblasts and resorption in osteoclasts maintain 
bone homeostasis. Previous studies have revealed that the Ca2+ transporters are 
present in bone. Recently, van der Eerden et al. localized TRPV5 exclusively to the 
ruffled border of osteoclasts (16). They identified TRPV5 as an epithelial Ca2+ 
channel that is essential for osteoclastic bone resorption and demonstrated the 
significance of transcellular Ca2+ transport in osteoclastic function. We did not 
detect changes in bone TRPV5 mRNA in the TNFΔARE model. Remarkably, a 
significant decrease in calbindin-D9k mRNA expression was observed in TNFΔARE/+ 
mouse femurs. However, to date the role of calbindin-D9k in bone homeostasis is 
still unclear. Besides increased tDPD levels in serum, the bone structural analysis 
performed using μCT indicated that bone metabolism is severely affected in 
TNFΔARE/+ mice. The reduced bone size suggests a developmental delay in bone 
formation in TNFΔARE/+ mice. However, more specific analysis is required to define 
the phenotype more precisely. Still, the reduced bone size parameters (maximum 
10% less compared to wild-type) can only partially explain the severe reductions in 
cortical and trabecular bone volume and thickness. Together with the fact that 
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despite a smaller bone size, the endocortical volume (Ec.V) is similar to that in 
wild-type mice, we suggest that increased endocortical bone resorption occurs, 
thereby confirming the elevated tDPD levels in serum of TNFΔARE/+ mice. The 
reduced trabecular thickness may also be well explained by enhanced bone 
resorption but drawing conclusions is hampered by the lack of evidence concerning 
dynamic bone formation/mineralization data in these mice. Taking the bone data 
together, we suggest that TNFΔARE/+ mice display a severe phenotype, including 
enhanced bone resorption and developmentally reduced bone formation.  
Moreover, cytokines like IL-1, IL-6 and TNFα are postulated to stimulate bone 
resorption through stimulating osteoclast maturation and activity. Because the used 
murine model has highly increased TNFα serum levels, the effect of TNFα on bone 
resorption could significantly contribute to low BMD and can, therefore, not be 
neglected. Furthermore, previous studies reported that 1,25(OH)2D3 
supplementation can reduce inflammation through inhibition of TNFα production 
(40, 41). However, the impact of TNFα on 1,25(OH)2D3, the Ca2+ transporters and 
bone has not been extensively studied to date.  
Evaluating the Ca2+ homeostasis in TNFΔARE/+ mice, revealed decreased 
expression of duodenal Ca2+ transporters, suggesting diminished Ca2+ absorption 
from the diet. Reduced Ca2+ absorption eventually causes an overall Ca2+ shortage 
in the body. Together with unchanged serum Ca2+ levels, this implicates that the 
Ca2+ resorption in bone is increased to compensate for this deficiency. Indeed, 
enhanced bone resorption was reported in the TNFΔARE/+ mice, using the specific 
bone matrix degradation product tDPD in serum as a bone resorption marker and 
detailed structural analysis of the femurs. Inevitably, increased bone resorption will 
result in low BMD. These findings are in line with a study in interleukin-10 knockout 
(IL-10-/-) mice (42). This colitis model also displayed osteoporotic hallmarks 
including reduced bone mass, increased mechanical fragility, and suppressed 
bone formation. They concluded that the presence of colitis is an important 
contributor to osteoporosis in IL-10-/- mice. However, in contrast with our study the 
IL-10-/- mice did not show decreased vitamin D serum levels compared to wild-type 
littermates (43). Most likely, the difference in disease location could explain the 
discrepancy between both mouse models. It is known that disturbance of the 
integrity of the ileum causes reduced vitamin D absorption (38, 39), but the colon is 
the main side of inflammation in the IL-10-/- mice and, therefore, malabsorption of 
dietary vitamin D may be less profound. However, the involvement of Ca2+ 
transporters was not evaluated in the IL-10-/- mouse model.  
In conclusion, we showed that the TNFΔARE mouse model maintains normal 
serum Ca2+ levels despite decreased expression of Ca2+ transporters in duodenum 
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and kidney, presumably as a result of reduced serum 1,25(OH)2D3 levels. This 
initiated increased Ca2+ resorption from bones causing low BMD. Because of the 
high similarity of this mouse strain with the human situation, we state that the 
TNFΔARE/+ mouse is an interesting model to further study low BMD in human CD 
patients.  
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Abstract 
 
Ca2+ is absorbed in the gastro-intestinal (GI) tract via a transcellular process 
requiring the Ca2+ transporters transient receptor potential vanilloid subtype 6 
(TRPV6), calbindin-D9k and plasma-membrane Ca2+-ATPase (PMCA1b), as well as 
by means of paracellular fluxes. The latter transport mechanism involves tight 
junction (TJ) structures that reside within the paracellular space and are mainly 
composed of claudin proteins. The large claudin family consists of over 20 different 
isoforms, which are thought to regulate epithelial permeability to ions and solutes. 
Noteworthy, Ca2+ malabsorption is frequently observed in patients with intestinal 
inflammatory lesions, like Crohn’s disease, Ulcerative colitis and Coeliac disease.  
In order to increase our understanding of Ca2+ (mal)absorption processes, a 
detailed expression study was performed to evaluate mRNA levels of the Ca2+ 
transporters as well as claudin isoforms in different segments of the healthy human 
GI tract using real-time polymerase chain reaction (PCR). In addition, the 
abundance of Ca2+ transporters and a subset of claudin isoforms were quantified in 
the duodenum of inactive inflammatory bowel disease (IBD) and coeliac disease 
patients.   
Expression profiling showed that TRPV6 and calbindin-D9k transcripts were 
primarily located in the duodenum, whereas PMCA1b was widely expressed 
throughout the entire GI tract. The different claudin isoforms demonstrated 
individual expression patterns, in which claudin-3, -4 and -8 mainly resided in the 
colon, claudin-2 and -15 were confined to the small intestine, claudin-7 and -12 
displayed a ubiquitous expression pattern, and claudin-18 was exclusively present 
in the gastric region. No difference in duodenal TRPV6, calbindin-D9k, PMCA1b, 
claudin-2, claudin-3 and claudin-4 mRNA expression was observed in IBD and 
coeliac disease patients as compared to a healthy control group. 
In conclusion, the transporters involved in transcellular Ca2+ absorption are 
primarily localized in the duodenum, whereas claudin isoforms display individual 
expression gradients throughout the human GI tract. Finally, intestinal expression 
of Ca2+ transporters as well as claudin-2, -3, and -4 is not altered in IBD and 
coeliac disease patients and, therefore, not likely to be involved in Ca2+ 
malabsorption during inactive IBD and coeliac disease.    
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Introduction 
 
Ca2+ is one of the most abundant cations in our body where it is involved in many 
physiological functions including bone modeling, muscle contraction, 
neurotransmission, cell signaling and enzyme activity. Consequently, serum Ca2+ 
concentration is carefully controlled via absorption in the intestine, reabsorption 
from the pro-urine in renal tubules to fine-tune urinary Ca2+ excretion, and constant 
exchange with the bone matrix (1). During this regulatory process, Ca2+ has to 
cross epithelial monolayers that line both the intestinal lumen and the renal tubular 
system. Therefore, balanced transport across epithelial cell layers plays a central 
role in overall Ca2+ homeostasis.  
Epithelial Ca2+ transport can be subdivided in two distinct pathways. One 
constitutes a paracellular route in which Ca2+ flows through the intercellular space 
of two adjacent cells, driven by both concentration and electrochemical gradients. 
This passive diffusion process is regulated via tight junctions (TJs), which reside 
most apically in the paracellular space (2). TJs entail large strands of 
transmembrane proteins, spanning the paracellular space to bind stands located in 
the membrane of neighboring cells. In this way, they provide a barrier between the 
apical and basolateral compartments to create membrane polarity and regulate 
epithelial permeability to ions and small molecules. To date, the claudin family, 
which comprises more than 20 different isoforms, is described as the most 
essential TJ protein, forming pore-like structures with size and charge selectivity (3-
5). The composition of claudin isoforms varies in each tissue, which is thought to 
determine epithelial permeability for cations, including Ca2+ and Mg2+.  
A second, transcellular pathway involves a three-step process, consisting of 
apical entry into the cell via the Ca2+-selective channels transient receptor potential 
vanilloid (TRPV) subtype 5 and 6, buffering of cytosolic Ca2+ and diffusion to the 
basolateral membrane via the Ca2+-binding proteins calbindin-D9k and calbindin-
D28k, and finally extrusion into the blood compartment mediated by the plasma 
membrane Ca2+-ATPase (PMCA1b) and Na+/Ca2+-exchanger (NCX1) (1). Data 
from knockout (KO) models revealed that ablation of TRPV5 resulted in a primary 
renal Ca2+ defect characterized by severe urinary Ca2+ wasting (6). In contrast, 
TRPV6 KO mice illustrated a mostly intestinal phenotype consisting of Ca2+ 
malabsorption (7). From additional localization and functional studies, it is 
concluded that TRPV6 together with calbindin-D9k and PMCA1b are the key 
players in intestinal Ca2+ absorption, whereas TRPV5, calbindin-D28k and NCX1 are 
the major contributors in the kidney. This transcellular transport mechanism 
demands energy to transmigrate Ca2+ across the basolateral membrane. However, 
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its advantage includes the strong hormonal regulation, mainly via 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3), independent of luminal Ca2+ concentrations. 
The transcellular machinery is stimulated in times of Ca2+ shortage and/or 
increased Ca2+ requirements, such as during growth or lactation. On the other 
hand, when luminal Ca2+ is high and/or Ca2+ demands are fulfilled, the paracellular 
pathway prevails (8, 9).  
To obtain and maintain adequate Ca2+ supplies, absorption from the intestine is 
crucial since the diet is the only Ca2+ source for the body. The localization of 
paracellular and transcellular Ca2+ absorption is confined to special areas in the 
gastro-intestinal (GI) tract. Ca2+ can be absorbed in a paracellular manner 
throughout the whole GI tract, but chiefly occurs in the small intestine. There, the 
ileum takes up the majority of total Ca2+ load, mainly because of the long residence 
time of chyme in this segment (8-10). On the contrary, transcellular Ca2+ absorption 
is primarily located in the duodenum (11-13). Detailed GI expression patterns of 
individual Ca2+ transport proteins have already been mapped in various mouse 
studies (1, 14). However, these expression profiling studies have not been 
evaluated in a human setting. Knowledge about the exact site of intestinal Ca2+ 
absorption might become essential during intestinal diseases or after surgical 
resections. Of interest, disorders in which the intestine is recurrently inflamed, such 
as untreated coeliac disease and more rarely active inflammatory bowel diseases 
(IBD), e.g. Ulcerative colitis or Crohn’s disease, are associated with Ca2+ 
malabsorption and changes in epithelial permeability (15). Furthermore, IBD 
patients have increased prevalence of low bone mineral densities, ranging from 31 
to 59% (16, 17). Besides the direct negative effect of inflammatory cytokines on 
bone metabolism, alterations in expression of the Ca2+ transporters and claudin 
isoforms are additionally implicated in the etiology of described IBD- and coeliac 
disease-related Ca2+ disturbances.  
The study design was, therefore, two-fold. First, we analyzed in detail the GI 
expression pattern of human genes involved in transcellular and paracellular Ca2+ 
transport via mRNA measurements in mucosal GI biopsies. Moreover, we analyzed 
the expression of the apically localized transporters transient receptor potential 
melastatin subtype 6 (TRPM6) and the sodium-inorganic phosphate cotransporter 
IIb (NaPi-IIb) that are involved in transcellular Mg2+ and inorganic phosphate (Pi) 
absorption, respectively. Alterations in serum concentration of these two cations 
often coexist with disturbances in Ca2+ flux. Finally, the mRNA abundance of 
several genes involved in transcellular and paracellular Ca2+ transport was 
investigated in duodenal mucosal biopsies from patients with inactive IBD and 
coeliac disease and compared with the expression in healthy controls. Altogether, 
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this study provides more insight into the expression of human intestinal Ca2+ 
transporters and claudin isoforms during health and in case of intestinal 
inflammatory disorders.  
 
Methods 
 
Human material 
Detailed expression profiling was performed on human mucosal GI biopsies, which 
were obtained from subjects undergoing gastroscopy and/or colonoscopy owing to 
indefinite gastric or colonic complaints. In more detail, two mucosal biopsies were 
collected from each site, comprising the esophagus, upper gastric region (fundus), 
lower gastric region (antrum), duodenum (3-5 centimeter beyond the pylorus), 
ileum, ascending colon, transverse colon, descending colon, sigmoid colon and 
rectum. The jejunum could not be reached for sample collection. All biopsies were 
taken from healthy mucosa. In order to analyze expression of the Ca2+ transporters 
and the claudin isoforms -2, -3 and -4 during GI disorders, two duodenal biopsies 
were collected from Crohn’s disease, Ulcerative colitis and Coeliac disease 
patients, which were age-matched with a healthy control group. In case of active 
disease at the site of interest, two extra biopsies were obtained from the 
inflammatory lesion. However, none of the included IBD and coeliac disease 
patients demonstrated active inflammatory lesions in the duodenum. Furthermore, 
two subjects of the coeliac disease group were on a gluten-free diet. The tissue 
specimens were immediately snap-frozen in liquid nitrogen to prevent mRNA 
degradation and were subsequently stored at -80ºC. Afterwards, the endoscopic 
outcome and the individual patient files were consulted to make sure the patients 
were correctly classified and the healthy subjects were free of GI disease. In 
addition, information about age, gender, disease activity and drug history was 
recorded. Intestinal resections, active hyperparathyroidism, renal insufficiency and 
liver insufficiency were defined as exclusion criteria. Information about the number 
of included patients in each group, and its gender and age distribution are listed in 
Table 1. Two subjects, in the healthy control and coeliac disease group, were on 
prednisolone therapy (5 mg/day). Serum 1,25(OH)2D3 and Ca2+ levels were similar 
in all groups (data not shown). This study was approved by the ethical committee 
of Tampere University Hospital, Finland, and the Radboud University Nijmegen, 
The Netherlands. Written informed consent was obtained from each subject.  
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Table 1. Patient demographics 
Study Group Number  Female (%) Age (yrs) 
Expression profiling Controls gastroscopy 5 80  54 ± 3 
 Controls colonoscopy 5 80 56 ± 5 
IBD / coeliac disease Healthy controls 10 70 51 ± 4 
 Ulcerative colitis 5 40 27 ± 3 
 Crohn’s disease 9 67 49 ± 3 
 Coeliac disease 5 80 50 ± 7 
 
 
 
Quantitative real-time PCR analysis 
Total RNA was extracted from the intestinal mucosal biopsies using Trizol Total 
RNA Isolation Reagent (Life Technologies BRL, Breda, The Netherlands). The 
obtained RNA was subjected to DNAse treatment to prevent genomic DNA 
contamination. Thereafter, 1.5 μg of RNA was reverse transcribed by Moloney-
murine leukemia virus-reverse transcriptase (Life Technologies BRL), as described 
previously (18). The obtained cDNA was used to determine mRNA levels of 
TRPV5, TRPV6, calbindin-D9k, calbindin-D28k, PMCA1b, TRPM6, NaPi-IIb and the 
claudin isoforms -2, -3, -4, -7, -8, -12, -14, -15, -18, as well as mRNA levels of the 
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) that 
served as endogenous control. Polymerase chain reaction (PCR) primers and 
fluorescent probes were designed using the computer program Primer Express 
(Applied Biosystems, Foster City, CA, USA) and purchased from Biolegio (Malden, 
The Netherlands) or Eurogentec (Maastricht, The Netherlands). The primer and 
probe sequences are listed in Table 2. The claudin isoforms were amplified using 
SybrGreen PCR master mix (Applied Biosystems, Foster City, CA, USA) on an iQ5 
iCycler Detection System (Bio-rad, Hercules, CA, USA). Expression levels of the 
Ca2+, Mg2+ and Pi transporters were quantified using Taqman probes on an ABI 
Prism 7900 Sequence Detection System (PE Biosystems, Rotkreuz, Switzerland). 
  
Statistical analysis 
Data are expressed as mean ± SEM. Statistical comparisons were analyzed using 
ANOVA. P<0.05 was considered statistically significant.  
 
Information about gender and age of the patients that are included in the expression profiling and 
intestinal inflammation studies. Data are expressed as mean ± SEM. Yrs, years. 
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Results 
 
mRNA expression profiling of Ca2+, Mg2+ and Pi transporters in the GI tract 
The mRNA abundance of different ion transporters was evaluated throughout the 
entire human GI tract, starting from the esophagus and ending in the rectum (Fig. 
1). Interestingly, the transporters TRPV6, calbindin-D9k and PMCA1b, involved in 
transcellular Ca2+ absorption, revealed diverse expression patterns for each 
individual transporter. Most TRPV6 transcripts were identified in the duodenum (47 
± 10%), although considerable amounts were also observed in the stomach with 29 
± 7% and 15 ± 3% for the fundus and antrum, respectively. TRPV6 expression was 
minor in the ileum and completely absent in the large intestine. Strikingly, the 
localization of calbindin-D9k was restricted to the duodenum, for nearly 100% of 
total mRNA levels were identified in this GI segment. In contrast, the basolateral 
Ca2+ transporter PMCA1b showed a wide expression throughout the GI tract with 
equal amounts in both the small and large intestine. TRPV5 and calbindin-D28k 
mRNA transcripts were undetectable in the human intestine (data not shown). 
Furthermore, the Mg2+ transporter TRPM6 and the Pi transporter NaPi-IIb displayed 
unique distribution patterns. TRPM6 was more colon-orientated with the highest 
quantities identified in the distal large intestine, which included the transverse colon, 
descending colon, sigmoid colon and rectum. On the contrary, the large intestine 
completely lacked NaPi-IIb that predominantly resided in the duodenum (63 ± 6%) 
and to a lesser extent in the ileum (26 ± 9%).   
 
mRNA expression profiling of claudin isoforms in the GI tract  
Like the ion transporters, the members of the large claudin family showed specific 
localization patterns in the GI tract, which varied significantly among the different 
isoforms (Fig. 2). For instance, claudin-2 and -15 were mainly expressed in the 
small intestine, whereas claudin-3, -4 and -8 predominantly resided in the large 
intestine. Noteworthy, claudin-8 displayed a remarkable steady raise in expression 
from the stomach towards the distal colon. Furthermore, claudin-18 was fully 
restricted to the gastric region. In contrast, claudin-7 and -12 illustrated a more 
ubiquitous expression throughout the whole length of the intestine. The GI 
abundance of claudin-14 was below the detection limit.  
 
Abundance of duodenal Ca2+ transporters and claudin isoforms in IBD and 
coeliac disease 
To evaluate whether a change in Ca2+ transporters or claudin isoforms is 
associated   with  IBD-   and  coeliac   disease-related  intestinal  Ca2+  malabsorption, 
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Figure 1. mRNA expression profiling of Ca2+, Mg2+ and Pi transporters in the human GI 
tract. TRPV6, calbindin-D9k and PMCA1b are involved in Ca2+ absorption, and TRPM6 and NaPi-
IIb in Mg2+ and Pi transport, respectively. Values are expressed as mean ± SEM of N=5 biopsies 
and subsequently described as % of total mRNA expression in the GI tract.  
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Figure 2. mRNA expression profiling of claudin isoforms in the human GI tract. Values are 
expressed as mean ± SEM of N=5 biopsies and subsequently described as % of total mRNA 
expression in the GI tract. 
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Figure 3. mRNA expression of duodenal Ca2+ transporters and claudin isoforms in IBD and 
coeliac disease. (A) Expression of the Ca2+ transporters TRPV6, calbindin-D9k and PMCA1b (B) 
Expression of the claudin isoforms -2, -3 and -4. mRNA levels were measured by quantitative 
real-time PCR and presented as % of controls. Values are expressed as mean ± SEM of N=5-10 
subjects. P<0.05 was considered significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
duodenal mRNA expression of the Ca2+ transporters TRPV6, calbindin-D9k and 
PMCA1b as well as the claudin isoforms -2, -3 and -4 was determined in Crohn’s 
disease, Ulcerative colitis and Coeliac disease patients and ultimately compared to 
the expression in healthy controls (Fig. 3). The abundance of Ca2+ transporters did 
not change compared to the healthy controls, although the Crohn’s disease group 
showed a slight, but not significant, tendency to increase Ca2+ transporter levels. In 
addition, no significant alterations in the abundance of claudin isoforms were 
notified. Nevertheless, claudin-2 expression strongly varied among the different 
patient groups with a remarkably large decline observed in Coeliac disease 
patients to 15 ± 3% of control values (p=0.29). Overall, the inter-individual 
expression levels showed large variations.   
A 
B 
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Discussion 
 
The present study provides mRNA expression profiles of Ca2+, Mg2+ and Pi 
transporters as well as claudin isoforms in the human GI tract, which are involved 
in transcellular and paracellular ion absorption, respectively. This analysis is 
important to map in detail the localization of individual absorption processes and to 
subsequently unravel the underlying mechanisms of malabsorption during intestinal 
disorders, for example Ca2+ malabsorption in IBD and coeliac disease. Such 
complete and detailed expression profiling covering the entire GI tract has not been 
performed with human material before and, therefore, represents a unique set of 
data. 
Previous studies in mouse and rat intestine demonstrated a predominant 
duodenal expression of the Ca2+ transporters TRPV6 and calbindin-D9k (19-21). 
These findings were supported by several reports describing the presence of 
TRPV6 in human duodenum (22-25). The current study in a collection of unique 
human mucosal biopsies confirmed the specific duodenal localization of TRPV6 
and calbindin-D9k, which suggests that human transcellular Ca2+ absorption is 
mainly restricted to this area. Nonetheless, high amounts of TRPV6 transcripts 
were also identified in the stomach, which is in line with previous investigations (24, 
26). The function of TRPV6 in the stomach, however, remains elusive since the ion 
channel is inactivated in an acidic environment. The role of duodenal Ca2+ 
transporters, on the other hand, has been thoroughly investigated using mouse 
models. The generation of 1,25(OH)2D3-deficient mice revealed a profound 
reduction in duodenal TRPV6 and calbindin-D9k levels with a concomitant drop in 
transcellular Ca2+ absorption, indicating the potent stimulatory effect of 
1,25(OH)2D3 on transcellular Ca2+ absorption (27, 28). The consumption of a high 
Ca2+ diet or the injection of 1,25(OH)2D3 could fully restore the impaired Ca2+ 
absorption in these mice via increased expression of the Ca2+ transporters (29). 
Furthermore, TRPV6 KO and TRPV6/calbindin-D9k double KO mice showed a 
marked decline in Ca2+ uptake (7, 30). In addition, a high Ca2+ diet in wildtype mice 
reduced the amount of duodenal TRPV6 and calbindin-D9k, whereas low dietary 
Ca2+ intake stimulated their expression via increased serum 1,25(OH)2D3 (28, 31). 
Conclusively, these studies signify that in case of high luminal Ca2+ concentrations, 
Ca2+ is mainly absorbed via the paracellular pathway driven by a steep Ca2+ 
concentration gradient across the intestinal epithelium (8). However, duodenal 
transcellular Ca2+ absorption, involving TRPV6, calbindin-D9k and PMCA1b, is 
primarily promoted via 1,25(OH)2D3 in case of low dietary Ca2+, once the driving 
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force for paracellular Ca2+ absorption is vanished and Ca2+ has to be absorbed 
against a concentration gradient via an energy-demanding process.   
The low abundance of transcellular Ca2+ transporters in the ileum and colon 
presumes that under normal physiological conditions transcellular Ca2+ absorption 
does not take place at these sites. However, several studies reported that in case 
of a low Ca2+ diet also the ileum and colon were capable of absorbing Ca2+ in a 
transcellular manner (32-35). In addition, the colon has shown to possess 
1,25(OH)2D3-responsive Ca2+ uptake (36), a characteristic feature of transcellular 
transport. This hallmark might become relevant during disease-related Ca2+ 
malabsorption, for example after extensive intestinal resections or due to severe 
inflammations of the gut wall during IBD. Under these conditions, the ileum and 
colon might be able to partly counterbalance the Ca2+ absorption defects in the 
small intestine by increasing the amount of Ca2+ transporters and concomitantly 
enhance transcellular Ca2+ absorption. Moreover, conflicting results are described 
regarding TRPV5 and calbindin-D28k expression in the digestive tract. A few reports 
revealed the presence of calbindin-D28k mRNA in mouse and human colon as well 
as a low TRPV5 abundance in duodenum, jejunum and colon (23, 37). In contrast, 
other studies were unable to detect these intestinal mRNA transcripts, including the 
current human GI analysis (26). Importantly, however, all studies measured a 
negligible amount of intestinal TRPV5 and calbindin-D28k compared to the 
abundance of duodenal TRPV6 and calbindin-D9k. This indicates that human 
transcellular Ca2+ absorption primarily takes place in the duodenum and is 
performed via the Ca2+ transporters TRPV6, calbindin-D9k and PMCA1b, whereas 
TRPV5 and calbindin-D28k are not involved.  
Also TRPM6 and NaPi-IIb which facilitate transcellular Mg2+ and Pi absorption, 
respectively, displayed specific distribution profiles. Human TRPM6 prevailed in the 
colon, which is in accordance with a study by Groenestege et al. illustrating that 
TRPM6 expression is confined to mouse cecum and colon while it is absent in the 
proximal intestine (38). The important role of the colon in TRPM6-mediated Mg2+ 
absorption is underlined in a rat study in which total colectomy resulted in markedly 
reduced dietary Mg2+ uptake (39). Refering to these observations, it would be 
interesting to examine the capacity of the small intestine to increase TRPM6 
expression and assist the colon in transcellular Mg2+ absorption after (partial) 
colectomy or during colonic inflammations. In contrast to Mg2+ absorption, uptake 
of Pi occurs in the small intestine exclusively, but exact localization differs among 
species. In mice, the ileum is the main site of NaPi-IIb expression and Pi absorption 
(40). Rat Pi transport is maximal in the duodenum with a concomitant NaPi-IIb 
expression in duodenum and jejunum. Although human jejunal biopsies could not 
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be analyzed, the present study suggests that in humans the duodenum is more 
important in transcellular Pi absorption than the ileum, supported by a two-fold 
higher duodenal NaPi-IIb expression. Hence, rats seem a suitable model to study 
human intestinal Pi transport.                   
Besides ion transporters, a wide array of claudin isoforms is expressed along 
the GI tract (5, 14). This large claudin family constitutes the main component of TJ 
structures (5, 41). Importantly, the various claudin isoforms have individual 
properties with respect to gut permeability and paracellular cation flow (41). 
Overexpression of claudin-2 in renal epithelial cells resulted in a rapid reduction of 
transepithelial resistance (42), whereas overexpressed claudin-3 and -4 created a 
more tight cell layer (41). In addition, claudin isoforms are reported to form pore like 
structures with charge and size selectivity (43, 44). For instance, claudin-2 
expression induced cation-selective channels in TJs of renal epithelial cells (45). 
This indicates that the composition of isoforms in each tissue determines the 
ultimate epithelial permeability to ions and small molecules. Furthermore, 
mutations in human claudin-16 and claudin-19 induced urinary Mg2+ and Ca2+ 
wasting due to impaired paracellular Ca2+ reabsorption in the kidney. These last 
findings support the assumption that claudin isoforms specifically influence 
paracellular Ca2+ and Mg2+ transport and suggests a role of these proteins in Ca2+ 
and Mg2+ malabsorption. Consequently, knowledge about expression and 
localization of the isoforms in the human GI tract is essential, but limited. Extensive 
distribution profiling in mouse intestine revealed differential expression patterns for 
individual claudin isoforms (14, 46). The current study is the first analysis of human 
intestinal claudin expression profiles and hence comprises unique information. 
Generally, the observed human profiles are consistent with the murine situation. 
Nevertheless, claudin-2, -3 and -4 displayed a ubiquitous expression profile in mice, 
whereas in humans the localization of claudin-3 and -4 was primarily colon-
orientated and the small intestine was the main site for claudin-2 expression, which 
was almost absent in colon (14). Furthermore, the current human study identified 
claudin-18 exclusively in the gastric region, although other studies reported minor 
expression in mouse duodenum and mouse and human colon (14, 47). The 
observed differential expression patterns of claudin isoforms in the human GI tract 
might contribute to local diversity of transepithelial resistance and paracellular 
cation flow. Therefore, detailed information about claudin expres sion provides 
valuable resources to study the significance of individual claudin isoforms in 
absorption processes, and especially in Ca2+ and Mg2+ malabsorption during GI 
disorders.  
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Patients suffering from active IBD and untreated coeliac disease are prone to 
malabsorption of dietary Ca2+ (15). The involvement of impaired transcellular Ca2+ 
absorption is frequently postulated. Recently, long-term glucocorticoid treatment, 
often prescribed to IBD patients, showed a direct decline in duodenal TRPV6 and 
calbindin-D9k mRNA and a subsequent reduction in dietary Ca2+ absorption in mice 
(19, 48). However, glucocorticoid treatment can only partly explain the impaired 
Ca2+ absorption in the gut, since IBD patients without glucocorticoid therapy exert 
similar Ca2+ absorption defects. Patients with coeliac disease are frequently 
maintained on a gluten-free diet which alleviates inflammatory and malabsorption 
symptoms. To further unravel the etiology of Ca2+ malabsorption during GI 
inflammatory disorders, we analyzed the abundance of the Ca2+ transporters 
TRPV6, calbindin-D9k and PMCA1b in the duodenum of IBD patients with an 
inactive disease state and receiving no glucocorticoid therapy, as well as in 
subjects with coeliac disease. We hypothesized that the abundance of duodenal 
Ca2+ transporters is consistently low in IBD and coeliac disease, for subnormal 
1,25(OH)2D3 serum levels are commonly reported (49, 50). However, no 
differences in TRPV6 and calbindin-D9k expression were observed compared to 
tissue from healthy controls. This indicates that during inactive IBD and coeliac 
disease impaired transcellular Ca2+ absorption does not play a role in Ca2+ 
malabsorption. On the other hand, inflammatory activity might affect the results, 
because serum 1,25(OH)2D3 levels are lower during active disease due to reduced 
uptake of vitamin D precursors from the inflamed intestine. This divergence in 
1,25(OH)2D3 serum levels between active and inactive IBD or coeliac disease can 
influence the expression of duodenal Ca2+ transporters, since 1,25(OH)2D3 is their 
main regulator. In the current study 1,25(OH)2D3 serum levels were similar in all 
groups. Consequently, it is interesting to expand future studies with intestinal 
biopsies from patients with active disease including information about serum 
1,25(OH)2D3 and Ca2+ concentrations.   
Information about a possible relationship between intestinal claudin expression 
and IBD is emerging, although, still limited. Previous studies correlated changes in 
claudin expression and distribution to IBD-related changes in gut permeability. 
Prasad et al. described enhanced claudin-2 expression and a decline of claudin-3 
and -4 in inflamed mucosa of Ulcerative colitis and Crohn’s disease patients (51). 
Another study confirmed this increase in claudin-2 expression during active 
Crohn’s disease and concomitantly identified an impaired intestinal barrier function 
as indicated by a reduction in epithelial resistance (52). Also claudin-1 and claudin-
18 were elevated in colon biopsies of active IBD patients (47, 53). Furthermore, a 
study using genome-wide cDNA microarrays revealed an increase of claudin-3 and 
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claudin-4 in intestinal biopsies from Crohn’s disease patients (54). Also in active 
coeliac disease different TJ proteins, such as occludin and zonula occludens-1, 
were reduced in inflamed mucosa compared to inactive coeliac disease or healthy 
mucosa (55). Conversely, we were not able to detect any changes in duodenal 
claudin expression of patients with inactive IBD and coeliac disease. Importantly, 
previous studies elucidated the strong effect of inflammatory cytokines on the 
expression of various TJ proteins in cell models as well as in patient material (51, 
55-57). Most likely, the increased levels of inflammatory cytokines during active 
disease (mainly tumor necrosis factor α, interferon-γ, and interleukins) play a major 
role in the regulation of claudin expression. Weber et al. described a positive 
correlation between changes in claudin-1 and -2 expression and inflammatory 
activity (53). Interestingly, increased intestinal permeability, possibly due to 
changes in claudin isoform expression, is implicated in the pathogenesis of IBD via 
enhanced epithelial invasion of pathogens in the gut and a resulting induction of 
inflammatory responses. More studies are necessary to prove whether changes in 
TJ proteins affect the integrity of the gut epithelium in vivo, impair paracellular Ca2+ 
uptake and ultimately contribute to Ca2+ malabsorption. Finally, the power of the 
study has to increase to overcome the large variations within the experimental 
groups.   
In summary, the present study revealed individual expression profiles of Ca2+, 
Mg2+ and Pi transporters as well as claudin isoforms in the human GI tract. These 
data give more insight into the localization of intestinal absorption processes and, 
in addition, might predict which pathways are impaired during intestinal resections 
or in case of intestinal disease. For a complete overview including all members of 
the claudin family, evaluation of the remaining claudin isoforms  (i.e. -1, -5, -6, -9, -
10, -11, -13, -16, -17, -19, -20) in the human GI tract is recommended. Furthermore, 
quantitative measurements of the Ca2+ transporters and the claudin-2, -3, and -4 
isoforms did not obtain altered duodenal expression values in inactive IBD and 
coeliac disease patients compared to healthy controls, implying that these proteins 
do not contribute to the pathogenesis of IBD- and coeliac disease-related Ca2+ 
malabsorption. However, future studies should contain mucosa from IBD and 
coeliac disease patients with an active disease state to investigate the possible 
involvement of inflammatory cytokines in the regulation of Ca2+ transporters and 
claudin isoforms. Finally, ion transport and permeability studies in claudin KO 
mouse models and in vitro cell systems are required to ultimately proof the 
functional role of individual claudin isoforms in the paracellular absorption of 
cations from the gut.   
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Abstract 
 
Transport of Ca2+ across renal and intestinal epithelial layers is a critical step in 
Ca2+ homeostasis and entails both transcellular and paracellular fluxes. The 
paracellular transport pathway involves tight junction (TJ) structures that are 
located apically within the intercellular space. The claudin protein family, existing of 
over 20 different isoforms, has been described as the most essential component of 
TJs, forming cation-selective pores with charge and size selectivity. Interestingly, 
patients with Williams-Beuren (WB) syndrome, deficient in claudin-3 and claudin-4, 
are frequently characterized by intestinal Ca2+ hyperabsorption, indicating a 
potential role of these claudin isoforms in paracellular Ca2+ transport.  
The aim of the present study was, therefore, to establish three different 
experimental setups to examine the involvement of claudin isoforms, in particular 
claudin-3 and claudin-4, in paracellular Ca2+ transport. First, mutation analysis of 
the claudin-3 and claudin-4 genes was performed in two patients displaying 
significant intestinal Ca2+ hyperabsorption; however, no mutations were identified in 
the coding region. Secondly, Madine-Darby canine kidney (MDCKII) and human 
colorectal adenocarcinoma (Caco-2) cell lines stably expressing claudin-3 and 
claudin-4 were generated and characterized. Exogenous claudin-4 localized at the 
lateral plasma membrane of MDCKII monolayers and induced a transepithelial 
electrical resistance (TEER) varying from 25 to 140% compared to controls. Over-
expressed claudin-3 mainly retained into cytosolic vesicles, nevertheless TEER 
decreased compared to mock-transfected MDCKII cells. In contrast, claudin-3 
over-expression in Caco-2 monolayers increased TEER in 80% of analyzed 
clones, although control values varied from 218 to 868 Ω x cm2. Finally, the effect 
of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) on intestinal claudin isoform expression 
was analyzed in 1,25(OH)2D3-deficient as well as 1,25(OH)2D3-supplemented 
mouse models. Duodenal claudin-2 was significantly upregulated in wild-type mice 
after 1,25(OH)2D3 injection, whereas claudin expression was unaffected in mice 
lacking this hormone.  
In conclusion, the three applied approaches described in this paper need 
additional characterization; however, they are promising tools to efficiently 
investigate the role of claudins, primarily claudin-3 and claudin-4, in paracellular 
Ca2+ transport.   
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Introduction 
 
In clinic, physicians frequently observe patients displaying a disbalanced Ca2+ 
regulation. A shift in serum Ca2+ concentration is most critical, since hypocalcemia 
can modify nerve and muscle function causing cardiac arrhythmias, whereas 
hypercalemia induces renal failure and vascular calcification. Hence, serum Ca2+ 
level is accurately controlled via the concerted actions in the intestine, kidney and 
skeleton, where Ca2+ is absorbed from the diet, reabsorbed from the pro-urine to 
regulate urinary excretion, and exchanged with the bone matrix, respectively (1). In 
these organs, Ca2+ has to cross epithelial cell layers, implying that the rate of 
epithelial Ca2+ transport is an important parameter for the maintenance of Ca2+ 
balance.  
Two distinct pathways are suggested to play a role in epithelial Ca2+ transport. 
One constitutes a transcellular route in which Ca2+ enters the cell via apically 
located transient receptor potential vanilloid (TRPV) 5 and 6 ion channels, binds to 
cytosolic Ca2+-binding proteins (calbindin-D9k/-D28k) that translocate Ca2+ to the 
basolateral membrane, where it is finally extruded into the blood stream via the 
plasma-membrane Ca2+-ATPase (PMCA1b) and Na+/Ca2+-exchanger (NCX1) (1-
3). This pathway is thoroughly investigated since it is tightly controlled, mainly via 
the hormone 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) (4). In a second, paracellular 
route, Ca2+ flows through the intercellular space where it passes tight junction (TJ) 
protein complexes. For many decades it has been anticipated that this paracellular 
flow is solely concentration-driven and not mediated via hormones, which made it 
less interesting as a therapeutic target.  
Recently, however, the identification of claudin TJ proteins and the resulting 
new insights into TJ assembly challenged this assumption. TJs are complex 
formations of trans-membrane protein strands that bind to strands at neighbouring 
cells to span the paracellular space. The obtained epithelial seal provides a 
protective barrier that regulates epithelial permeability to ions and solutes. The 
large claudin family of trans-membrane proteins, which includes more than 20 
different isoforms, is recognized as the essential component of TJ strands (5, 6). 
Every isoform shows specific features. Hence, the unique composition of claudin 
isoforms in each strand defines epithelial permeability.  
Moreover, the arrangement of individual claudin isoforms is thought to create 
pore-like structures that show charge and size selectivity (7, 8). This claudin pore 
model is supported in vivo by mutations in human claudin-16 and claudin-19 
causing urinary Mg2+ and Ca2+ wasting due to a selective impairment of renal 
paracellular reabsorption (9-12). Dependent on the kind of point mutation this 
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phenotype results from the modification of a negative into a positive amino acid, 
thus altering the electrochemical properties of the claudin pore. In addition, an 
abolished interaction with TJ scaffolding proteins can affect plasma-membrane 
localization of claudins due to accumulation in lysosomes (9, 11, 13). In addition, 
transgenic knockdown of claudin-16 in mice induces hypermagnesuria and 
hypercalciuria (14). Importantly, other studies highlight the stimulatory effect of 
1,25(OH)2D3 not only on transcellular, but also on paracellular Ca2+ transport in 
relation to claudin expression (15-17). Altogether, these studies collectively support 
the formation of cation-selective pores that can influence paracellular Ca2+ 
transport, possibly via 1,25(OH)2D3.  
The clinical importance of claudins might be further illustrated by observations 
in Williams-Beuren (WB) syndrome patients. This syndrome is characterized by a 
large deletion of about 26 genes, including claudin-3 and claudin-4, located on 
chromosome 7 (18, 19). Hypercalcemia resulting from enhanced intestinal Ca2+ 
absorption is a commonly observed symptom during WB syndrome, suggesting an 
etiologic role for claudin-3 and claudin-4 deficiency in the disturbed paracellular 
Ca2+ absorption (18). Consequently, we hypothesized that claudin-3 and claudin-4 
are involved in the formation of claudin pores that can selectively regulate 
paracellular Ca2+ flow.  
The aim of the present study was, therefore, to confirm this hypothesis using 
three different approaches. First, we selected two patients with Ca2+ 
hyperabsorption for claudin-3 and claudin-4 mutation analysis. Secondly, we 
generated and characterized Madine-Darby canine kidney (MDCKII) and human 
colorectal adenocarcinoma (Caco-2) cell lines stably expressing claudin-3 and 
claudin-4, and subsequently evaluated epithelial permeability features. Finally, we 
investigated the influence of 1,25(OH)2D3 on claudin expression via the 
quantification of various claudin isoforms (claudin-2, -3, -4, -7, -12, -15) in 
1,25(OH)2D3-deficient and 1,25(OH)2D3-supplemented mouse models.  
 
Methods 
 
Mutation analysis 
Two patients diagnosed with severe hypercalcemia (>3.0 mmol/l) as a result of 
intestinal Ca2+ hyperabsorption were included for claudin-3 (NM_001306) and 
claudin-4 (NM_001305) mutation analysis. Genomic DNA was isolated from the 
patient’s blood using standard procedures. Primers were designed to amplify 
claudin-3 and claudin-4 exon sequences by means of optimized Polymerase Chain 
Reaction (PCR) conditions (Table 1). PCR products were purified using the 
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GenElute PCR Purification kit or the GenElute gel extraction kit (Sigma-Aldrich, St. 
Louis, MO, USA) according to the manufacturer’s protocols. Mutation analysis of 
claudin-3 and claudin-4 coding regions was performed by forward and reverse 
sequencing using the same primers as in the PCR reaction (Table 1).  
 
Mouse models  
Three different mouse models were assessed, each representing different 
1,25(OH)2D3 serum levels. 1) TRPV5 knock-out (KO) mice lack the ability to 
reabsorb Ca2+ in the kidney via the transcellular pathway involving TRPV5 Ca2+ 
channels. As a consequence, these mice suffer from severe urinary Ca2+ wasting 
and show a compensatory increase in intestinal Ca2+ absorption due to enhanced 
serum 1,25(OH)2D3 levels (20). 2) In 1α-hydroxylase KO (1αKO) mice, ablation of 
the 1α-hydroxylase gene disables the conversion of vitamin D precursors into the 
active metabolite 1,25(OH)2D3. Therefore, 1αKO mice are 1,25(OH)2D3 deficient 
and as a result exhibit markedly reduced intestinal Ca2+ absorption (21). 3) Finally, 
wild-type mice were intraperitoneally injected with 50 ng 1,25(OH)2D3 (dissolved in 
peanut oil) once daily for 7 succeeding days. Wild-type mice injected with the 
vehicle phosphate buffered saline (PBS) served as control group. The KO strains 
were compared to their wild-type littermates. Each group contained 6-7 animals. At 
the end of each experiment, mice were sacrificed and the first two cm of the 
duodenum, part of the ascending colon, and the kidney were sampled and 
immediately frozen in liquid nitrogen. Samples were stored at -80ºC until further 
processing. All animal protocols were approved by the Animal Ethics board of the 
Radboud University Nijmegen, The Netherlands.  
 
Quantitative real-time PCR 
Total RNA was extracted from the duodenum, colon and kidney using Trizol Total 
RNA Isolation Reagent (Life Technologies BRL, Breda, The Netherlands). The 
obtained RNA was subjected to DNAse treatment to prevent genomic DNA 
contamination. Thereafter, 1.5 μg of RNA was reverse transcribed by Moloney-
murine leukemia virus-reverse transcriptase (Life Technologies BRL), as described 
previously (22). The obtained cDNA was used to determine claudin-2, -3, -4, -7, -
12, and -15 mRNA levels, as well as mRNA levels of the housekeeping gene 
hypoxanthine-guanine phosphoribosyl transferase (HPRT) as an endogenous 
control. PCR primers were designed using the computer program Primer Express 
(Applied Biosystems, Foster City, CA, USA) and purchased from Biolegio (Malden, 
The Netherlands). The primer sequences are described in Table 2. Expression 
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levels were quantified using the SybrGreen real-time PCR Master mix (Applied 
biosystems) on an iQ5 iCycler Detection System (Bio-rad, Hercules, CA, USA). 
 
Table 1. Primer sequences for human claudin-3 and claudin-4 mutation analysis 
gene exon 
_part 
forward primer (5’→3’) reverse primer (5’→3’) prod
(bp) 
ann  
(°C) 
MgCl2 
(mM) 
claudin-3 1_1 ACTGTCCTTAGGCCCTGGAG AGATGTTCTGCGACGTGATG 453 52 2 
claudin-3 1_2 GGCACCATCGTGTGCTGCG CTTGGTGGCCGTGTACTTC 531 50 1.5 
claudin-3 1_3 GTCGGCCAACACCATTATCC TGAGGTTTCACAGTCCATGC 492 54 2.5 
claudin-3 1_4 CTACGACCGCAAGGACTACG GCTCAGCTTACAACCCCATC 539 52 2.5 
claudin-4 1_1 AGCATGGGCTTTGAGGAAG GCGATGCCCATTACCTGTAG 453 52 2.5 
claudin-4 1_2 TGCACTCTGCGAACGTTAAG CACCGGCACTATCACCATAAG 514 54 2.5 
claudin-4 1_3 AACTGCCTGGAGGATGAAAG CTTGGGAAGTTGTCCGAGTG 504 54 2.5 
claudin-4 1_4 TGTTCTTCCCTGGACTGAGC CTCTAAACCCGTCCATCCAC 491 52 1.5 
claudin-4 1_5 - - - - - 
 
 
 
 
 
Table 2. Mouse primer sequences for quantitative real-time PCR analysis 
gene forward primer (5’→3’) reverse primer (5’→3’) 
HPRT TTATCAGACTGAAGAGCTACTGTAATGATC TTACCAGTGTCAATTATATCTTCAACAATC 
claudin-2 TGGTGGGCATGAGATGCA CTCCACCCACTACAGCCACTCT 
claudin-3 GCACCCACCAAGATCCTCTA GTAGTCCTTGCGGTCGTAGG 
claudin-4 CAACCCTATGGTGGCTTCC GTGTAGGGCTTGTCGTTGCT 
claudin-7 GGATTGGTCATCAGATTGTCACA TGGCAGGTCCAAACTCGTACT 
claudin-12 TCACATTCAACAGAAACGAGAAGAA CCATCATACCGGGCACACTT 
claudin-15 CGTGGTACGCCGTCAACAT GGGCCCAGTTCATACTTGGTT 
 
 
 
 
Immunoblotting 
For protein analysis, frozen duodenal, colonic and renal tissues from 1,25(OH)2D3 
and vehicle-treated wild-type mice were homogenized in ice-cold solubilization 
buffer as previously described (23). Protein concentration of the homogenates was 
determined (Bio-Rad Protein Assay; Bio-Rad München, Germany) and samples 
were normalized accordingly. Subsequently, total protein fractions (20 μg) were 
Primers (Biolegio, Malden, The Netherlands) were designed to amplify the entire exon 1 
sequence of claudin-3 and claudin-4. Subsequently, each purified PCR product was sequenced 
for mutation analysis using the forward and reverse primers. The generation of a PCR product 
belonging to the last part of the 3’ untranslated region of claudin-4 was unsuccessful. Ann, 
annealing temperature; prod, product; bp, base pair. 
Primers for SybrGreen quantitative real-time PCR were designed using Primer Express (Applied 
Biosystems, Foster City, CA, USA) and purchased from Biolegio (Malden, The Netherlands). 
HPRT, hypoxanthine-guanine phosphoribosyl transferase.  
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separated on a 14% (wt/vol) sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) gel and blotted to polyvinylidine difluoride (PVDF)-
nitrocellulose membranes (Immobilon-P; Millipore Corporation, Bedford, MA, USA). 
Blots were incubated o/n at 4ºC with the primary antibodies mouse claudin-2 
(1:2,500), rabbit claudin-3 (1:1,500), rabbit claudin-4 (1:250) (Zymed, South San 
Francisco, CA, USA) or mouse β-actin (1:25,000). Thereafter, blots were incubated 
with a goat anti-rabbit (claudin-3, claudin-4) or goat anti-mouse (claudin-2, β-actin) 
peroxidase coupled secondary antibody (1:10,000) (Sigma-Aldrich, St. Louis, MO, 
USA). Immunoreactive protein was detected using the chemiluminescence (ECL) 
method as described by the manufacturer (Pierce, Rockford, USA). 
Immunopositive bands were scanned using an imaging densitometer (Bio-Rad Gs-
690) to determine pixel density (Molecular Analyst Software; Bio-Rad Laboratories, 
Hercules, CA, USA).  
 
Constructs 
Full-length human cDNA clones were obtained for claudin-3 (No: 
IRAUp969F0173D, ImaGenes GmbH, Berlin, Germany) and claudin-4 (No: 
SC119294, Origene, Rockville, USA). To generate N-terminal Vesicular Stomatitis 
Virus (VSV)-tagged claudin-3 (VSV-claudin-3) and claudin-4 (VSV-claudin-4) 
constructs, the open reading frames were amplified by PCR using the primers 
forward 5’-GCTCTAGATCCATGGGCCTGGAGATCAC-3’ and reverse 5’-
CCCACCGGTTTAGACGTAGTCCTTGCGGTC-3’ for claudin-3 and forward 5’-
GCTCTAGAGCCTCCATGGGGCTACAGGT-3’ and reverse 5’-CCCACCGGTTTA 
CACGTAGTTGCTGGCAGC-3’ for claudin-4. Using the XbaI and AgeI restriction 
sites, the obtained PCR products were cloned into a PCB7 vector enclosing a VSV 
sequence (15 residue peptide KRQIYTDIEMNRLGK) between restriction sites KpnI 
and XbaI. Constructs were verified by DNA sequence analysis. An empty PCB7 
vector was used as negative control. All constructs contained the CMV promoter 
and a hygromycin resistance cassette.  
 
Stable transfection of Caco-2 and MDCK cells 
Intestinal Caco-2 and renal MDCK type II cells were cultured in DMEM (Bio 
Whittaker Europe, Vervier, Belgium) containing 13 mM NaHCO3, 2 mM L-
glutamine, 10 μg/ml ciproxin (Bayer, Mijdrecht, The Netherlands) and 20% or 5% 
(vol/vol) fetal calf serum (PAA, Linz, Austria), respectively, at 37ºC in a humidity-
controlled incubator with 5% (vol/vol) CO2. For stable transfection of Caco-2 cells, 
4x106 cells were seeded on Petri dishes (57 cm2) and grown to 80% confluency. 
Subsequently, 16 μg of construct DNA (VSV-claudin-3, VSV-claudin-4 or empty 
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PCB7) was stably transfected using 40 μl of lipofectamin 2000 (Invitrogen Life 
Technologies, Breda, The Netherlands) according to the manufacturer’s 
instructions and incubated for 6 hours. Cells were trypsinized 24 hours after 
transfection, seeded on Petri dishes, and cultured for three weeks in selection 
medium containing 2 mg/ml Hygromycin B (Invitrogen). MDCKII cells were stably 
transfected using the Ca2+ phosphate precipitation technique (24). In short, cells 
(0,25x106) were seeded on Petri dishes (57 cm2) and grown to 50% confluency. 
The transfection mix consisted of 25 μg construct DNA, 63 μl CaCl2, 500 μl Tris-
EDTA buffer and 500 μl 2x Hepes-buffered saline (HBS) that was incubated for 25 
minutes at room temperature.  The cells were exposed to the transfection mix for 5 
hours at 37ºC and a glycerol shock was performed afterwards. Cells were 
trypsinized 24 hours after transfection, seeded on Petri dishes, and cultured for 10-
14 days in selection medium containing 75 μg/ml Hygromycin B. Individual clones 
were isolated using cloning rings and expanded. Total cell lysates (Laemmli/ 
Dithiothreitol) were obtained from individual clones and subjected to 14% (wt/vol) 
SDS-PAGE and Western blotting. Clones were screened for VSV-claudin-3 and 
VSV-claudin-4 protein expression using the primary antibody mouse anti-VSV 
(1:10,000) (Sigma-Aldrich) and the peroxidase-coupled goat anti-mouse antibody 
(1:10,000) (Sigma-Aldrich). Protein signals were visualized using the ECL method 
(Pierce, Rockford, USA) as described above. Selected positive clones were 
maintained in medium containing 1 or 0.05 mg/ml Hygromycin B for Caco-2 and 
MDCKII cells, respectively.  
 
TEER measurements  
Stably transfected MDCKII and Caco-2 cells were seeded on 0.4 μm pore size 
Transwell polycarbonate permeable supports (Costar, Corning Europe, 
Badhoevedorp, The Netherlands) at a density of 4x105 and 1.75x105 cells/cm2, 
respectively. Transepithelial electrical resistance (TEER) of confluent monolayers 
was measured using an epithelial volt-ohm meter (EVOM) (World Precision 
Instruments, Berlin, Germany) after 7 and 21 days respectively. The resistance (Ω) 
of empty filters was subtracted and the final TEER was calculated as Ω x cm2.   
 
Immunocytochemistry                                                                                     
Stably transfected MDCKII and Caco-2 cells were seeded on Transwell filters as 
described above, and grown for 4 or 6 days, respectively. Thereafter, monolayers 
were washed twice with ice-cold PBS supplemented with 0.1 mM CaCl2 and 1 mM 
MgCl2 and were fixed in PBS containing 3% (wt/vol) paraformaldehyde for 30 min 
on ice. Subsequently, cells were permeabilized for 15 minutes in 0.3% Triton-X100 
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in PBS, blocked for 30 minutes in goat serum diluted buffer (containing 16% vol/vol 
goat serum, 0.3% vol/vol Triton-X100 and 0.3 M NaCl) and incubated o/n at 4°C 
with the primary antibodies mouse anti-VSV (1:300) (Sigma-Aldrich) and rabbit 
anti-Zona occludens-1 (ZO-1) (1:300) (Zymed). Staining was visualized using the 
secondary antibodies goat anti-mouse Alexa 488 and goat anti-rabbit Alexa 594 
(1:500) (Molecular probes, Eugene, OR, USA). Images were obtained with a 
FluoView 1000 confocal laser scanning microscope (Olympus, Hamburg, 
Germany).  
 
Results 
 
Claudin-3 and claudin-4 mutation analysis  
To evaluate whether mutations in the coding region of the TJ proteins claudin-3 
and claudin-4 are linked to changes in dietary Ca2+ absorption, genomic DNA from 
two patients with intestinal Ca2+ hyperabsorption (but not WB syndrome) was 
sequenced for claudin-3 and claudin-4. The results are listed in Table 3. Both 
genes contain one exon encoding a 1318 and 1846 bp mRNA product, 
respectively, with large 5’ and 3’ untranslated regions (UTR). Patient 1 enclosed 
two single nucleotide polymorphisms (SNPs) in the 5’UTR region of claudin-3, 
whereas no claudin-3 SNPs were identified in patient 2. On the other hand, in both 
patients five SNPs were found in the claudin-4 gene, however, all SNPs were 
located outside the translated region. Unfortunately, no PCR product could be 
amplified from the last part of the 3’UTR of claudin-4, which contained a highly GC-
rich area.  
 
Table 3. SNPs identified in the claudin-3 and claudin-4 genes  
patient  gene region dbSNP allele dbSNP rs# cluster ID 
1 claudin-3 exon1 / 5’UTR C→G rs7084 
1 claudin-3 exon1 / 5’UTR A→G rs11549499 
1 + 2 claudin-4 5’ UTR near region A→G rs4558741 
1 + 2 claudin-4 exon1 / 5’UTR C→T rs8629 
1 + 2 claudin-4 exon1 / 5’UTR A→G rs1127155 
1 + 2 claudin-4 exon1 / 3’UTR C→T rs1127156 
1 + 2 claudin-4 exon1 / 3’UTR C→G rs11316 
 
 
 
 
Mutation analysis of the genes claudin-3 and claudin-4 in two patients characterized by intestinal 
Ca2+ hyperabsorption. All identified SNPs are listed in the database of the National Center for 
Biotechnology Information (NCBI) and are recognized via the dbSNP rs# cluster ID number. Db, 
database; SNP, single nucleotide polymorphism; UTR, untranslated region.  
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Effect of 1,25(OH)2D3 on intestinal claudin expression 
mRNA expression of claudin-2, -3, -4, -7, -12 and -15 was quantified in the 
duodenum of 1,25(OH)2D3-injected wild-type mice as well as in 1αKO and TRPV5 
KO (V5KO) mice to investigate whether variations in 1,25(OH)2D3 serum levels 
affect intestinal claudin abundance (fig. 1A, D, E). Injections of the hormone in 
wild-type mice upregulated duodenal claudin-2 mRNA to 270 ± 29% of control 
values, whereas claudin-7 and claudin-15 were significantly reduced to 67 ± 8% 
and 56 ± 8%, respectively. Claudin expression remained equal in the duodenum of 
both 1αKO and TRPV5 KO mice as compared to their wild-type littermates. To 
further evaluate claudin abundance in 1,25(OH)2D3-supplemented wild-type mice, 
mRNA expression was also assessed in the colon and kidney (Fig. 1B, C). In the 
colon, claudin-4 mRNA expression diminished two-fold after 1,25(OH)2D3 
treatment, but claudin-12 significantly increased to 125 ± 6%. Claudin-2, -7 and -15 
were unaffected. Opposite to the effects in the duodenum and colon, renal claudin-
2 and claudin-12 expression declined, whereas renal claudin-4 mRNA abundance 
enhanced. Subsequently, the effect of 1,25(OH)2D3 injections on claudin-2, -3 and -
4 protein levels was investigated in the duodenum, colon and kidney by 
immunoblotting (fig. 2). In line with the mRNA data, duodenal claudin-2 protein 
doubled by 1,25(OH)2D3 treatment. However, the observed mRNA differences in 
the colon and kidney could not be confirmed on protein level.   
 
Stable overexpression of claudin-3 and claudin-4 in MDCK and Caco-2 cells 
MDCKII and Caco-2 cells were stably transfected with the constructs VSV-claudin-
3, VSV-claudin-4, and empty PCB7 vector as negative control (mock). Staining 
with antibodies against VSV and the TJ marker zona occludens-1 (ZO-1) verified 
the localization of overexpressed claudin protein by confocal laser scanning 
microscopy. In MDCKII cells, VSV staining revealed a nice expression of 
exogenous claudin-4 at the lateral membrane in all analyzed clones (Fig. 3A). 
Additional double-staining of clone 15 showed full co-localization with the TJ 
marker ZO-1, which strengthened the correct integration of overexpressed protein 
in the TJ complex. Subsequently, each individual clone was grown to confluency 
on filter and TEER values were evaluated after 7 days as a measure of TJ 
permeability (Fig. 3B). TEER in VSV-claudin-4 expressing monolayers reduced 
more than 50% in clones 3, 10 and 32, but was comparable to mock levels in 
clones 15 and 33. VSV-claudin-3 protein was highly expressed in MDCKII cells, but 
mainly resided in intracellular vesicular structures and was only slightly visible at
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Figure 1. Effect of the hormone 1,25(OH)2D3 on intestinal claudin expression. Claudin (cldn) 
mRNA levels in the duodenum (A), colon (B) and kidney (C) of 1,25(OH)2D3-injected wild-type 
mice as compared to vehicle-treated mice. Duodenal claudin mRNA expression in 1αKO (D) and 
V5KO (E) mice as compared to their wild-type littermates. mRNA levels were measured by 
quantitative real-time PCR and presented as % of controls. Values are expressed as mean ± 
SEM of N=6-7 animals per group. P<0.05 was considered statistically significant. Cldn, claudin; 
WT, wild-type; vitD3, 1,25-dihydroxyvitamin D3; 1αKO, 1α-hydroxylase knockout mice; V5KO, 
transient receptor potential vanilloid subtype 5 knockout mice. 
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the lateral membrane where the TJs are situated (Fig. 3A). Only clone 19 showed 
clear membrane staining. Nevertheless, TEER decreased to around 25% of mock 
values in most clones, except for clone 19, which surprisingly illustrated a two-fold 
increase in TEER (Fig. 3B). A large variation in TEER was observed between most 
individual transfected clones. Mock was negative for VSV staining (data not 
shown). In Caco-2 cells, clones transfected with VSV-cld-3 and empty PCB7 vector 
were evaluated (Fig. 4A). Confocal microscopy revealed robust VSV-claudin-3 
staining at the lateral membrane which fully co-localized with the TJ marker ZO-1 
in clone 9A and to a lesser extent in clone 12C, where claudin-3 was visible in 
intracellular vesicles as well. Clone 8B showed vesicular staining exclusively. 
Subsequent TEER measurements identified a large variation in mock values with 
levels around 250 Ω x cm2 for clone 20A and 2B, but with a level as high as 860 Ω 
x cm2 for clone 21A (Fig. 4B). Overall, Caco-2 cells overexpressing VSV-claudin-3 
illustrated an increase in TEER, except for clone 8B.  
 
Discussion 
 
This study described three experimental approaches to investigate the role of 
various claudin isoforms, in particular claudin-3 and claudin-4, in the regulation of 
intestinal paracellular Ca2+ transport. First, a mutation analysis for the screening of 
claudin-3 and claudin-4 genes was established, however, no mutations were 
identified in two patients with significant hypercalcemia and intestinal Ca2+ 
hyperabsorption. Secondly, stable overexpression of claudin-3 and claudin-4 
proteins in MDCKII and Caco-2 cell lines induced alterations in epithelial 
permeability as measured by TEER levels across confluent monolayers. Finally, 
the effect of 1,25(OH)2D3 on claudin mRNA and protein expression was examined 
using mouse models displaying variable 1,25(OH)2D3 serum concentrations. 
1,25(OH)2D3-injected wild-type mice exerted changes in intestinal and renal claudin 
expression, with the strongest effect observed on claudin-2. 
Since the identification of claudin proteins as important components of TJs, 
evidence has emerged supporting a claudin pore model in which four individual 
claudin isoforms create a pore-like structure that favours epithelial permeability to 
cations (7, 8). In line with this model, mutations in human claudin-16 and claudin-
19 have shown to induce urinary Mg2+ and Ca2+ wasting due to impaired 
paracellular reabsorption in the kidney (10, 12). In addition, claudin-16 knock-down 
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Figure 3. MDCKII cells stably overexpressing claudin-3 and claudin-4. (A) MDCKII cells were 
stably transfected with the constructs VSV-claudin-3 or VSV-claudin-4 and stained with anti-VSV 
antibody to localize overexpressed claudin-3 and claudin-4. VSV-claudin-4 clone #15 was double 
stained with antibodies against VSV and the TJ protein ZO-1. The merged pictures show the 
colocalization of claudin-4 and ZO-1. (B) TEER measurements for the individual clones measured 
after 7 days. Data are expressed as mean ± SEM of three separate filters. ZO-1, zona occludens-
1; TEER, transepithelial electrical resistance; TJ, tight junction. 
B 
0 
100 
200 
300 
400 
1 4 7 9 1 4 6 13 19 21 28 3 10 15 32 33 
TE
ER
 (Ω
 x
 c
m
2 ) 
mock VSV-claudin-3 VSV-claudin-4 
VSV-claudin-4 #15 VSV-claudin-4 
3 
10 
15 
33 
VSV-claudin-3 
4 
6 
13 
19 
VSV 
ZO-1 
merge 
A 
Claudins and paracellular Ca2+ transport 
 135
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
VSV-claudin-3 ZO-1 merge 
mock 
8B 
12C 
9A 
A 
Figure 4. Caco-2 cells stably overexpressing claudin-3. (A) Caco-2 cells were stably 
transfected with the construct VSV-claudin-3 or empty PCB7 vector (mock). Subsequently, cells 
were stained with antibodies against VSV and ZO-1 to localize overexpressed claudin-3 and the 
TJ protein ZO-1, respectively. Both images were merged to determine localization of 
overexpressed claudin-3 in TJ structures. (B) TEER measurements for the individual clones 
measured after 21 days. Data are expressed as mean ± SEM of three separate filters. ZO-1, zona 
occludens 1; TJ, tight junction. 
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mice exhibit increased urinary Mg2+ and Ca2+ excretion (14). Considering these 
data, the observed deletion of claudin-3 and claudin-4 in WB syndrome and the 
related high incidence of hypercalcemia with Ca2+ hyperabsorption as primary 
target, strongly points toward the involvement of claudin-3 and claudin-4 in 
paracellular Ca2+ uptake (18). Therefore, we sequenced the genes claudin-3 and 
claudin-4 in two patients with comparable Ca2+ disturbances as in WB syndrome, 
i.e.hypercalcemia resulting from intestinal Ca2+ hyperabsorption. Multiple SNPs 
were identified that are located outside the coding region and are frequently 
present in a Caucasian population (around 25%, National Center for Biotechnology 
Information). Consequently, it is unlikely that the Ca2+ disturbances in the two 
examined patients originate from these SNPs. To our knowledge, no claudin-3 and 
claudin-4 mutations have been reported in literature so far. Nevertheless, the 
described Ca2+ hyperabsorption may also result from mutations in the claudin-3 
and claudin-4 promoter region, post-translational alterations in claudin-3 and 
claudin-4 protein folding or mistrafficking of the protein to the TJs. Hence, inclusion 
of patients with intestinal Ca2+ hyperabsorption remains interesting for future 
mutation screening of the claudin-3 and claudin-4 genes as well as the claudin-3 
and claudin-4 promoter regions.   
To further evaluate the role of claudin-3 and claudin-4 in paracellular Ca2+ 
transport, renal and intestinal epithelial cell lines stably expressing claudin-3 and 
claudin-4 were generated. We hypothesized that claudin-3 and claudin-4 maintain 
a tight epithelial barrier characterized by high TEER levels. Any loss in claudin-3 
and claudin-4 might result in reduced TEER values and enhanced cation 
permeability. Consequently, the deletion of the claudin-3 and claudin-4 genes in 
WB syndrome increases epithelial cation permeability to selectively favour 
paracellular Ca2+ absorption. In line with this assumption, stable human claudin-4 
overexpression in MDCKII cells increased TEER levels and reduced paracellular 
conductance through a selective decrease in Na+ permeability without a significant 
effect on chloride permeability (13, 25). Retrieval of endogenous claudin-4 from the 
plasma-membrane in MDCKI cells reduced TEER and increased permeable flow of 
macromolecules in parallel (26). Furthermore, the incubation of Caco-2 cells with 
ochratoxin A, a substance that selectively removes claudin-3 and claudin-4 from 
the membrane TJ network, induced a reduction in TEER with a concomitant 
increase in the paracellular permeability of membrane impermeable tracers (27, 
28). Evaluation of exogenous protein localization in confluent MDCKII monolayers 
as described in the current study revealed that VSV-claudin-4 is well localized at 
the membrane, whereas VSV-claudin-3 is predominantly located in cytosolic 
vesicles. Subsequent permeability measurements displayed diminished TEER 
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values in MDCKII cells expressing claudin-3 and unchanged or reduced TEER 
values in claudin-4 overexpressing MDCKII cell layers. Since claudin-3 
overexpression showed altered TEER values, we presumed that the amount of 
VSV-claudin-3 expressed at the TJs was sufficient to exert a measurable effect.  
In this study, the observed effect of stable claudin-3 and claudin-4 transfection 
in MDCKII cells, which differs from similar experiments in literature, can be clarified 
by several explanations. Introduction of exogenous proteins in TJ strands might 
disturb the expression or localization of endogenous claudins. For instance, 
Amasheh et al. reported that the presence of claudin-2 causes the formation of 
cation-selective channels sufficient to transform a tight epithelium into a leaky one, 
which reduced TEER (7). Altered TJ claudin composition, especially changes in the 
claudin-2 abundance, can affect TJ properties independent of the overexpressed 
protein, thus affecting TEER. Investigation of endogenously expressed claudin 
isoforms like claudin-2 is, therefore, important to fully characterize the TJ features 
in the generated cell models. Another possibility for the observed discrepancy in 
TEER values, is the use of tagged proteins. Tags might affect trafficking to the 
membrane or disturb correct integration into the TJ structure via disabled binding to 
other claudin isoforms. Application of untagged proteins could be an alternative, 
however, lack of discrimination between endogenous and exogenous proteins is a 
significant disadvantage. In contrast to the data in MDCKII cells, overexpression of 
VSV-claudin-3 in Caco-2 monolayers mainly increased TEER levels in clones with 
VSV-claudin-3 membrane localization, which is in line with the described 
hypothesis. Unfortunately, a large interclone variation was observed in both cell 
lines which hampered a plain evaluation of results. The cell models characterised 
in this study need further evaluation to elucidate the results in more detail. Once 
the MDCKII and Caco-2 cell lines are thoroughly characterised, they could serve 
as excellent in vitro models to demonstrate the possible involvement of claudin-3 
and claudin-4 in renal and intestinal paracellular Ca2+ transport, respectively.   
Beside cell models, we used mouse models to assess regulation in claudin 
expression in vivo. The hormonal control of transcellular Ca2+ transport, mainly via 
1,25(OH)2D3, has been widely accepted and successfully applied as therapy for 
bone disorders in clinic. In contrast, only a small number of studies investigated the 
potential effect of this hormone on claudin expression and related paracellular Ca2+ 
transport. Stimulation of confluent Caco-2 monolayers with 1,25(OH)2D3 has shown 
to promote a dose-dependent reduction in TEER and a concomitant rise in 
paracellular Ca2+ transport (15). Micro-array analysis of 1,25(OH)2D3-deficient rats 
supplemented with 1,25(OH)2D3 revealed a decline in duodenal claudin-3 mRNA 
(29), which might indicate a loss of barrier function and enhanced epithelial 
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permeability. Moreover, a study by Efrati et al. showed that 1,25(OH)2D3 inhibits 
claudin-16 promoter activity and, in this way, might modulate paracellular Mg2+ 
transport via reduced claudin-16 transcription (16). Finally, Fujita et al. observed a 
1,25(OH)2D3-mediated upregulation of claudin-2 and claudin-12 expression in 
intestinal cells via the vitamin D receptor (VDR). In agreement with this result, 
claudin-2 and claudin-12 were down-regulated in the gut of VDR KO mice, a model 
representing 1,25(OH)2D3 deficiency (17). To confirm the effect of 1,25(OH)2D3 on 
claudin-2 and claudin-12, we analyzed intestinal claudin expression in 1αKO mice. 
However, lack of 1,25(OH)2D3 did not alter claudin levels in this model. The VDR 
and 1αKO models share many features, illustrated by reduced expression of 
transcellular Ca2+ transporters, impaired intestinal Ca2+ uptake, hypocalcemia and 
severe bone loss (21, 30). Currently, we are not able to explain these observed 
differences in claudin expression.  
On the contrary, this study using 1,25(OH)2D3-injected wild-type mice displayed  
enhanced claudin-2 and diminished claudin-4 mRNA levels in the intestine, 
whereas in kidney exactly the opposite effect was observed. Since claudin-2 
expression is associated with a leaky epithelium (7, 31) and claudin-4 with a tight 
epithelium (25), the observed changes might be physiologically linked to enhanced 
paracellular Ca2+ absorption and reduced renal paracellular Ca2+ reabsorption, 
respectively. This is in line with the phenotype of 1,25(OH)2D3-treated wild-type 
mice, including Ca2+ hyperabsorption and increased urinary Ca2+ excretion.  
Typically, TRPV5 KO mice illustrated by a 300% induction of serum 
1,25(OH)2D3 levels did not display changes in claudin expression (20). Possibly, 
1,25(OH)2D3 injections represent short-term effects whereas TRPV5 KO mice 
exhibit long-term adaptations after chronic hypervitaminosis D. The lack of 
changes in paracellular Ca2+ transport proteins suggests that the Ca2+ disturbances 
in TRPV5 KO mice are mainly induced via altered transcellular transport 
processes, although more information about TJ composition and function is 
required to draw conclusions. Interestingly, a recent publication examined intestinal 
Ca2+ absorption in TRPV6/calbindin-D9k double KO mice, which fully lack the 
transcellular Ca2+ absorption pathway. These double KO mice showed dose-
dependent 1,25(OH)2D3-induced Ca2+ absorption, supporting the importance of 
paracellular Ca2+ transport and its regulation via 1,25(OH)2D3 (32). Thus, further 
evaluation of this double KO strain, especially the abundance of various intestinal 
claudin isoforms, could be an interesting aspect to obtain more insight into claudin-
dependent paracellular Ca2+ transport.  
In summary, this study demonstrated three experimental approaches for claudin 
research, i.e. claudin-3 and claudin-4 mutation analysis, characterization of cell 
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models stably expressing claudin-3 and claudin-4, and mRNA and protein 
expression measurements in vivo. After complete characterization and 
optimalization of these newly established models, they can be used to investigate 
the role of claudins in paracellular Ca2+ transport and more specifically in the 
etiology of robust intestinal Ca2+ hyperabsorption. Furthermore, the generation and 
characterization of claudin specific KO mice as well as the examination of 
TRPV6/calbindin-D9k double KO mice can give new insights into the challenging 
research area of claudin-dependent paracellular Ca2+ transport in vivo.   
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Ca2+ homeostasis 
 
The regulation of the body’s extracellular Ca2+ level is vital for a healthy body, since 
Ca2+ is involved in processes like nerve innervation, muscle contraction, cell 
signaling and bone formation. The maintenance of extracellular Ca2+ 
concentrations within a physiological range is coordinated by a fine-tuned interplay 
of dietary absorption in the intestine, reabsorption from the pro-urine in the kidney 
and Ca2+ exchange with the skeleton (1). A central role in Ca2+ homeostasis plays 
the transfer of Ca2+ across epithelial cell layers lining the lumen of the intestine and 
the renal tubules. Ca2+ crosses this epithelial barrier via two distinct pathways (Fig. 
1). In a paracellular route Ca2+ diffuses through the intercellular space entirely 
driven by electrochemical gradients. Therefore, luminal Ca2+ mainly defines 
paracellular Ca2+ flow. In a transcellular pathway, however, specialized transport 
proteins facilitate the passage of Ca2+ via the cell involving an energy-requiring 
step to transmigrate Ca2+ across the basolateral membrane. This process is highly 
regulated by hormones such as 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and 
parathyroid hormone (PTH), which enables a tight regulation of Ca2+ transport 
independent of luminal Ca2+ concentrations (1, 2). Consequently, paracellular 
transport dominates when luminal Ca2+ is high and/or Ca2+ demands are fulfilled, 
whereas the transcellular machinery is stimulated in times of Ca2+ shortage and/or 
increased Ca2+ requirements (1, 2).  
An impaired Ca2+ balance can induce serious health problems of which reduced 
bone mineral density (BMD) (osteoporosis) is a well-known and frequent clinical 
example (2, 3). Particularly postmenopausal women and people with chronic 
recurrent intestinal inflammations, such as Crohn’s disease, ulcerative colitis and 
coeliac disease, are prone to develop osteoporosis (4-7). To treat these Ca2+ 
disturbances effectively, understanding of the Ca2+ transport mechanisms, primarily 
the involved proteins and the regulation via hormones, dietary components and 
drugs, is essential. The current thesis focuses on intestinal Ca2+ (mal)absorption 
processes and describes in more detail its regulation in health, during ageing and 
in patients with intestinal inflammatory disorders.  
 
Transcellular Ca2+ transport  
 
Involvement of Ca2+ transport proteins 
The transcellular Ca2+ transport pathway is emphasized as a three step model, 
consisting of  luminal entry  into  the epithelial  cell  via Transient  Receptor  Potential 
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Figure 1. Overview of Ca2+ transport pathways in the intestine and their regulatory 
pathways. Ca2+ crosses the intestinal epithelium via an energy-dependent transcellular pathway 
involving the proteins TRPV6, calbindin-D9k and PMCA1b. Hormones, like 1,25(OH)2D3 and 
estrogen, but also dietary Ca2+, dietary fibers and glucocorticoids influence the expression of Ca2+ 
transporters via gene regulation. 1,25(OH)2D3 binds to the VDRE in the genes of TRPV6 and 
calbindin-D9k. Also luminal pH can influence TRPV6, since an acidic environment inhibits TRPV6 
channel activity. In a paracellular pathway Ca2+ flows through the intracellular space where tight 
junctions are located. It is postulated that 4 individual claudin isoforms aggregate with their ECL1 
to form charge- and size- selective pore structures. The claudin ECL1 is composed of a mixture of 
positive-, neutral-, and negative-charged amino acids, which are hypothesized to determine the 
final charge-selectivity of the pore region. A more negative-charged pore facilitates cation 
transport, including Na+ and Ca2+. The expression of tight junction proteins, such as claudin and 
ZO-1, is down-regulated via cytokines, which impairs barrier function. 1,25(OH)2D3 is reported to 
stimulate claudin-2 expression in the intestine, but the effect on other claudin isoforms is 
indefinite. SCFAs produced after the fermentation of dietary fibers in the colon reduces luminal 
pH, which improves Ca2+ solubility and consequently enhances the amount of Ca2+ available for 
Ca2+ transport. The effect of glucocorticoids and dietary components on claudin expression 
remains to be elucidated. TRPV6, Transient Receptor Potential Vanilloid subtype 6; PMCA1b, 
plasma-membrane Ca2+-ATPase; 1,25(OH)2D3, 1,25-dihydroxyvitamin D3; TJ, tight junction; 
ECL1, extracellular loop 1; ZO-1, zona occludens-1; GR, Glucocorticoid Receptor; VDR, Vitamin 
D Receptor; VDRE, vitamin D-responsive element; ER, estrogen receptor. 
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Vanilloid subtype 5 or 6 Ca2+-selective ion channels (TRPV5, TRPV6), intracellular 
binding to Ca2+-binding proteins (calbindin-D9k, calbindin-D28k) that shuttle Ca2+ to 
the basolateral membrane, where it is finally extruded into the blood stream via 
plasma-membrane Ca2+-ATPase (PMCA1b) or Na+/Ca2+ exchanger 1 (NCX1) (Fig. 
1) (1). TRPV5, calbindin-D28k and NCX1 are reported as key players in the kidney, 
where they co-localize in renal epithelial cells of the late distal convoluted tubules 
(DCT2) and connecting tubules (CNT). In the intestine, TRPV6, calbindin-D9k and 
PMCA1b are postulated as the responsible mediators of transcellular absorption (1, 
2, 8) that primarily takes place in the duodenum as shown by the specific 
expression of TRPV6 and calbindin-D9k in this segment of the human gut (chapter 
5).                                                                                                                                                     
 
Function of Ca2+ transport proteins: lessons from KO mouse models 
The generation of knockout (KO) mice in which genes of individual Ca2+ transport 
proteins are ablated, gained important information about the transcellular Ca2+ 
transport model (Table 1). TRPV5 KO mice display a predominant renal phenotype 
characterized by severe urinary Ca2+ excretion due to impaired tubular Ca2+ 
reabsorption (9). Renal calbindin-D28k and NCX1 expression is concomitantly 
diminished in these mice, despite elevated serum 1,25(OH)2D3 levels, suggesting a 
regulatory mechanism controlled primarily by TRPV5. Furthermore, calbindin-D28k 
translocates towards the apical membrane where it buffers Ca2+ and regulates the 
Ca2+ concentration in close vicinity to the TRPV5 pore by direct association with 
the channel (10). Strikingly, in most studies, calbindin-D28k KO mice do not show 
renal Ca2+ wasting (11, 12). Nevertheless, Lee et al. and Sooy et al. describe a 
diet-dependent two- to three-fold raise in urinary Ca2+ excretion in calbindin-D28k 
KO mice (13, 14), though this increase is markedly smaller than in the TRPV5 KO 
strain (ten-fold), indicating that TRPV5 is more critical for renal transcellular Ca2+ 
reabsorption than calbindin-D28k. In line with these results, TRPV5/calbindin-D28k 
double KO mice do not exhibit aggravation of the renal Ca2+ leakage as observed 
in TRPV5 KO mice (11, 15). Overall, these data establish the involvement of 
TRPV5, calbindin-D28k and NCX1 in renal transcellular Ca2+ transport, and verify 
apical Ca2+ influx via TRPV5 as the rate-limiting step.  
The physiological relevance of the proposed transcellular Ca2+ transport model 
in the gut, requiring TRPV6, calbindin-D9k and PMCA1b, however, is still under 
debate. In support of the model is the marked reduction in transcellular Ca2+ 
absorption in TRPV6 KO mice (16). In addition, depletion of 1,25(OH)2D3 in Vitamin 
D Receptor (VDR) and 1α-hydroxylase KO mice impairs transcellular Ca2+ 
yuiuyiyuioyui 
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Parameters are evaluated in mice maintained on a normal or low Ca2+ diet. All data are compared 
to wild-type mice on similar Ca2+ diet. KO, knockout; Ca2+, calcium; PTH, parathyroid hormone; 
vitD3, 1,25-dihydroxyvitaminD3; TRPV, transient receptor potential vanilloid; C28k, calbindin-D28k; 
C9k, calbindin-D9k; 1α-OHase, 1α-hydroxylase; VDR, vitamin D receptor; L, low Ca2+ diet; N, 
normal Ca2+ diet; x, absent; nd, not determined; ref, reference.  
Tabel 1. Serum parameters and expression of renal and intestinal Ca2+ transport proteins 
in KO mouse models.    
 Serum kidney intestine  KO strain 
diet Ca2+ PTH vitD3 TRPV5 TRPV6 C28k C9k TRPV6 C9k ref 
TRPV5  N ↔ ↔ ↑ x nd ↓ ↓ ↑ ↑ (9, 18) 
 L ↔ ↑ ↑ x nd ↓ ↑ ↑ ↑ (11) 
TRPV6  N ↔ ↑ ↑ ↔ x ↔ ↔ x ↔ (15, 16) 
 L ↓ ↔ ↔ ↓ x nd nd x ↔ (15, 16) 
C28k  N ↔ ↔ ↔ ↔ ↔ x ↔ ↔ ↔ (12, 20) 
 L ↔ ↔ ↔ nd nd x ↔ ↔ ↔ (11) 
C9k  N ↔ ↔ ↔ ↔ ↔ ↔ x ↔ x (15, 21, 22) 
C9k/C28k N ↔ nd nd ↔ ↔ x x ↔ x (20) 
TRPV5/C28k  L ↔ ↑ ↑ x nd x ↑ ↑ ↔ (11) 
TRPV6/C9k  N ↔ ↑ nd ↔ x ↔ nd x x (15) 
1α-OHase  N ↓ ↑ x ↓ nd ↓ ↓ ↓ ↓ (17, 18, 23) 
VDR  N ↓ ↑ ↑ ↔ ↓ ↔ ↓ ↔ ↓ ↓ ↓ (12, 19) 
 L ↓ ↑ ↑ ↔ ↔ ↓ ↓ ↓ ↓ (19) 
TRPV5/1α-OHase N ↓ ↑ x x nd ↓ ↓ ↓ ↓ (18) 
C28k/ VDR N ↓ ↑ ↑ ↓ ↓ x ↓ nd ↓ (12) 
absorption via a concomitant reduction in duodenal TRPV6 and calbindin-D9k 
expression (17-19). Also the observed compensatory intestinal Ca2+ 
hyperabsorption in TRPV5 KO mice is induced by a 1,25(OH)2D3-mediated 
increase in duodenal TRPV6 and calbindin-D9k expression (9). Generally, these 
data underline the important role of TRPV6 and calbindin-D9k in transcellular Ca2+ 
absorption from the gut. Of notice, ablation  of calbindin-D9k does not impair or 
aggravate intestinal Ca2+ absorption in calbindin-D9k KO and TRPV6/calbindin-D9k 
double KO mice, respectively (15, 21, 22), showing that the apical TRPV6-
dependent Ca2+ influx step is most critical for intestinal transcellular Ca2+ transport. 
On the other hand, the phenotypes of TRPV6 KO, calbindin-D9k KO and 
TRPV6/calbindinD9k double KO mice are not fully in line with the current intestinal 
transcellular Ca2+ transport model. For example, in TRPV6 KO mice duodenal 
calbindin-D9k mRNA is equal to the amount in wild-type littermates despite elevated 
serum 1,25(OH)2D3 levels, suggesting that in the intestine TRPV6 and calbindin-
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D9k are independently regulated (16). Of notice, direct association between 
calbindin-D9k and TRPV6 has not been demonstrated to date. More importantly, 
Benn et al. describe an upregulation of duodenal transcellular Ca2+ transport in 
calbindin-D9k KO, TRPV6 KO and TRPV6/calbindin-D9k double KO mice on low 
Ca2+ diet (15). Furthermore, calbindin-D9k KO, TRPV6/calbindin-D9k double KO and 
1,25(OH)2D3-deficient TRPV6 KO mice display an increase in transcellular Ca2+ 
absorption after 1,25(OH)2D3 administration (15, 24, 25). These data reveal that 
beside TRPV6 and calbindin-D9k other unknown 1,25(OH)2D3-sensitive factors 
might facilitate the apical Ca2+ entry and cytosolic Ca2+-binding steps. 
Nevertheless, these TRPV6 and calbindin-D9k independent mechanisms are not 
sufficient to maintain normal Ca2+ homeostasis, as indicated by the substantial 
secondary hyperparathyroidism in TRPV6 KO and TRPV6/calbindin-D9k double KO 
mice and the inability to respond to further Ca2+ challenges (15, 16). Overall, the 
60% reduction in transcellular Ca2+ absorption observed in TRPV6 KO mice is 
adequately demonstrating that TRPV6 is an important member of the absorptive 
process under most physiological conditions (16). 
Calbindin-D9k KO and calbindin-D28k KO mice are comparable in phenotype to 
their wild-type littermates (11, 12, 15, 21, 22). Even calbindin-D9k/calbindin-D28k 
double KO mice do not show Ca2+ disturbances or changes in other renal and 
intestinal Ca2+ transporters when maintained on a normal Ca2+ diet (20). Only when 
challenged with a Ca2+ deficient diet calbindin-D9k/calbindin-D28k double KO mice 
exhibit reduced serum Ca2+ levels and a significant decrease in renal and intestinal 
TRPV6 expression (20). Possibly, the paracellular transport pathway is capable to 
maintain Ca2+ homeostasis when Ca2+ supplies are high. Other studies suggest a 
compensatory upregulation of renal and intestinal Ca2+ transporters (22, 26, 27). Of 
special interest is the regulation of additional proteins able to facilitate cytosolic 
Ca2+-binding and transfer. For instance, under low calcemic conditions TRPV5 KO 
and TRPV5/calbindin-D28k double KO mice show a compensatory increase in renal 
calbindin-D9k, which is abundantly present in the same tubular cells (DCT2 and 
CNT) as TRPV5 and calbindin-D28k (11). However, this increase might be due to 
the elevated serum 1,25(OH)2D3 levels instead of a direct effect of TRPV5 loss. In 
calbindin-D28k KO mice, characterized by normal serum 1,25(OH)2D3 values, the 
majority of studies do not observe a raise in renal calbindin-D9k (11, 12, 20), except 
for a report by Kim et al. (26). Importantly, calbindin-D9k is only present in mouse 
kidney but absent in rats and humans (28), which complicates physiological 
extrapolation and excludes it as a suitable Ca2+-binding protein in human kidney. In 
the intestine, calbindin-D28k expression is negligible (chapter 5) and therefore not a 
likely Ca2+-binding candidate. Additional alternatives for intestinal calbindin-D9k 
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have not been identified to date. Consequently, further research is required to fully 
unravel the Ca2+-buffering step in human transcellular Ca2+ transport, mainly in the 
intestine where the correlation between TRPV6 and calbindin-D9k is less definite.  
 
TRPV5/6 tissue distribution and role in other Ca2+-transporting epithelia  
In contrast to the specific localization of TRPV5 in kidney, TRPV6 is more 
ubiquitously expressed throughout the body, including the kidney, placenta, 
prostate, bone, duodenum and stomach (29-32). Interestingly, TRPV6 KO mice 
show enhanced urinary Ca2+ excretion, suggesting a possible role for TRPV6 in the 
kidney (16). This is in agreement with an earlier finding showing that 1,25(OH)2D3-
responsive TRPV6 is present in the DCT2, CNT and collecting ducts (33). Various 
in vitro studies hypothesize the formation of TRPV5 and TRPV6 heterotetrameric 
channels (34-36). This implies that different combinations of TRPV5 and TRPV6 
channels compose a functional and highly Ca2+-selective pore. When TRPV6 is 
genetically ablated, the remaining TRPV5 proteins in the tetrameric structure might 
form a less active Ca2+-selective channel, which could explain the renal phenotype 
as observed in TRPV6 KO mice. However, TRPV5 abundance is low in the 
intestine, which complicates the understanding of this proposed model in the gut. 
Moreover, TRPV6 KO fetuses have a reduced serum Ca2+ concentration and a 
40% lower Ca2+ transport across the placenta compared to wild-type fetuses, 
providing evidence that TRPV6 is involved in maternal-fetal Ca2+ transfer (16, 37). 
The high abundance of TRPV6 transcripts in the human gastric region (chapter 5) 
suggests the involvement of the stomach in transcellular Ca2+ absorption. 
However, TRPV6 channels are inactivated at low extracellular pH, which makes a 
functional role for TRPV6 in the stomach uncertain, unless the pH is buffered in 
close vicinity of the channel for example via the protective mucus layer. Otherwise, 
TRPV6 abundance might be upregulated to compensate for the reduced channel 
activity in the stomach.  
Finally, TRPV5/6, calbindin-D9k/-D28k, PMCA1b and NCX1 are present in bone 
tissue (38) (chapter 4). In general, elevated serum PTH levels are most 
detrimental for bone mineralization because it stimulates Ca2+ release from the 
matrix under low calcemic conditions. However, TRPV5 KO mice display reduced 
cortical and femoral bone mineralization without changes in PTH levels in 
combination with an increase in osteoclast number and size (9, 18). In bone, 
TRPV5 is localized exclusively to the ruffled border of osteoclasts (38). Additional 
studies in TRPV5 KO-derived bone marrow cultures illustrate loss of bone 
resorptive capacity, thus indicating involvement of TRPV5 in osteoclast-mediated 
bone resorption (38). However, treatment of TRPV5 KO mice with the bone 
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resorption inhibitor alendronate normalizes the reduced BMD, demonstrating that 
significant bone resorption still occurs in TRPV5 KO mice. TRPV6 did not 
compensate for the loss of TRPV5 in osteoclasts suggesting different functions for 
TRPV5 and TRPV6 in bone (9, 38). TRPV6 KO mice develop reduced BMD as well 
(15). The elevated serum PTH levels in combination with impaired dietary Ca2+ 
uptake promote bone resorption. However, the failure of a high Ca2+ diet to 
normalize BMD in TRPV6 KO mice suggests a TRPV6-dependent bone 
mineralization defect. The expression of other Ca2+ transport proteins in TRPV5 
and TRPV6 KO mice is not fully evaluated to date, but could contribute to the 
elucidation of the Ca2+ transport machinery in bone.   
 
Regulation of transcellular Ca2+ transport 
 
1,25(OH)2D3, PTH and calcitonin are the major calciotropic hormones and their 
impact on epithelial Ca2+ fluxes in kidney, intestine and bone is broadly established 
(1). In addition, under low calcemic conditions dietary Ca2+ directly regulates gene 
transcription of transcellular Ca2+ transport proteins independent of 1,25(OH)2D3 
(39-41). Recently, new dietary components and drugs, such as indigestible fibers 
and glucocorticoids, have been identified that influence intestinal Ca2+ transport 
(Fig. 1) (26, 42, 43).  
 
Dietary fibers 
The consumption of a diet enriched with 5-10% indigestible fibers, such as fructo-
oligosaccharides (FOS) or the polysaccharide inulin, has proven to stimulate net 
intestinal dietary Ca2+ absorption in rats, mainly in the large intestine, i.e. the 
cecum, colon and rectum (44-46). Indigestible fibers reach the large intestine 
intact, where they are fermented by bacteria that colonize the intestinal lumen. 
During this fermentation process short-chain fatty acids (SCFA), including lactate, 
acetate, propionate and butyrate, are produced as by-products that concomitantly 
reduce luminal pH. It is postulated that this lowered pH improves Ca2+ solubility 
and increases the amount of Ca2+ available for paracellular diffusion across the 
epithelium. Other studies hypothesize that transcellular Ca2+ transport is involved, 
since FOS enhances colorectal mRNA expression of calbindin-D9k (45, 46). 
Recently, Fukushima et al. describe the induction of both TRPV6 and calbindin-D9k 
mRNA in rat colorectum after FOS treatment, whereas PMCA1b abundance 
remains unaffected (42). In addition, stimulation of Caco-2 monolayers with sodium 
propionate and sodium butyrate upregulates TRPV6 mRNA 17-fold and 41-fold, 
respectively. Moreover, a SCFA-responsive element is identified in the TRPV6 
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coding gene (42). These data suggest that fermentation products of FOS, mainly 
butyrate and propionate, promote the expression of colorectal TRPV6 and 
calbindin-D9k to ultimately enhance intestinal Ca2+ absorption. However, the 
potential involvement of the transcellular Ca2+ machinery remains elusive, since the 
increase in Ca2+ absorption is mainly located in the colon where expression of 
transcellular Ca2+ transporters is relatively low compared to the duodenum 
(chapter 5) and a reduced extracellular pH inactivates TRPV6 channel activity. 
Overall, evidence supporting indigestible fiber-mediated changes in Ca2+ 
absorption is strong, however, a clear association with the paracellular or 
transcellular Ca2+ transport pathway is still lacking.  
 
Glucocorticoids 
Glucocorticoids, like prednisolone and dexamethasone, are frequently prescribed 
in clinic because of their anti-inflammatory properties. Although these drugs are 
efficient to treat, for instance, rheumatic arthritis and inflammatory bowel diseases 
(IBD), a well-known side-effect of long-term glucocorticoid therapy is the reduction 
of bone mineralization (4, 47-50). Diminished absorption of Ca2+ from the gut is 
implicated in the onset of glucocorticoid-mediated osteoporosis (51-53). This effect 
on Ca2+ uptake can be secondary due to reduced serum 1,25(OH)2D3 levels, which 
might affect the expression of transcellular Ca2+ transporters. However, earlier 
reports are inconclusive regarding this subject, since several studies show 
decreased serum 1,25(OH)2D3 levels after glucocorticoid treatment, whereas 
others do not observe any changes (54, 55). In chapter 3 the effect of 7-day 
prednisolone administration on Ca2+ absorption is assessed in mice. Prednisolone 
diminishes dietary Ca2+ uptake with a concomitant decline in intestinal TRPV6 and 
calbindin-D9k mRNA expression. Furthermore, serum 1,25(OH)2D3 levels are 
normal indicating a 1,25(OH)2D3-independent effect of prednisolone on TRPV6 and 
calbindin-D9k gene transcription. The expression of renal Ca2+ transporters is 
unchanged, suggesting a local interaction with the intestine, since prednisolone is 
ingested orally. These data are in line with a previous study of Hahn et al. (56) who 
demonstrate that prednisolone has a minor effect on serum 1,25(OH)2D3 levels in 
12 patients, whereas intestinal Ca2+ absorption drops by 30%. Recently, a study by 
Kim et al. has observed similar results after subcutaneous dexamethasone 
injections in mice for 5 days, showing reduced duodenal TRPV6 and calbindin-D9k 
mRNA, while dexamethasone did not have an effect in the kidney (26). 
Furthermore, they detected reduced expression of duodenal glucocorticoid 
receptors (26). In addition, Lee et al. examined the effect of mifepristone, a 
glucocorticoid receptor antagonist. This drug completely abolished the decline of 
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calbindin-D9K mRNA caused by dexamethasone (57). Altogether, this implicates 
that the glucocorticoid-induced decrease in intestinal Ca2+ uptake is 1,25(OH)2D3-
independent and might be caused by a direct effect on the glucocorticoid receptor. 
In contrast, a single dose of dexamethasone in rats increased expression of renal 
and intestinal Ca2+ transporters, together with enhanced urinary Ca2+ wasting (58). 
The authors suggest the impairment of Na+-driven renal paracellular Ca2+ 
reabsorption in proximal tubules and TAL where on average 70-90% of total Ca2+ is 
reabsorbed. Indeed, dexamethasone is known to inhibit the function and 
expression of the renal Na+/phosphate co-transporter (59-61) and impair Na+ 
reabsorption. The resulting reduction of paracellular Ca2+ reabsorption in the 
proximal tubules and TAL increases luminal Ca2+ concentration in the more distal 
tubules where it can trigger a compensatory upregulation of transcellular Ca2+ 
transporters. Another explanation could be the variation in acute or chronic 
treatment, since it is known that the glucocorticoid-mediated effects are time- and 
dose-dependent.  
 
Paracellular Ca2+ transport 
 
Involvement of tight junction proteins 
An additional route for epithelial Ca2+ transport is the flow of Ca2+ through the 
narrow paracellular space located between epithelial cells. However, tight junction 
(TJ) structures located most apically inside the paracellular space provide a barrier 
between the apical and basolateral compartments that restricts free passage of 
ions and solutes (62, 63). The TJ is a network of numerous large transmembrane 
protein strands that are connected to equivalent strands anchored in the 
membrane of neighboring cells (chapter 1, Fig. 4) (63-65). In this way, the TJ 
spans the paracellular space forming pore-like structures with charge- and size-
selectivity (Fig 1.) (66). Although four different classes of transmembrane proteins 
are identified in TJ strands, the large claudin family is described as the most vital 
element to create ion-selective pores and determine epithelial barrier function (65). 
The specific assembly of the first extracellular loop (ECL1) of four individual claudin 
isoforms is postulated to form the actual Ca2+ selective region (Fig. 1) (66, 67). The 
composition of positive-, neutral- or negatively-charged amino acids in the ECL1 of 
claudins determines the overall ion-selectivity of the pore. Thus a more negatively-
charged pore could favor paracellular Ca2+ transport. Importantly, each claudin 
isoform holds individual features and is differently expressed throughout epithelial 
tissues. Consequently, the mixture of claudin isoforms in the TJ and the 
composition of claudin isoforms forming the ion-selective pores establish final TJ 
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and membrane properties (63-65). This is nicely exemplified by the conversion of 
tight into leaky Madine-Darby canine kidney (MDCKI) monolayers due to the 
insertion of endogenously absent claudin-2 (68), whereas claudin-4 is reported to 
enhance barrier tightness (69, 70).  
 
Distribution of claudin isoforms in Ca2+-transporting epithelia 
In chapter 5, the distribution of claudin isoforms along the human GI tract is 
investigated via evaluation of mRNA expression levels in biopsies from different GI 
segments. The samples are obtained from healthy subjects without signs of Ca2+ 
disturbances and represent a healthy situation. Claudin isoforms display a wide 
variation in expression profiles, since claudin-3, -4 and -8 mainly reside in the 
colon, claudin-2 and -15 are confined to the small intestine, claudin-7 and -12 
display a ubiquitous expression pattern and claudin-18 is exclusively present in the 
gastric region. Also in the renal tubular system claudin isoforms are abundantly 
present where they show strong individual distribution patterns (71). Interestingly, 
the expression of claudins in specific renal or intestinal segments could untangle 
the properties of individual isoforms. For instance the “leaky” claudin-2 is located in 
the proximal tubule and thin descending limb of Henle’s loop, but is absent in the 
more distal regions represented by the DCT and CNT (71). This is in good 
agreement with the observation that paracellular reabsorption primarily takes place 
across the leaky proximal tubule, however, is limited across the more tight epithelia 
of the DCT and CNT. Similarly, in the human intestine claudin-2 is exclusively 
present in the small intestine (chapter 5), where the epithelium is leaky and the 
majority of nutrients is absorbed in a paracellular fashion (72-74). Therefore, 
detailed expression profiles could provide useful information to clarify the role of 
individual claudin isoforms in permeability and/or (re)absorption processes.  
Claudins are not only located in the kidney and intestine, but are also identified 
in primary rat osteoblasts, except for claudin-13 and -21 (75). 
Immunohistochemical staining of claudin-5, -11, -14, -15 and -16 demonstrates 
expression in bone-lining cells. Moreover, cultures of primary osteoblasts form 
monolayers with transepithelial resistance, indicative of developed and functional 
TJs (75). The presence of claudin isoforms in bone suggests a role in bone 
modeling, however no direct proof has been provided yet. The evaluation of 
claudin expression in mouse models with low BMD or with a disturbed Ca2+ 
homeostasis could be interesting to correlate claudin expression with bone 
abnormalities.  
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Claudins and paracellular Ca2+ transport 
In the kidney, the correlation between claudins and paracellular cation transport is 
established by the identification of gene mutations in human claudin-16 and 
claudin-19 that cause impairment of renal paracellular Mg2+ and Ca2+ reabsorption, 
inducing the autosomal recessive disorder termed familial hypomagnesaemia with 
hypercalciuria and nephrocalcinosis (FFHNC) (76-79). Claudin-16 is exclusively 
located in the thick ascending limb of Henle’s loop (TAL) (71). Immunofluorescence 
staining of mouse kidney identified claudin-19 in the TAL, where it co-localized with 
claudin-16, as well as in the thin ascending limb of Henle’s loops (80). Of 
significance, the TAL is the site where 60% and 20% of filtered load of Mg2+ and 
Ca2+, respectively is reabsorbed in a paracellular manner. In line with the proposed 
claudin pore model, a study by Hou et al. demonstrates that claudin-16 interacts 
with claudin-19 and that their association creates a TJ with cation selectivity (81). 
Likely, mutations in the ECL1 region of claudin-16 and claudin-19 transform a 
negatively-charged amino acid into a positively-charged amino. This change could 
compose a more positively-charged and, therefore, cation-resistant pore inhibiting 
paracellular Ca2+ transport. In addition, claudin-16 knockdown mice show a similar 
renal phenotype with severe urinary Mg2+ and Ca2+ wasting, due to impaired 
paracellular reabsorption in the tubules (82). This indicates that claudin-16 is 
important for the formation of Ca2+-selective pores.  
A possible link between claudins and intestinal Ca2+ absorption is observed in 
Williams-Beuren syndrome patients, who lack part of chromosomes 7 including the 
genes claudin-3 and claudin-4 (83). Many Williams-Beuren syndrome patients are 
characterized by intestinal Ca2+ hyperabsorption, supporting a role for claudin-3 
and claudin-4 in dietary Ca2+ uptake (84). Presently, an increasing amount of 
evidence is in favour of this hypothesis. First, claudin-3 and claudin-4 are 
abundantly expressed throughout the entire GI tract, where they are primarily 
located in the large intestine (chapter 5). Secondly, retrieval of endogenous 
claudin-4 from the plasma-membrane in MDCKI cells reduced transepithelial 
electrical resistance (TEER) and increased permeable flow of macromolecules in 
parallel (85). Moreover, incubation of Caco-2 cells with ochratoxin A, a substance 
that can selectively remove claudin-3 and claudin-4 from the intracellular TJ 
network, induced a reduction in TEER with a concomitant increase in the 
paracellular permeability of membrane impermeable tracers (86, 87). Probably, a 
more permeable membrane due to lack of claudin-3 and claudin-4 facilitates 
increased Ca2+ transport across the intestinal epithelium which is in line with the 
observed hyperabsorption in Williams-Beuren syndrome patients. Similarly, 
overexpression of claudin-3 and caudin-4 in epithelial cell layers is associated with 
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enhanced TEER, indicative of reduced solute permeability (65, 69). Despite these 
effects on epithelial permeability, functional studies investigating actual Ca2+ 
transport have to be performed to ultimately proof the relation between claudin-3, 
claudin-4 and paracellular Ca2+ flow. Importantly, van Italie et al. demonstrated the 
ability of claudin-4 overexpression to reduce paracellular Na+ flux via changes in TJ 
selectivity. Na+ is important to set the driving force for paracellular Ca2+ flow across 
the epithelium. Consequently, a reduction in Na+ transport could diminish the 
paracellular Ca2+ flux.   
The role of claudin-3 and claudin-4 in barrier function and paracellular Ca2+ 
transport is further investigated in chapter 6. In a first approach, DNA from patients 
with a history of Ca2+ hyperabsorption was evaluated for mutations in claudin-3 and 
claudin-4. However, no abnormalities could be identified. A role of claudin-3 or 
claudin-4 in the aetiology of Ca2+ hyperabsorption in these patients is therefore 
unlikely. In addition, Caco-2 and MDCKII cell lines stably overexpressing claudin-3 
or claudin-4 have been generated to assess their effect(s) on epithelial resistance. 
To our surprise, the majority of clonal MDCKII cell monolayers, exogenously 
expressing claudin-3 or claudin-4, had a decreased TEER. Likely, based on 
immunohistochemical labeling, the claudin proteins retained in intracellular 
vesicles, thus not reaching the cell membrane. In most of the characterized Caco-2 
clones, however, TEER levels were enhanced. These results from Caco-2 cells are 
another indication for the involvement of claudin-3 and claudin-4 in the formation of 
tight epithelia and that any loss might induce a destruction of barrier function. 
Although only the first results are presented in chapter 6, especially the data in 
Caco-2 cells are promising to continue the TEER experiments and subsequently 
focus on actual paracellular Ca2+ transport. Importantly, the effect of 
overexpression on the regulation of other claudin isoforms should be taken into 
account as well, since they could compensate for the loss or gain of claudin-3 or 
claudin-4, in this way influencing epithelial membrane properties and/or 
paracellular Ca2+ transport.   
 In conclusion, claudins are abundantly expressed in Ca2+-transporting epithelia 
where they are possibly involved in the regulation of paracellular Ca2+ transport via 
the formation of charge-selective pores in the TJ complex.  
 
Regulation of paracellular Ca2+ transport 
 
Knowledge about the regulation of epithelial permeability and paracellular Ca2+ 
transport is evolving and mainly focuses on TJ assembly and the expression of 
individual TJ proteins.  
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Cytokines 
An extensively investigated regulatory pathway of epithelial permeability and TJ 
structure are inflammatory cytokines. In various in vitro and in vivo models, TNFα, 
interferon-γ (INF-γ) and interleukins have shown to reduce mRNA expression of 
both claudin isoforms, occludin and zona occludens-1 (ZO-1) (88-91). Interestingly, 
Mankertz et al. demonstrate that TNFα and INF-γ diminish occludin mRNA 
expression via reduced occludin promoter activity (89). However, cytokines not 
only exert changes in TJs, they are also implicated in a reduction of cell growth and 
the promotion of cell death, factors which impair barrier function. Although proven 
that a combination of alterations in TJs, cell growth and cell death can increase 
epithelial permeability in renal and intestinal monolayers, no direct link has been 
substantiated with Ca2+ transport. Hypothetically, when the TJs become more 
leaky, increased paracellular Ca2+ transport takes place. However, cytokines can 
also exert an effect on individual TJ proteins and, in this way, they might 
specifically influence Ca2+ flow via altered composition of charge-selective claudin 
pores.  
 
1,25(OH)2D3 
A study by Chirayath et al. showed for the first time that stimulation of Caco-2 
monolayers with 1,25(OH)2D3 increases paracellular Ca2+ flow (92). Subsequently, 
another study demonstrated that paracellular Mg2+ transport is regulated via the 
binding of 1,25(OH)2D3 to the claudin-16 promoter region (93). Also in a micro-
array approach intestinal claudin-3 showed 1,25(OH)2D3-responsiveness (94). 
Recently, a study by Fujita et al. revealed 1,25(OH)2D3-mediated upregulation of 
claudin-2 and claudin-12 mRNA in Caco-2 cells (95). Subsequent transfection of 
claudin-2 and -12 in Caco-2 cell monolayers induced a reduction in TEER and a 
concomitant increase in 45Ca2+ transport. Corresponding to these results, TEER 
increased in a claudin-2 and claudin-12 siRNA approach. An important explanation 
for these results could be the information that claudin-2 forms TJ pores that 
selectively facilitate paracellular Na+ transport. For example, overexpression of 
claudin-2 in MDCKI cells lacking endogenous claudin-2 increases paracellular Na+ 
permeability (67, 68, 70), whereas knockdown of endogenous claudin-2 expression 
in MDCKII cells reduces paracellular Na+ transport and increases TEER (96). In the 
described paper by Fujita et al. overexpression of claudin-2 in Caco-2 cells indeed 
resulted in enhanced Na+ permeability and accordingly increased paracellular Ca2+ 
transport. This indicates that claudin-2 forms Na+ and Ca2+ selective pore 
structures. In contrast, overexpression of claudin-12 in Caco-2 cells enhanced 
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paracellular Ca2+ transport without altering the Na+ permeability, suggesting that 
claudin-12 mainly forms Ca2+ selective pores. 
Furthermore, Fujita et al. depicted down-regulated jejunal, ileal and colonic 
claudin-2 and claudin-12 mRNA in VDR KO mice (95). To confirm these in vivo 
results, the effect of 1,25(OH)2D3 on claudin expression was assessed in 
1,25(OH)2D3-deficient 1α-hydroxylase KO (1αKO) mice (chapter 6). However, the 
expression of duodenal claudin-2, -3, -4, -7, -12, -15 mRNA was equal in 1αKO 
mice compared to wild-type littermates. This is remarkable, because VDR KO and 
1αKO mice have similar Ca2+ disturbances characterized by severe hypocalcemia, 
high serum PTH, decreased BMD, marked reduced intestinal Ca2+ transporters and 
a concomitant decrease in intestinal Ca2+ absorption (17, 19). The principal 
distinction between both mouse strains is the serum 1,25(OH)2D3 level that is high 
in VDR KO, but undetectably low in 1αKO mice. Furthermore, the analyzed GI 
region is different: in the VDR KO model, the jejunum, ileum and colon were 
investigated, whereas the duodenum was the examined GI segment in the 1αKO 
strain. Chapter 5 has shown that in humans claudin-2 is mainly located in the 
ileum, whereas claudin-12 is more ubiquitously expressed throughout the entire GI 
tract. In mice, however, claudin-12 expression was mainly observed in the jejunum, 
and ileum and lower in duodenum (97, 98). Possibly analysis of different GI 
segments with varying expression of claudin-2 and claudin-12 could explain the 
discrepancy between both 1,25(OH)2D3-depleted mouse models. Analysis of other 
GI segments has to be performed to make a good comparison. 
In contrast to the 1αKO model, supplementation of 1,25(OH)2D3 to wild-type 
mice doubled duodenal claudin-2 mRNA and protein expression, whereas it down-
regulated renal claudin-2 mRNA (chapter 6). Since claudin-2 expression makes 
epithelia more permeable, an increase of claudin-2 in the intestine would probably 
increase Ca2+ absorption. Down-regulation of claudin-2 in the kidney results in a 
more tight renal epithelium, reducing Ca2+ reabsorption from the kidney. Indeed, 
1,25(OH)2D3 injected wild-type mice are characterized by intestinal Ca2+ 
hyperabsorption and hypercalciuria. The described data in chapter 6 support the 
1,25(OH)2D3-sensitivity of claudin-2, but not claudin-12, as observed by Fujita et al. 
(95). Also claudin-4, claudin-7 and claudin-15 show 1,25(OH)2D3-responsiveness 
albeit not in all analyzed tissues (chapter 6). It suggests that high 1,25(OH)2D3 
levels regulate claudin expression. In contrast, TRPV5 KO mice, in which 
1,25(OH)2D3 serum levels are constantly high, do not observe changes in intestinal 
claudin expression (chapter 6). Possibly, in TRPV5 KO mice the effect of 
1,25(OH)2D3   is   attenuated   after   prolonged    high    serum   1,25(OH)2D3   levels.  
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Interestingly, 1,25(OH)2D3 administration to TRPV6/calbindin-D9k KO mice induced 
an increase in intestinal Ca2+ absorption, despite the absence of the transcellular 
Ca2+ transport proteins TRPV6 and calbindin-D9k (15). The question remains 
whether claudins and other TJ proteins are involved in the observed effect. 
 
Intestinal inflammatory disorders and osteoporosis  
 
Patients suffering from IBD and coeliac disease are prone to develop osteoporosis, 
which is commonly associated with an increase in fracture risk (4, 47, 48, 50). The 
osteoporotic onset is an interplay between altered bone turnover, reduced dietary 
Ca2+ absorption and enhanced renal Ca2+ excretion (99), induced via multifactorial 
mechanisms as depicted in Figure 2.  
 
Cytokines  
During active disease state IBD and coeliac disease patients have increased 
systemic levels of pro-inflammatory cytokines, mainly TNFα, interferon-γ and 
interleukin-1β, whereas cytokine concentrations are locally elevated in the vicinity 
of the intestinal lesion (99). These inflammatory mediators directly affect bone via 
stimulation of osteoclast growth and development (osteoclastogenesis) and 
subsequent enhanced bone resorption (100). Indirectly, pro-inflammatory cytokines 
impair the epithelial barrier via regulation of tight junction protein expression. In 
vitro studies exposing renal and intestinal monolayers to TNFα, interferon-γ or 
interleukins displayed altered expression of ZO-1, occludin and several claudin 
isoforms and reduced TEER (88-91). In addition, analyses of colonic mucosa from 
IBD patients revealed a dramatic downregulation in claudin-1 expression (101) and 
a reduction or redistribution of claudin-3 and claudin-4 in diseased epithelium (91), 
whilst claudin-2 was upregulated compared to normal colon (91). In chapter 5, the 
expression of claudin-2, -3 and -4 was evaluated in duodenal mucosal biopsies 
from IBD and coeliac disease patients. In contrast to data in literature, no shift in 
claudin mRNA abundance was observed, possibly due to the collection of biopsies 
during disease inactivity when the concentration of inflammatory mediators is low. 
Overall, the results support cytokine-induced changes in epithelial permeability due 
to transformations in the claudin-composed TJ pore or alterations in the TJ 
regulatory pathway (Fig. 1). Reduced epithelial barrier in IBD is frequently 
implicated with disease pathogenesis via enhanced invasion of pathogens. 
However, more data are required to link these epithelial changes with actual 
modifications in paracellular Ca2+ transport. Finally, cytokines could impair 
transcellular Ca2+ transport via down-regulation of the Ca2+ transport proteins. 
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Figure 2. Intestinal inflammations and the pathways inducing osteoporosis. During intestinal 
inflammatory diseases, Ca2+ homeostasis is disturbed by different mechanisms. Increased 
inflammatory cytokines negatively influence bone turnover, affect intestinal and renal TJ 
permeability via the regulation of claudin proteins, possibly resulting in altered paracellular Ca2+ 
transport. Furthermore, the inflammations in the gut decrease the absorptive area, thereby 
reducing the absorption of Ca2+ and 1,25(OH)2D3 precursors. The diminished 1,25(OH)2D3 serum 
level, in turn, downregulates transcellular Ca2+ transporters in the intestine and kidney. In addition, 
the use of glucocorticoids decreases the abundance of intestinal transcellular Ca2+ transporters, 
thereby diminishing net Ca2+ absorption. Finally, corticosteroids directly affect bone turnover via 
influencing the processes in osteoblasts and osteoclasts. Dashed lines (---) indicate pathways 
However, analysis of duodenal biopsies from IBD and coeliac disease patients did 
not reveal altered TRPV6, calbindin-D9k, or PMCA1b mRNA expression (chapter 
5), excluding a cytokine-induced effect via the transcellular Ca2+ transport pathway. 
Nonetheless, the latent disease state of the investigated patients could undervalue 
the inflammatory effects. 
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Diminished absorption of Ca2+ and 1,25(OH)2D3 precursors  
Inflammation of large parts of the GI tract, villous atrophy in coeliac disease, or the 
high prevalence of intestinal resections in IBD patients are examples of conditions 
that reduce total absorptive area. Particularly resections of a significant part of the 
small intestine, where normally 90% of total Ca2+ load is absorbed, have great 
impact. In addition to a major decrease in Ca2+ absorption, it also diminishes the 
uptake of other components, such as 1,25(OH)2D3 precursors. The majority of 
studies investigating IBD patients display reduced serum 1,25(OH)2D3 levels (5, 
102), often associated with disease activity, although some reports describe normal 
1,25(OH)2D3 concentrations (55). These data are consistent with the observation 
that Ca2+ disturbances are more profound during the active disease state. 
Importantly, 1,25(OH)2D3 is the most potent activator of transcellular Ca2+ transport 
and low serum levels down-regulate the abundance of TRPV6 and calbindin-D9k 
proteins. In chapter 5, the IBD and coeliac disease patient groups had similar 
serum 1,25(OH)2D3 and Ca2+ levels accompanied by equal mRNA expression of 
duodenal TRPV6 and calbindin-D9k. To incorporate the effect of inflammatory 
cytokines, future studies should collect mucosal material from patients with both 
inactive and active disease. Interestingly, 1,25(OH)2D3 supplementation together 
with a high Ca2+ diet significantly relieved inflammation in a colitis mouse model. 
These data support a model where dietary Ca2+ and 1,25(OH)2D3 treatment directly 
or indirectly inhibit the TNFα pathway and suppress IBD (103). Furthermore, loss of 
the VDR aggravates inflammation in an experimental colitis mouse model, 
implicating that the VDR is required to control the inflammatory process (104, 105). 
Speculatively, 1,25(OH)2D3 might also change intestinal barrier function and the 
consequent invasion of inflammation-inducing pathogens.  
 
Glucocorticoids 
The anti-inflammatory drug prednisolone, which is frequently prescribed to IBD 
patients, decreases intestinal TRPV6 and calbindin-D9k mRNA levels in mice after 
one week treatment, and it consequently reduces dietary Ca2+ absorption (chapter 
3). This effect accounts also for other members of the glucocorticoid family, such 
as dexamethasone (26, 57), and is dose- and time-dependent, because high dose 
long-term prednisolone treatment affects bone most severely. Nonetheless, also 
low dose prednisolone treatment has been shown to impair bone demineralization 
(106). This is of clinical relevance because only during acute inflammatory activity, 
IBD patients receive short-term high-dose glucocorticoid treatment, whereas most 
other IBD patients with inactive disease state receive long-term (years) low-dose 
therapy. The unaltered serum 1,25(OH)2D3 levels in prednisolone-treated wild-type 
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mice suggests a 1,25(OH)2D3-independent effect on transcellular Ca2+ transport 
(chapter 3). Furthermore, Lee et al. showed the direct involvement of 
glucocorticoid receptors in dexamethasone-induced Ca2+ malabsorption (57). In 
addition, glucocorticoids exert a direct effect on bone via inhibition of osteoblast 
proliferation and maturation in combination with reduced osteoclast apoptosis and 
the early activation of genes associated with osteoclastogenesis (107). Finally, 
glucocorticoids have shown to regulate TJ proteins in the endothelium and brain 
(108-110), however the impact on renal and intestinal TJ proteins and epithelial 
permeability has not been assessed to date.   
 
Ca2+ disturbances in a Crohn’s disease mouse model 
The TNFΔARE/+ Crohn’s disease mouse model, characterized by high serum TNFα 
levels and inflammations in the ileum and (less profound) in the proximal colon 
(111), showed a marked reduction in duodenal TRPV6 and calbindin-D9k mRNA 
expression, indicating diminished Ca2+ absorption. Additionally TNFΔARE/+ mice 
illustrate a severe bone phenotype marked by enhanced bone resorption and a 
reduction of femoral bone (chapter 4). Of notice, the expression of Ca2+ transport 
proteins in bone is not affected in this mouse model, except for calbindin-D9k that is 
significantly reduced to 30% of wild-type levels, suggesting a role for calbindin-D9k 
in cytokine-mediated bone resorption. The down-regulation of intestinal Ca2+ 
transporters in TNFΔARE/+ mice is a result of decreased 1,25(OH)2D3 serum levels. 
Most likely, an inflammation-induced decline in 1,25(OH)2D3 precursor absorption, 
illustrated by low serum 25(OH)D concentrations, is the origin. This impairment of 
intestinal transcellular Ca2+ absorption in combination with the stimulatory effect of 
TNFα on osteoclasts promotes the detrimental bone phenotype. The role of pro-
inflammatory cytokines on intestinal claudin expression was not evaluated, but 
would be an interesting extension of the study design. These findings are in line 
with a study in interleukin-10 KO mice (112). This colitis model also displayed 
osteoporotic hallmarks including reduced bone mass, increased mechanical 
fragility, and suppressed bone formation. However, serum Ca2+ and the expression 
of renal and intestinal Ca2+ transport proteins were not further characterized. In 
conclusion, the investigated TNFΔARE/+ mouse model shows many similarities with 
the human IBD situation and it is, therefore, a useful tool to further investigate the 
full understanding of IBD-related Ca2+ disturbances.   
 
Treatment strategies 
Treatment of IBD and coeliac disease patients to prevent osteoporosis depends on 
several conditions. The patients at highest risk are those that have an advanced 
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age, are postmenopausal, use glucocorticoid therapy and have intestinal 
inflammatory activities. In most cases a high Ca2+ diet in combination with 
1,25(OH)2D3 supplementation is sufficient to prevent osteoporotic onset, although 
therapeutic doses have to be set carefully to prevent 1,25(OH)2D3 excess. Most 
efficiently, treatment of the inflammations will not only be beneficial for the overall 
disease state, but also reduces the cytokine-induced effects on bone. 
Concomitantly it restores intestinal Ca2+ and 1,25(OH)2D3 precursor absorption. In 
coeliac disease a gluten-free diet significantly reduces inflammation and villous 
atrophy which improves Ca2+ absorption (113). However, the reduced inflammatory 
activity due to low dose prednisolone treatment was not able to fully restore the 
diminished bone mineralization, indicating that the glucocorticoid-induced effect is 
significant (106). Therefore, the reduction of glucocorticoid dose to a minimum is 
advised as well as the consideration of alternative anti-inflammatory drugs that are 
less bone destructive, such as infliximab and anti-TNFα therapy (100). 
Osteoporosis can be specifically treated via bisphosphate supplementation, which 
increases BMD (100). For example, the bone resorption inhibitor alendronate was 
effective in prevention and treatment of corticosteroid-induced osteoporosis and, 
therefore, may be particularly important in IBD (114). Interestingly, Nijenhuis et al. 
showed that alendronate enhances TRPV5 expression in bone and normalized the 
reduced bone thickness in TRPV5 KO mice, indicating the rescue of osteoclast-
mediated bone resorption in these mice (115). Overall, a number of strategies are 
available to treat IBD-related osteoporosis, but the best option depends on the 
individual conditions of the patient.   
 
Ca2+ transport & aging 
 
It is generally known that the elderly have reduced mineralization of the skeleton, 
resulting from a combination of different age-related changes in Ca2+ handling. 
PTH levels are reported to increase during advanced age, which promotes bone 
resorption activities in osteoclasts (116). Furthermore, the capacity of the kidney to 
generate the active metabolite 1,25(OH)2D3 declines with age, thus leading to Ca2+ 
malabsorption (31, 117). Postmenopausal women are typically prone to develop 
low BMD, due to the lack of estrogen that has shown to stimulate TRPV5 and 
TRPV6 expression and intestinal dietary Ca2+ uptake (118). To analyze the 
possible involvement of age-related changes in renal and intestinal transcellular 
Ca2+ transport, mRNA measurements of TRPV5/6, calbindin-D9k/-D28k, PMCA1b 
and NCX1 were assessed in 12-, 30- and 52-week old TRPV5 KO and wild-type 
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mice (chapter 2). Aging of wild-type mice results in a tendency toward increased 
renal Ca2+ excretion and significantly decreased intestinal Ca2+ absorption. This is 
accompanied by reduced expression of TRPV5 and TRPV6, respectively, despite 
an age-induced increase in serum 1,25(OH)2D3 levels, indicating loss of VDR-
sensitivity. Similarly, in TRPV5 KO mice the existing urinary Ca2+ wasting is more 
pronounced in older animals, whereas the compensatory intestinal Ca2+ absorption 
and TRPV6 expression declines with advanced age. In TRPV5 KO no age-induced 
increase in serum 1,25(OH)2D3 levels was observed, however, serum 1,25(OH)2D3 
remains constantly elevated. In addition, in both mouse strains aging resulted in 
diminished renal VDR mRNA levels, whereas serum Ca2+ concentration remained 
constant. Furthermore, 52-week-old TRPV5 KO mice show severe 
hyperparathyroidism, while PTH levels in elder wild-type mice are increased in 30-
week old mice, but do not further increase after 52 weeks (chapter 2). PTH is 
reported to stimulate renal and intestinal transcellular Ca2+ transport. Although 
serum PTH levels remained constant or increased during aging, renal Ca2+ 
reabsorption and intestinal Ca2+ absorption declined with age, indicating a 
desensitization mechanism. Several reports demonstrated blunting of PTH-
mediated signal transduction pathways as well as loss of renal and intestinal PTH 
receptors (119-123). In line with these results, duodenal VDR and TRPV6 
expression is reduced in postmenopausal women (31, 124). In addition, VDR 
protein levels and 1,25(OH)2D3 binding in subcellular duodenal fractions from 
young and aged rats are diminished with ageing (125). Finally, in heterozygous 
VDR KO mice low levels of the VDR produce resistance to 1,25(OH)2D3-dependent 
intestinal Ca2+ absorption (126). All together, the reduced VDR levels in 
combination with decreased sensitivity of the VDR to its ligand down-regulates 
renal and intestinal transcellular Ca2+ transporters. Ultimately, this affects intestinal 
and renal Ca2+ (re)absorption processes during aging (127).  
Recently, a new protein was identified, called klotho, which exhibits anti-aging 
properties (128). Klotho KO mice are characterized by a reduced life-span in 
combination with low BMD and increased urinary Ca2+ wasting (128). 
Overexpression of klotho in mice extended life-span and improved the urinary Ca2+ 
leakage problem, thus illustrating the important role of this hormone in renal Ca2+ 
handling (129). This is further underlined by the identification of human klotho 
polymorphisms that are associated with reduced BMD (130, 131). Chang et al. 
were the first to identify that klotho is secreted in the pro-urine where it can 
hydrolyze the extracellular sugar residues of TRPV5, resulting in increased channel 
activity (132, 133). Recently, Lu et al. demonstrate the klotho-mediated activation 
of both TRPV5 and TRPV6 in HEK293 cells (134). Klotho expression is reduced 
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during aging, which possibly declines TRPV5/6 channel activity and reduces renal 
and intestinal Ca2+ (re)absorption.  
The effect of aging on paracellular Ca2+ transport, in particular on the 
expression of TJ proteins, has not been implicated to date. Initially, Holmes et al. 
identified changes in claudin expression during birth and adulthood (98). This is an 
important topic that needs further evaluation. All together, the osteoporotic onset in 
the aging population is a multifactorial process, involving hyperparathyroidism, 
estrogen loss in women, a reduction of the 1,25(OH)2D3 stimulatory pathway 
impairing renal and intestinal Ca2+ transport processes and a possible role for the 
anti-aging hormone klotho. 
 
Conclusions & suggestions for further research 
 
• TRPV6 and calbindin-D9k are primarily localized in the human duodenum and 
are here mainly regulated by 1,25(OH)2D3. These transporters mediate 
transcellular Ca2+ absorption under most physiological conditions, although 
other unknown 1,25(OH)2D3-sensitive transporters might be involved as well.  
• Glucocorticoid treatment diminishes transcellular Ca2+ absorption via the 
reduction of duodenal TRPV6 and calbindin-D9k expression following a 
1,25(OH)2D3-independent pathway, possibly mediated via the glucocorticoid 
receptor.   
• Aging causes reduced expression of renal and intestinal Ca2+ transporters 
possibly via the impairment of the 1,25(OH)2D3 stimulatory pathway due to 
reduced sensitivity of the VDR to its ligand. Investigating the differences in 
klotho levels between children, adults and the elderly could give more insight 
into klotho-related changes in renal and intestinal Ca2+ transport. In addition, the 
effect of aging on paracellular Ca2+ absorption and TJ proteins needs to be 
further evaluated.  
• The generation of tissue-specific KO mice could provide useful information 
about the role of individual Ca2+ transport proteins. Particularly kidney- and 
stomach-specific TRPV6 KO mice could improve our understanding of the 
function of renal and gastric TRPV6 in Ca2+ homeostasis.  
• Claudin isoforms are abundantly expressed throughout the GI tract where they 
exert a wide array of distribution profiles. The acquired data postulate that each 
isoform has a specific effect on epithelial permeability in a defined area of the 
gut and kidney. However, the generation of KO mice is compulsory to 
investigate the actual in vivo function of single claudin isoforms.  
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• Claudin isoforms might regulate intestinal paracellular Ca2+ transport via the 
formation of Ca2+-selective pores in the intracellular space. Further analysis is 
required to unravel detailed claudin pore assembly and to confirm functional 
changes in paracellular Ca2+ transport. This could be studied via 45Ca2+ 
transport assays and/or ex vivo Ussing chamber experiments.  
• The postulated role of claudin-3 and claudin-4 in paracellular Ca2+ transport is 
inconclusive. Our studies require further analysis via characterization of the 
stable transfected MDCKII and Caco-2 cell lines overexpressing claudin-3 or 
claudin-4. The generation of double-stable claudin-3 and claudin-4 
overexpressing cell lines is essential, since the assembly of claudin-3 and 
claudin-4 could form a more or less Ca2+-selective pore, like in the claudin-16 
and claudin-19 pore model. In addition, a claudin-3 and claudin-4 siRNA 
approach could support the results. Also the compensatory capacity of other 
claudin isoforms requires additional attention.  
• The obtained data concerning the stimulatory role of 1,25(OH)2D3 on TJ 
proteins is presently inconclusive, but suggests a role for this hormone in the 
regulation of claudin expression. More in vitro and in vivo research is needed to 
link changes in claudin expression with actual paracellular Ca2+ transport.  
• People suffering from intestinal inflammatory disorders are prone to develop low 
BMD and frequently have a disturbed Ca2+ transport process in the gut. The 
cause is multifactorial and the influence of transcellular and paracellular 
transport proteins is implicated, although more research is desired. Because 
inflammatory cytokines are mentioned as involved mediators it is essential to 
gather intestinal biopsies from patients with an active disease state.  
• The TNFΔARE/+ is a Crohn’s disease mouse model that displays many similarities 
with the human IBD situation, including reduced 1,25(OH)2D3 levels, reduced 
duodenal TRPV6 and calbindin-D9k expression and a severe bone phenotype 
with marked reduced BMD. Therefore, this model can be a useful tool to study 
IBD-related Ca2+ abnormalities in the future.  
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Calcium homeostasis 
Calcium (Ca2+) is one of the most abundant cations in our body and is generally 
recognized as the main component of bone tissue. In addition, Ca2+ plays a vital 
role in many other physiological functions including muscle contraction, 
neurotransmission and cell signaling. Consequently, the maintenance of a 
balanced extracellular Ca2+ concentration is essential for a normal functioning 
body. Therefore, serum Ca2+ level is tightly controlled by the combined regulatory 
actions of the intestine, kidney and bone. In more detail, this interplay comprises 
intestinal absorption from the diet, renal filtration and tubular reabsorption 
regulating urinary Ca2+ excretion, while a dynamic bone turnover ensures Ca2+ 
storage during overload and favors Ca2+ release when needed. A central role in 
Ca2+ homeostasis plays the transfer of Ca2+ across epithelial cell layers lining the 
lumen of the intestine and renal tubules. Ca2+ crosses this epithelial barrier via two 
distinct pathways. In a paracellular route Ca2+ diffuses through the intercellular 
space entirely driven by concentration and electrochemical gradients. Therefore, 
luminal Ca2+ mainly defines paracellular Ca2+ flow. In a transcellular pathway, 
however, specialized transport proteins facilitate the passage of Ca2+ via the cell 
involving an energy-requiring step to transmigrate Ca2+ across the basolateral 
membrane. This process is highly regulated by hormones such as 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3) and parathyroid hormone, which enables a tight 
regulation of Ca2+ transport independent of luminal Ca2+ concentrations. 
Consequently, paracellular transport dominates when luminal Ca2+ is high or Ca2+ 
demands are fulfilled, whereas the transcellular machinery is stimulated in times of 
Ca2+ shortage or increased Ca2+ requirements.  
 
Transcellular Ca2+ transport 
The process of Ca2+ transport across the cell consists of three consecutive steps in 
which specific Ca2+ transport proteins are involved. At the apical membrane Ca2+ 
enters the cell via highly Ca2+-selective Transient Receptor Potential Vanilloid 
subtype 5 and 6 ion channels (TRPV5, TRPV6). In the cell Ca2+ is subsequently 
bound to cytosolic Ca2+-binding proteins (calbindin-D9k and calbindin-D28k) that 
transfer Ca2+ to the basolateral membrane, where it is finally extruded into the 
blood stream via the plasma-membrane Ca2+-ATPase (PMCA1b) or Na+/Ca2+ 
exchanger 1 (NCX1). In the intestine, TRPV6, calbindin-D9k and PMCA1b are the 
major Ca2+ transport proteins involved, whereas TRPV5, calbindin-D28k and NCX1 
play key roles in the kidney. The transcellular Ca2+ transport pathway is 
predominantly regulated by hormones that influence the expression of intestinal 
and renal Ca2+ transport proteins. 1,25(OH)2D3 is one of the most important 
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hormones in Ca2+ homeostasis, since it strongly stimulates dietary Ca2+ absorption 
via an increase in duodenal TRPV6 and calbindin-D9k expression.  
 
Paracellular Ca2+ transport 
The lumen of the intestine and renal tubules are lined with a continuous monolayer 
of epithelial cells that provides a protective barrier between the diet/urine and the 
blood compartment. Nevertheless, a small opening exists between two adjacent 
cells, i.e. the paracellular space, enabling the passage of ions and small solutes 
across the epithelium. This diffusion process is regulated via tight junctions (TJs), 
which reside most apically inside the paracellular space. TJs entail large strands of 
trans-membrane proteins, spanning the paracellular space to bind stands located 
in the membrane of neighboring cells. In this way, they create pore-like structures 
that can regulate the passage of ions, like Ca2+, depending on charge- and size 
selectivity. The trans-membrane protein strands of the TJs mainly consist of 
claudins. This large protein family comprises over 20 different claudin isoforms that 
are abundantly present in the epithelium of the intestine and kidney. A few of these 
isoforms are linked to the regulation of paracellular Ca2+ transport. For example, in 
the kidney a mutation of claudin-16 causes a reduction in paracellular Ca2+ 
reabsorption resulting in urinary Ca2+ loss. Possibly, other claudin isoforms are also 
involved in the regulation of intestinal and renal paracellular Ca2+ transport. 
 
Disturbed Ca2+ homeostasis 
A wide array of incidents disturb the balance between the different Ca2+ transport 
processes in kidney, intestine and bone. Ultimately, these can result in serious 
complaints such as low bone mineral density (osteoporosis). Especially post-
menopausal women (that have low serum estrogen concentrations), the older 
generation in general and patients suffering from chronic intestinal inflammations, 
such as Crohn’s disease, Ulcerative colitis and coeliac disease, are prone to 
develop osteoporosis. To identify the exact mechanisms of osteoporotic onset and 
subsequently develop new effective treatment strategies, it is important to fully 
unravel the Ca2+ transport processes in kidney, intestine and bone. This thesis 
mainly focuses on intestinal Ca2+ absorption in healthy people, the elderly and in 
patients with chronic intestinal inflammations.  
 
Chapter 2 describes the effect of aging on Ca2+ homeostasis, in particular on 
transcellular Ca2+ transport. In 10-, 30-, and 52-weeks old mice a number of blood 
parameters (Ca2+, 1,25(OH)2D3, parathyroid hormone) and the amount of renal and 
intestinal transcellular Ca2+ transport proteins is evaluated. Serum Ca2+ 
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concentrations are similar in all age groups. However, the expression of TRPV5 
and TRPV6 in kidney and duodenum, respectively, declines with age despite an 
increase in serum 1,25(OH)2D3, the most important hormone that stimulates 
TRPV5 and TRPV6 expression. This indicates reduced sensitivity to 1,25(OH)2D3 
with advanced age. Consequently, older mice show diminished absorption of Ca2+ 
from the diet and enhanced urinary Ca2+ excretion. The loss of capacity to 
transport Ca2+ via the transcellular pathway likely contributes to the high 
prevalence of osteoporosis in the elderly.  
 
In chapter 3 the effect of prednisolone on intestinal Ca2+ absorption is evaluated. 
Prednisolone is an anti-inflammatory drug that is often prescribed to patients with 
chronic intestinal inflammations. A well-known side-effect of prednisolone is the 
development of osteoporosis. To investigate the effect of this drug on transcellular 
Ca2+ transport, the intestine, kidney and blood are sampled from mice after one 
week of oral therapy. Prednisolone reduces the expression of duodenal TRPV6 
and calbindin-D9k protein, resulting in diminished dietary Ca2+ absorption. No effect 
of prednisolone is observed in the kidney. Importantly, serum 1,25(OH)2D3 levels 
are not affected. These data indicate that prednisolone reduces intestinal 
transcellular Ca2+ absorption via a 1,25(OH)2D3-independent effect on duodenal 
TRPV6 and calbindin-D9k expression. Long-term treatment with prednisolone can, 
therefore, induce a disturbance in the body’s Ca2+ balance and promote the 
development of osteoporosis.  
 
Crohn’s disease patients suffer from chronic intestinal inflammations. Moreover, 
they often illustrate a disturbed Ca2+ balance with osteoporosis as a result. To 
unravel the etiology of Crohn’s disease-related bone problems, chapter 4 displays 
the overall Ca2+ homeostasis in a TNFΔARE/+ Crohn’s disease mouse model 
characterized by increased serum TNFα levels and inflammations in the terminal 
ileum. In TNFΔARE/+ mice serum Ca2+ concentrations remain normal. However, 
serum 1,25(OH)2D3 levels are markedly reduced, most likely due to diminished 
absorption of dietary 1,25(OH)2D3 precursors from the inflamed intestine. The low 
1,25(OH)2D3 status mediates a down-regulation of Ca2+ transport proteins in the 
duodenum (TRPV6, calbindin-D9k, PMCA1b) and kidney (calbindin-D28k, NCX1). 
Impairment of the transcellular Ca2+ transport pathway generally results in 
decreased dietary Ca2+ absorption and increased urinary Ca2+ excretion. To 
compensate this loss of Ca2+ and maintain normal serum Ca2+ levels, Ca2+ is 
released from bone tissue as demonstrated by the reduced trabecular and cortical 
bone thickness and volume in TNFΔARE/+ mice compared to wild-type littermates. 
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The TNFΔARE/+ mouse model closely resembles human Crohn’s disease and, 
therefore, is an attractive model to further study the Ca2+ balance in Crohn’s 
disease patients.  
 
Chapter 5 illustrates detailed expression profiles of Ca2+ transport proteins and 
claudin isoforms throughout the entire gastro-intestinal (GI) tract. TRPV6 and 
calbindin-D9k are primarily located in the duodenum, which underlines that 
transcellular Ca2+ transport mainly takes place in this specific area. Furthermore, 
claudin isoforms are abundantly present in the GI-tract and show distinct 
expression patterns, in which claudin-3, -4 and -8 mainly reside in the colon, 
claudin-2 and -15 are confined to the small intestine, claudin-7 and -12 display a 
ubiquitous expression pattern, and claudin-18 is exclusively found in the gastric 
region. These differences in claudin isoform expression and localization can 
contribute to local variations in paracellular nutrient absorption, since each isoform 
has its own effect on intestinal epithelial permeability. Patients with chronic 
intestinal inflammations are frequently associated with reduced dietary Ca2+ 
absorption. To examine the possible involvement of the transcellular and 
paracellular Ca2+ transport pathways, the amount of transcellular Ca2+ transporters 
(TRPV6, calbindin-D9k, PMCA1b) and several claudin isoforms is analyzed in 
duodenal biopsies of inactive Crohn’s disease, Ulcerative colitis and coeliac 
disease patients and compared to the expression in healthy controls. The results 
demonstrated, however, that the expression of Ca2+ transporters or claudin-2, -3, 
and -4 is not different in the patient groups and, therefore, not likely to be involved 
in Ca2+ malabsorption during inactive Crohn’s disease, Ulcerative colitis and 
coeliac disease. Future studies should preferentially contain mucosa from patients 
with active inflammations to validate these findings. 
 
The aim of the study described in chapter 6 is to examine the involvement of 
claudin isoforms, in particular claudin-3 and -4, in paracellular Ca2+ transport. First, 
claudin-3 and claudin-4 mutation analysis is performed in two patients with 
hypercalcemia due to intestinal Ca2+ hyperabsorption. However, mutations are not 
detected in these patients. Secondly, intestinal and renal cell lines (Caco-2 and 
MDCK respectively) stably expressing claudin-3 or claudin-4 are generated. 
Culturing an epithelial monolayer of these cell lines enables to study the role of 
both proteins in the maintenance of epithelial barrier function. The data show that 
overexpression of claudin-3 and claudin-4 in MDCK cells increases epithelial 
permeability, whereas overexpression of claudin-3 in Caco-2 cells generates a 
tighter epithelial layer that reduces the permeability for ions and small solutes. This 
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cell model has to be validated in more detail before it is suitable to study the direct 
relationship between claudin-3 or -4 expression and the rate of paracellular Ca2+ 
transport. Finally, the effect of 1,25(OH)2D3 on intestinal and renal claudin isoform 
abundance is evaluated. Therefore, the amount of claudin-2, -3, -4, -7, -12 and -15 
expression in the duodenum, colon and kidney of different mouse models with low 
or high 1,25(OH)2D3 serum concentrations is measured. The lack of 1,25(OH)2D3 
has no effect on claudin expression in 1,25(OH)2D3-deficient mice. On the contrary, 
1,25(OH)2D3 injections in wild-type mice up-regulate duodenal claudin-2 
expression. This indicates that 1,25(OH)2D3 can regulate the abundance of certain 
claudin isoforms.  
 
Conclusion 
The observations described and discussed in this thesis increase our 
understanding of transcellular and paracellular Ca2+ transport across intestinal and 
renal epithelia. It emphasizes the specific role of the duodenum in transcellular 
dietary Ca2+ absorption and the strong regulation of this process by the hormone 
1,25(OH)2D3. In the elderly reduced sensitivity to 1,25(OH)2D3 causes down-
regulation of intestinal and renal Ca2+ transport protein expression, which in turn 
reduces the capacity to transport Ca2+ in a transcellular manner. The involvement 
of Ca2+ transport proteins and claudin isoforms in the development of osteoporosis 
in patients with chronic intestinal inflammations requires further research, 
especially in patients with active inflammations. Additionally, the TNFΔARE/+ mouse 
strain is a good model to study changes in the Ca2+ balance during Crohn’s 
disease. Long-term treatment of these patients with the anti-inflammatory drug 
prednisolone contributes to a disturbed Ca2+ balance via diminished duodenal 
TRPV6 and calbindin-D9k expression and a resulting drop in dietary Ca2+ 
absorption. Claudin isoforms play a key role in epithelial permeability. To date, 
however, detailed information about claudin isoforms and their function in the 
regulation of paracellular Ca2+ transport is lacking. The future generation of mouse 
models in which one specific claudin isoform is ablated can possibly provide more 
information about the physiological role of individual claudin isoforms.  
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Calcium huishouding 
Calcium is een belangrijk mineraal in ons lichaam, omdat het betrokken is bij de 
meest vitale lichaamsprocessen, zoals de samentrekking van spieren, de geleiding 
van zenuwprikkels en de communicatie in en tussen cellen. Daarnaast is calcium 
een van de hoofdbestanddelen van het skelet waar het zorgt voor de stevigheid 
van het lichaam. Om al deze processen goed te laten verlopen is het essentieel de 
concentratie calcium in het bloed constant te houden, wat gebeurt via een 
samenwerking van drie organen. Als eerste wordt calcium in de darmen 
opgenomen uit de voeding, die de primaire calciumbron is voor het lichaam. De 
nieren reguleren de hoeveelheid calcium die wordt uitgescheiden in de urine. 
Tevens bestaat er uitwisseling van calcium met het skelet. Calcium wordt 
opgeslagen in bot wanneer het in overvloed aanwezig is, maar wordt hieruit weer 
vrijgemaakt en opgenomen in de bloedbaan in tijden van calciumschaarste. Zowel 
de darmwand als de nierbuizen zijn bedekt met epitheel. Het epitheel is een 
aaneengesloten laag cellen die zorgt voor een barrière tussen enerzijds de 
voeding in de darmholte of de voorurine in de nierbuizen en anderzijds het bloed. 
Calcium kan op twee verschillende manieren vanuit de voeding of de voorurine 
deze epitheellaag passeren en in het bloed terechtkomen. Ten eerste wordt 
calcium getransporteerd via de epitheelcellen en deze vorm van transport wordt 
daarom ook wel transcellulair genoemd. Deze energieverbruikende route wordt 
sterk gereguleerd door hormonen, zoals vitamine D3, parathyroidhormoon, 
oestrogeen en klotho. Ten tweede kan calcium diffunderen tussen de cellen door, 
omdat zich hier een nauwe opening bevindt (de paracellulaire ruimte) waarlangs 
ionen en kleine opgeloste stoffen vrij kunnen bewegen. Deze route wordt gedreven 
door concentratie- en ladingsverschillen over de epitheellaag. Met name 
natriumtransport is een belangrijke drijvende kracht voor paracellulair 
calciumtransport. Ook een hoge concentratie calcium in de darmen of in de 
nierbuizen stimuleert calciumopname via de paracellulaire route. Wanneer de 
concentratie calcium in de voeding of in de voorurine echter lager is dan in het 
bloed, zal calcium tegen het concentratieverschil in moeten worden vervoerd via 
het energiebehoevende transcellulaire transport. 
 
Het transcellulaire calciumtransport  
Het proces van calciumopname via de cel bestaat uit drie achtereenvolgende 
stappen waarbij speciale transporteiwitten betrokken zijn. Als eerste bevinden zich 
aan de luminale (voedings of voorurine) zijde van de cel kanaaltjes die calcium 
selectief kunnen doorlaten, namelijk TRPV5 en TRPV6 kanalen. Eenmaal in de cel 
wordt calcium gebonden aan calciumbindende eiwitten (calbindine-D9k en 
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calbindine-D28k) die calcium vervoeren naar de overkant van de cel. Tenslotte 
verlaat calcium de cel met behulp van twee energieverbruikende mechanismen, 
een natrium/calcium-uitwisselaar (NCX1) en een ATP-afhankelijke calciumpomp 
(PMCA1b), om in het bloed te worden opgenomen. In de darmen spelen tijdens dit 
proces de transporteiwitten TRPV6, calbindin-D9k en PMCA1b een exclusieve rol, 
terwijl TRPV5, calbindine-D28k en NCX1 met name een hoofdrol vervullen in de 
nier. Het transcellulaire calciumtransport wordt sterk gereguleerd door calciotrope 
hormonen, die de hoeveelheid en activiteit van de transporteiwitten in de darmen 
en nieren kunnen beïnvloeden. Het hormoon vitamine D3 heeft een belangrijke 
functie in de darmen, omdat het onder andere de opname van calcium uit de 
voeding sterk stimuleert door een verhoogde aanwezigheid van TRPV6 en 
calbindine-D9k eiwitten in de darm. 
 
Het paracellulaire calciumtransport  
Via de paracellulaire ruimte kunnen ionen en kleine stoffen de epitheellaag 
passeren. Gedurende lange tijd werd aangenomen dat dit proces ongehinderd kon 
plaatsvinden, totdat in de paracellulaire ruimte een complex van eiwitten werd 
waargenomen die later tight junction werd genoemd. De tight junction bestaat uit 
lange strengen van aaneengeschakelde eiwitten die zich bevinden aan de 
buitenzijde van de cel en binden aan identieke eiwitketens van de aangrenzende 
cel. Hierdoor overbrugt de tight junction de paracellulaire ruimte tussen twee cellen 
van de epitheellaag en vormt ze structuren die lijken op poriën. Mogelijk kunnen 
deze porie-structuren de passage van ionen zoals calcium en kleine stoffen 
beïnvloeden door een selectie op de grootte of de elektrische lading van de 
deeltjes. De eiwitketens in de tight junction bestaan voornamelijk uit claudines. 
Deze grote eiwitfamilie bestaat uit meer dan 20 verschillende type claudines, die 
zowel in de nier als in de darm veelvuldig voorkomen. Een aantal van deze 
claudines wordt in verband gebracht met de regulatie van paracellulair 
calciumtransport. Een mutatie van claudine-16 zorgt bijvoorbeeld in de nier voor 
een verminderd transport van calcium uit de voorurine naar het bloed met als 
gevolg een verhoogde calciumuitscheiding in de urine. Mogelijk zijn andere 
claudines ook betrokken bij de regulatie van paracellulair calciumtransport in de 
nieren en darmen.   
 
Een verstoorde calciumhuishouding 
De balans tussen de verschillende calciumtransportprocessen in de darmen, 
nieren en bot kan door uiteenlopende oorzaken verstoord raken. Hierdoor kunnen 
ernstige klachten ontstaan, waaronder een sterk verminderde mineralisatie van het 
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bot, ook wel osteoporose genoemd. Met name vrouwen na de menopauze (met 
een verminderde concentratie van het hormoon oestrogeen), de oudere populatie 
in het algemeen en patiënten met chronische darmontstekingen ontwikkelen vaak 
botklachten. Om de oorzaak hiervan te onderzoeken en effectieve behandelingen 
te ontwikkelen is het noodzakelijk meer te weten over de calciumtransport-
processen in de nieren, darmen en het bot. In dit proefschrift is de opname van 
calcium uit de darm onderzocht in gezonde mensen, in ouderen en in patiënten 
met darmontstekingen.  
 
In Hoofdstuk 2 is onderzoek verricht naar het effect van een hoge leeftijd op de 
calciumbalans in het lichaam en met name naar de capaciteit van het 
transcellulaire calciumtransport. In muizen van verschillende leeftijden (10, 30 en 
52 weken) is een aantal bloedwaarden gemeten (calcium, vitamine D3 en 
parathyroidhormoon) en is de hoeveelheid calciumtransporteiwitten in de darm en 
in de nier bepaald. De calciumconcentratie in het bloed is hetzelfde in alle 
leeftijdsgroepen. Echter, de hoeveelheid TRPV5 en TRPV6 in respectievelijk de 
nier en darm neemt af met de leeftijd ondanks een verhoging van de concentratie 
vitamine D3 in het bloed, het hormoon dat de aanmaak van TRPV5 en TRPV6 
stimuleert. Dit duidt op een verminderde gevoeligheid van het lichaam voor 
vitamine D3 in oudere muizen. Als gevolg vertonen oudere muizen een 
verminderde calciumopname uit de voeding en een verhoogde uitscheiding van 
calcium via de urine. Het verlies aan vermogen om calcium via de transcellulaire 
route te transporteren kan mogelijk bijdragen aan het verhoogde risico op 
osteoporose in de oudere populatie.  
 
In Hoofdstuk 3 is het effect van het medicijn prednisolon op de opname van 
calcium uit de darm bestudeerd. Prednisolon is een ontstekingsremmend medicijn 
dat vaak voorgeschreven wordt aan patiënten met darmonstekingen. Een bekende 
bijwerking van prednisolon is de verhoogde kans op het ontwikkelen van 
botklachten, zoals osteoporose. Om het effect van prednisolon op het 
transcellulaire calciumtransport te onderzoeken zijn muizen gedurende één week 
behandeld met dit medicijn. Prednisolon verminderde de hoeveelheid TRPV6 en 
calbindine-D9k eiwitten in de darm, resulterend in een verminderde calciumopname 
uit de voeding. In de nier is geen effect van prednisolon op de 
calciumtransporteiwitten waargenomen. Het gehalte van het hormoon vitamine D3, 
dat de aanmaak van calciumtransporteiwitten stimuleert, in het bloed is echter niet 
veranderd door behandeling met prednisolon. Hieruit kan geconcludeerd worden 
dat prednisolon de transcellulaire opname van calcium in de darm vermindert via 
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een vitamine D3-onafhankelijke afname in de hoeveelheid TRPV6 en calbindine-
D9k transporteiwitten. Een langdurige behandeling met dit medicijn kan daarom 
zorgen voor een verstoring van de calciumbalans in het lichaam. 
 
In Hoofdstuk 4 is de calciumhuishouding onderzocht in TNFΔARE/+ muizen, die een 
verhoogde concentratie TNFα, een eiwit betrokken bij ontstekingsreacties, in het 
bloed hebben. Als gevolg hiervan ontwikkelen deze muizen ontstekingen in het 
laatste deel van de dunne darm (ileum) en worden daarom gebruikt als een 
onderzoeksmodel voor de humane ziekte van Crohn, waarbij darmontstekingen 
chronisch optreden. Patiënten met deze ziekte hebben vaak een verstoorde 
calciumhuishouding en een verhoogd risico op osteoporose. Om de precieze 
oorzaak van deze klachten te achterhalen, zijn studies naar de calciumbalans in 
muismodellen voor de ziekte van Crohn belangrijk. In TNFΔARE/+ muizen is de 
calciumconcentratie in het bloed normaal. Echter, het gehalte aan vitamine D3 is 
sterk verlaagd, waarschijnlijk door een verminderde opname van vitamine D uit de 
voeding als gevolg van de ontstekingen. Dit resulteert in een verlaagde 
hoeveelheid aan calciumtransporteiwitten in zowel de darmen (TRPV6, calbindine-
D9k, PMCA1b) als de nieren (calbindine-D28k, NCX1). Het is aannemelijk dat 
afname van het transcellulaire calciumtransport zorgt voor minder opname van 
calcium uit de voeding en een toegenomen uitscheiding van calcium in de urine. 
Dit verlies aan calcium in het lichaam wordt gecompenseerd door calcium vrij te 
maken uit het bot. Op deze wijze wordt de concentratie in het bloed constant 
gehouden ten koste van de mineralisatie van het bot. Inderdaad hebben TNFΔARE/+ 
muizen een ernstig verminderde botdichtheid in vergelijking met normale muizen. 
De TNFΔARE/+ muizen vertonen sterke overeenkomsten met de humane ziekte van 
Crohn en zijn daarom een geschikt model om de calciumbalans gedurende 
inflammatoire darmziekten verder te onderzoeken.   
 
In Hoofdstuk 5 is de verspreiding en hoeveelheid van calciumtransporteiwitten en 
claudines onderzocht in het gehele humane maag-darmstelsel. TRPV6 en 
calbindine-D9k komen exclusief voor in het eerste deel van de dunne darm 
(duodenum), wat aangeeft dat transcellulair calciumtransport specifiek op deze 
plek van het maag-darmstelsel plaatsvindt. Uit de analyse blijkt verder dat de 
meeste type claudines veelvuldig in de darm aanwezig zijn en verschillende 
verspreidingspatronen laten zien. Claudine-7 en -12 zijn in het gehele maag-
darmstelsel in gelijke hoeveelheden te vinden, claudine-3, -4, en -8 komen met 
name voor in de dikke darm, terwijl claudine-2 en -15 hoofdzakelijk zijn aangetoond 
in de dunne darm. Claudine-18 is alleen in de maag aangetroffen. Deze verschillen 
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in expressie en lokalisatie kunnen bijdragen aan segmentale variaties in de 
paracellulaire opname van nutriënten uit de voeding, omdat elk type claudine 
specifieke effecten heeft op de doorlaatbaarheid van het darmepitheel. Patiënten 
met chronische darmontstekingen worden vaak in verband gebracht met een 
verminderde opname van calcium uit de voeding. Om de mogelijke betrokkenheid 
van het transcellulaire of paracellulaire calciumtransport bij deze bijwerking te 
onderzoeken, is de expressie van transcellulaire calciumtransporteiwitten (TRPV6, 
calbindine-D9k, PMCA1b) en claudines bepaald in dunne darm biopten van 
gezonde vrijwilligers en patiënten met inflammatoire darmaandoeningen (Ziekte 
van Crohn, Colitis Ulcerosa, Coeliakie). De hoeveelheid van de onderzochte 
eiwitten was echter vergelijkbaar tussen alle groepen. Deze uitkomst stelt de 
betrokkenheid van deze calciumtransporteiwitten en claudines bij het ontstaan van 
darmontsteking-gerelateerde calcium malabsorptie ter discussie. Vervolgstudies 
met biopten van acute onstekingen zijn nodig om tot een definitieve conclusie te 
komen.  
 
In Hoofdstuk 6 is de relatie tussen de hoeveelheid claudine-3 en claudine-4 en de 
mate van paracellulair calciumtransport bestudeerd. Als eerste is het DNA 
materiaal van patiënten met een sterk verhoogde calciumopname uit de voeding 
onderzocht op de aanwezigheid van mutaties in de claudine-3 en claudine-4 
genen. Echter, er werden geen mutaties aangetroffen in de twee onderzochte 
patiënten. Ten tweede zijn cellijnen ontwikkeld die een overmaat aan claudine-3 en 
claudine-4 eiwitten bezitten (overexpressie). Door een epitheellaag van deze cellen 
te kweken kan de barrièrefunctie van het epitheel en de rol van claudine-3 en 
claudine-4 onderzocht worden. Overexpressie van claudine-3 en claudine-4 in 
niercellen zorgt voor een toegenomen doorlaatbaarheid van het epitheel, terwijl 
overexpressie van claudine-3 in darmcellen juist de doorlaatbaarheid van het 
darmepitheel vermindert en dus de barrièrefunctie bevordert. Dit celmodel moet 
nog verder gevalideerd worden voordat deze geschikt is om de directe relatie 
tussen claudine-3/-4 expressie en de mate van paracellulair calciumtransport te 
onderzoeken. Als laatste is het effect van vitamine D3 op de hoeveelheid van elk 
type claudine in kaart gebracht. In verschillende muismodellen met zowel lage als 
hoge vitamine D3 plasmawaarden is de hoeveelheid claudine-2, -3, -4, -7, -12 en -
15 in zowel de dunne darm, colon als nier gemeten. In vitamine D3-deficiënte 
muizen kon geen effect worden aangetoond op de expressie van claudine 
isovormen in de darm en nier. Echter, toediening van vitamine D3 aan normale 
muizen resulteerde in een toename van claudine-2 eiwitten in het duodenum. Dit 
wijst erop dat vitamine D3 de hoeveelheid van bepaalde claudines kan 
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beïnvloeden.   
 
Conclusie 
De bevindingen beschreven en bediscussieerd in dit proefschrift geven meer 
inzicht in het trans- en paracellulair calciumtransport over het darm- en 
nierepitheel. Het benadrukt de specifieke rol van het duodenum in de 
transcellulaire opname van calcium uit de voeding en de sterke regulatie van dit 
proces door het hormoon vitamine D3. In ouderen zorgt een verminderde 
gevoeligheid voor vitamine D3 voor een verlaagde hoeveelheid 
calciumtransporteiwitten in de darm en nier, wat de capaciteit van het 
transcellulaire calciumtransport sterk doet afnemen. De rol van transcellulair en 
paracellulair transport bij het ontstaan van botklachten in patiënten met 
darmontstekingen behoeft verder onderzoek, vooral in patiënten met acute 
ontstekingen. Het gebruik van TNFΔARE/+ muizen is een goede mogelijkheid om de 
calciumbalans tijdens de ziekte van Crohn verder te bestuderen. Vast staat dat een 
langdurige behandeling van deze patiënten met prednisolon bijdraagt aan de 
verstoring van de calciumhuishouding door een afname van TRPV6 en calbindine-
D9k in de darm met als gevolg minder transcellulair calciumtransport. Claudines 
spelen een belangrijke rol in de barrièrefunctie van de darm. Er is nog 
onvoldoende bekend over de rol van individuele type claudines in de regulatie van 
paracellulair calciumtransport. Studies in knock-out muismodellen, waarin één type 
claudine is uitgeschakeld, kan in de toekomst mogelijk veel ophelderen over de 
fysiologische rol van verschillende claudines bij de regulatie van paracellulair 
calciumtransport. 
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Het is eindelijk zover: het boekje is af! Graag wil ik deze laatste pagina’s benutten 
om alle mensen, zowel binnen als buiten het lab, te bedanken die op welke wijze 
dan ook hebben bijgedragen aan de totstandkoming van dit boekwerkje. Eén ding 
is zeker, zonder de hulp van velen was dit nooit gelukt. 
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bewonder jullie onuitputtelijke enthousiasme en gedrevenheid voor de wetenschap. 
Tijdens mijn AIO tijd heb ik veel dingen van jullie geleerd, die zeker goed van pas 
zullen komen in mijn toekomstige werkzaamheden. De prijzen en subsidies blijven 
binnenstromen als blijk van jullie succes.  
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voor de gezelligheid, het delen van vakantieverhalen, de hulp bij het uitvoeren van 
de vele (dier)experimenten en het aanhoren van al mijn (computer)problemen.  
 
Many thanks to all colleagues from the department of Physiology for the kind help 
with the experiments, the nice chats during the coffee and lunch breaks and all 
other social events outside the lab. 
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voor de goede hulp en gezelligheid tijdens de uitvoer van de proefdierstudies.  
 
Aron, als student heb jij het aangedurfd om bij mij stage te lopen. Wat hebben we 
samen een boel werk verzet voor het claudine project! Vooral het kweken van de 
stabiele cellijnen was een hels karwei. Uiteindelijk heeft het een mooi hoofdstuk  
opgeleverd. Bedankt ook voor je mooie plaatjes. Het is duidelijk dat jij een stuk 
handiger met computers bent dan ik. Je was altijd erg enthousiast en gedreven en 
een leuke collega. Veel succes met je studie biologie.  
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Crohn’s disease mouse model and Bram van der Eerden for performing the 
valuable bone analysis in these mice.     
 
Special thanks to Pasi Nevalainen. Without your support I wouldn’t have been able 
to perform the human profiling study. It’s always difficult to obtain human material, 
but with your enthusiasm we managed to collect a nice set of data. I never met 
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such a kind and dedicated physician and I really appreciate your interest and 
support. Hopefully, we can soon publish our results.   
 
Cynthia, Esther, Lucy, Marloes en Neeltje: bedankt voor de gezellige tijd, zowel 
tijdens onze studie Biomedische Wetenschappen als nu. Gelukkig waren jullie er 
altijd om al het AIO lief en leed te delen. Het was fijn om ervaringen uit te wisselen 
en te horen dat ook jullie tegen dezelfde dingen aanliepen, daar heb ik veel steun 
aan gehad. Lucy, jij hebt de eindstreep al gehaald. Neel, nog even doorzetten, het 
komt écht ooit af! Esther, als enige wilde jij nooit promoveren. Ik vind het erg leuk 
dat je het alsnog aandurft. Cynthia en Marloes, jullie hebben gekozen om iets heel 
anders te gaan doen. Ik weet zeker dat jullie daar erg succesvol in worden!      
 
Natuurlijk wil ik ook mijn familie graag bedanken. Helmond is en blijft voor mij altijd 
een fijne thuishaven. Pap, Mam, Inge, Wilma en Cor, bedankt voor jullie steun en 
geduld bij het aanhoren van al mijn verhalen uit Nijmegen, het delen van vele leuke 
momenten door de jaren heen en de hulp bij vanalles en nog wat. Als jullie er niet 
waren geweest...... Waarschijnlijk zijn jullie net zo blij als ik dat het boekje is 
afgerond zodat ik weer vaak richting het zuiden kan afreizen.   
 
Als laatste mijn lieve Joost. Ik kan me het moment nog herinneren dat Steve weg 
ging uit mijn U’tje en jij diezelfde dag nog meteen je spullen pakte om zijn plek in te 
nemen. Daarna waren wij al snel een labstel. Het is zonder twijfel het beste 
resultaat dat ik verkregen heb tijdens mijn AIO tijd. Bedankt dat je er altijd voor me 
bent. Samen op dezelfde dag promoveren is na ons huwelijk de tweede mooie 
gebeurtenis dit jaar. Hopelijk volgen er in de toekmost nog veel meer mooie 
momenten samen. We kunnen in ieder geval vanaf nu rustig gaan genieten: de 
boekjes zijn klaar! 
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List of abbreviations 
 
1α-OHase   25-hydroxyvitamin D3-1α-hydroxylase 
1αKO   1α-hydroxylase knock-out 
1,25(OH)2D3  1,25-dihydroxy-vitamin D3 
45Ca2+   radioactive ionized calcium isotope 
125I   radioactive-labeled iodine 
ADP   adenosine diphosphate 
ANOVA  analysis of variance 
AE   AU-rich element 
ATP   adenosine triphosphate 
BMD   bone mineral density 
BV/TV   trabecular bone fraction 
Ca2+   ionized calcium 
CaCl2   calcium chloride 
Caco-2   human colon cancer-derived cell line 
cAMP   adenosine 3’,5’-cyclic monophosphate 
CaSR   calcium-sensing receptor 
CCD   cortical collecting duct 
CD   collecting duct 
CD   Crohn’s disease 
CD/Ec.V  connectivity density 
cDNA   copy DNA 
CNT   connecting tubule 
Ct.Th   cortical thickness 
Ct.V   cortical volume 
DCT   distal convoluted tubule 
DMEM   Dulbecco’s modified Eagle’s medium 
DNA   deoxyribonucleic acid 
ECL1   extracellular loop 1 
ECL2   extracellular loop 2 
Ec.V   endocortical volume 
EDTA   ethylenediaminetetraacetate 
ELISA   enzyme-linked immunosorbent assay 
ER   estrogen receptor 
FFHNC familial hypomagnesaemia with hypercalciuria and      
 nephrocalcinosis 
Fh.V   femoral head volume 
List of abbreviations 
 197
FOS   fructo-oligosaccharides 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
GHS   genetic hypercalciuric stone-forming 
GI   gastro-intestinal 
GR   glucocorticoid receptor 
h   hour 
HBS   hepes-buffered saline 
HEK293  human embryonic kidney-293 
HPRT   hypoxanthine-guanine phosphoribosyl transferase 
HPT   hyperparathyroidism 
IBD   inflammatory bowel diseases 
IH   idiopathic hypercalciuria 
IL   interleukin 
INF-γ   interferon-γ 
OD   integrated optical density 
kDA   kilo Dalton 
KO   knock-out 
Mg2+   ionized magnesium 
MAPK   mitogen-activated protein kinase 
MDCK   Madin-Darby canine kidney 
MOI   moment of inertia 
MUPP   multiple-PDZ domain protein 
mRNA   messenger ribonucleic acid 
N   number 
Na+   ionized sodium 
NaCl   sodium chloride 
NaPi-IIb  sodium-inorganic phosphate cotransporter IIb 
NCX1   Na+/Ca2+-exchanger 
NOD2   nucleotide oligodimerisation domain 2 
PBS   phosphate-buffered saline 
PCR   polymerase chain reaction 
PDZ   postsynaptic density-95/Discs large/zona occludens-1 
Pi   inorganic phosphate 
PKA   protein kinase A 
PKC   protein kinase C 
PMCA1b  plasma membrane Ca2+-ATPase 
PT   proximal tubule 
PTH   parathyroid hormone 
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RIA   radioimmunoassay 
RNA   ribonucleic acid 
SCFA   short-chain fatty acids 
SDS   sodium dodecyl sulphate 
SEM   standard error of the mean 
SNP   single nucleotide polymorphism 
TAL   thick ascending limb of Henle’s loop 
Tb.N   trabecular number 
Tb.Th   trabecular thickness 
Tb.V   trabecular volume 
tDPD   total deoxypyridinoline 
TEER   transepithelial electrical resistance 
Th1   T helper cell type 1 
TJ   tight junction 
TNFα   tumor necrosis factor α 
Tris   tris(hydroxyl-methyl)aminomethane 
TRP   transient receptor potential 
TRPM6   transient receptor potential melastatin-subtype 6 
TRPV   transient receptor potential vanilloid-subtype 
TRPV5   transient receptor potential vanilloid-subtype 5 
TRPV6   transient receptor potential vanilloid-subtype 6 
UC   Ulcerative colitis 
UTR   untranslated region 
UV   ultraviolet light 
VDR   vitamin D receptor 
VDRE   vitamin D-responsive element 
VSV   Vesicular Stomatitis Virus 
v   volume 
vol   volume 
WB   Williams-Beuren syndrome 
WNK   with no lysine 
wt   weight 
ZO   zona occludens 
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